

Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

*The American Academy of Neurology affirms the value of this guideline
as an educational tool for neurologists.*

*Endorsed by the American Association of Neurological Surgeons, the Congress
of Neurological Surgeons, and the Society of NeuroInterventional Surgery*

B. Gregory Thompson, MD, Chair; Robert D. Brown, Jr, MD, MPH, FAHA, Co-Chair;
Sepideh Amin-Hanjani, MD, FAHA; Joseph P. Broderick, MD, FAHA;
Kevin M. Cockcroft, MD, MSc, FAHA; E. Sander Connolly, Jr, MD, FAHA;
Gary R. Duckwiler, MD, FAHA; Catherine C. Harris, PhD, RN, MBA, CRNP;
Virginia J. Howard, PhD, MSPH, FAHA; S. Claiborne (Clay) Johnston, MD, PhD;
Philip M. Meyers, MD, FAHA; Andrew Molyneux, MD; Christopher S. Ogilvy, MD;
Andrew J. Ringer, MD; James Torner, PhD, MS, FAHA; on behalf of the American Heart Association
Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on
Epidemiology and Prevention

Purpose—The aim of this updated statement is to provide comprehensive and evidence-based recommendations for management of patients with unruptured intracranial aneurysms.

Methods—Writing group members used systematic literature reviews from January 1977 up to June 2014. They also reviewed contemporary published evidence-based guidelines, personal files, and published expert opinion to summarize existing evidence, indicate gaps in current knowledge, and when appropriate, formulated recommendations using standard American Heart Association criteria. The guideline underwent extensive peer review, including review by the Stroke Council Leadership and Stroke Scientific Statement Oversight Committees, before consideration and approval by the American Heart Association Science Advisory and Coordinating Committee.

Results—Evidence-based guidelines are presented for the care of patients presenting with unruptured intracranial aneurysms. The guidelines address presentation, natural history, epidemiology, risk factors, screening, diagnosis, imaging and outcomes from surgical and endovascular treatment. (*Stroke*. 2015;46:000-000. DOI: 10.1161/STR.0000000000000070.)

Key Words: AHA Scientific Statements ■ cerebral aneurysm ■ epidemiology ■ imaging ■ natural history
■ outcome ■ risk factors ■ treatment

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This guideline was approved by the American Heart Association Science Advisory and Coordinating Committee on January 28, 2015, and the American Heart Association Executive Committee on February 16, 2015. A copy of the document is available at <http://my.americanheart.org/statements> by selecting either the “By Topic” link or the “By Publication Date” link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

The American Heart Association requests that this document be cited as follows: Thompson BG, Brown RD Jr, Amin-Hanjani S, Broderick JP, Cockcroft KM, Connolly ES Jr, Duckwiler GR, Harris CC, Howard VJ, Johnston SC, Meyers PM, Molyneux A, Ogilvy CS, Ringer AJ, Torner J; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Guidelines for the management of patients with unruptured intracranial aneurysms: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2015;46:000-000.

Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <http://my.americanheart.org/statements> and select the “Policies and Development” link.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp. A link to the “Copyright Permissions Request Form” appears on the right side of the page.

© 2015 American Heart Association, Inc.

Stroke is available at <http://stroke.ahajournals.org>

DOI: 10.1161/STR.0000000000000070

Unruptured intracranial aneurysms (UIAs) are relatively common in the general population, found in $\approx 3.2\%$ (95% confidence interval [CI], 1.9%–5.2%) of the adult population (mean age 50 years) worldwide, and they are being discovered incidentally with an increasing frequency because of the widespread use of high-resolution magnetic resonance imaging (MRI) scanning. The large majority of UIAs will never rupture. For example, of the 1 million adults in the general population with a mean age of 50 years, $\approx 32\,000$ harbor a UIA, but only 0.25% of these, or 1 in 200 to 400, will rupture.^{1–3} To put these numbers in perspective, in any given year, ≈ 80 of 32 000 of these UIAs would be expected to present with subarachnoid hemorrhage (SAH). Complicating matters further is the fact that aneurysms that rupture may not be the same as the ones found incidentally. Physicians are now often faced with the dilemma of whether to treat patients who present with an incidental finding of an unruptured aneurysm or to manage them conservatively. Patients and families may push for the surgical or endovascular management of an incidental UIA out of fear of the unknown and potentially catastrophic outcome that could occur. However, no treatment comes without risk, and the benefit of treating an incidental UIA must outweigh the potential risks of treating it.

Despite the relatively small number of rupture events that occur, many uncertainties remain. There are still concerns regarding the risk of rupture for particular aneurysm types such as multilobed aneurysms, those with irregularity of the aneurysm dome, those with selected morphological characteristics (such as size relative to the parent artery), those in selected locations, and those of larger diameter. Other concerns include presentations that may mimic sentinel headaches, patients who smoke or have hypertension, those who have a family history of aneurysmal rupture, and those with an enlarging aneurysm. How do these factors play a role in the natural history of incidental UIA, and should they alter management strategies? Should subsets of incidental UIAs be treated differently or more aggressively?

The purpose of this statement is to provide guidance for physicians, other healthcare professionals, and patients and to serve as a framework for decision making in determining the best course of action when a UIA is discovered. The committee chair nominated writing group members on the basis of their previous work in relevant topic areas. The American Heart Association (AHA) Stroke Council's Scientific Statement Oversight Committee and the AHA's Manuscript Oversight Committee approved all writing group members. All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document. Recommendations were formulated using standard AHA criteria (Tables 1 and 2).

Recent Data Regarding Natural History

Since the last US consensus statement was published in 2000, the International Study of Unruptured Intracranial Aneurysms (ISUIA)⁴ has published prospective data regarding a large cohort of patients with UIAs, stratified by size. The ISUIA reported 49 aneurysmal ruptures during its mean observation period of 4.1 years of follow-up of the enrolled population of

1692 prospective unoperated patients. Similarly, with a mean observation period of 3.5 years and 11 660 patient-years of follow-up in a large Japanese study of unruptured aneurysms (the Unruptured Cerebral Aneurysm Study [UCAS]),⁵ only 110 aneurysmal ruptures were reported. To date, there has been no completed randomized comparison of either clipping or coiling treatment with regard to natural history to evaluate its risk/benefit ratio. The Trial of Endovascular Aneurysm Management (TEAM) was initiated by Canadian researchers to examine this issue, but the study failed to recruit patients, and the trial grant was withdrawn on grounds of futility.⁶ A new Canadian trial has since commenced recruiting in a pilot study to compare endovascular treatment with clip ligation.⁷

Changes in the Treatment of Unruptured Aneurysms

Since the last recommendation document in 2000, major changes have emerged in the treatment of UIA, largely in the widespread use of endovascular techniques. The use of coil embolization increased substantially after publication of the results of the International Subarachnoid Aneurysm Trial (ISAT) in 2002 and 2005.^{8,9} ISAT was a randomized trial comparing clip ligation to coil occlusion in ruptured aneurysms; it showed improved clinical outcomes in the coiling arm at 1 year. Although trials of UIAs and ruptured aneurysms cannot be compared on the basis of outcomes or future risk, the relative safety and medium-term efficacy of both coiling and surgical clipping in preventing future hemorrhage from the treated aneurysm has been better established after ISAT. Furthermore, experience in treating aneurysms continues to increase, with an improved measure of safety and with better devices.

This guideline is the result of a collaborative effort of an expert committee researching the best available evidence in the English language on the prevalence, natural history, and management of UIA. The committee was composed of experts in the field with an interest in developing practice guidelines. This guideline is the continued review of existing literature that builds on the foundations of the recommendations made by the first consensus committee in 2000.¹⁰

Epidemiology

There are no data on incidence rates for UIAs, because these data require prospective, long-term follow-up studies of populations at risk with repeated assessments over time. The prevalence of UIAs depends on the population(s) studied, method of case ascertainment, reason for undergoing brain imaging, and whether the study was retrospective or prospective.

In a comprehensive systematic review and meta-analysis with strict inclusion criteria that included 68 studies reporting on 83 study populations, the prevalence of UIAs ranged from 0.0% to 41.8%, with an overall mean prevalence of 2.8% (95% CI, 2.0%–3.9%).¹¹ With these data, the estimated prevalence of UIA in a population without comorbidity and with a mean age of 50 years is calculated to be 3.2% (95% CI, 1.9%–5.2%).¹ The years included in these studies ranged from 1931 to 2008, including some with unknown years. When studies that used intra-arterial digital subtraction angiography (DSA)

Table 1. Applying Classification of Recommendations and Level of Evidence

ESTIMATE OF CERTAINTY (PRECISION) OF TREATMENT EFFECT	SIZE OF TREATMENT EFFECT				
	CLASS I <i>Benefit >>> Risk</i> Procedure/Treatment SHOULD be performed/ administered	CLASS IIa <i>Benefit >> Risk</i> Additional studies with focused objectives needed IT IS REASONABLE to per- form procedure/administer treatment	CLASS IIb <i>Benefit ≥ Risk</i> Additional studies with broad objectives needed; additional registry data would be helpful Procedure/Treatment MAY BE CONSIDERED	CLASS III <i>No Benefit</i> or CLASS III <i>Harm</i>	
				Procedure/ Test	Treatment
				COR III: No benefit	No Proven Benefit
				COR III: Harm	Excess Cost w/o Benefit or Harmful
LEVEL A Multiple populations evaluated* Data derived from multiple randomized clinical trials or meta-analyses	<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective Sufficient evidence from multiple randomized trials or meta-analyses 	<ul style="list-style-type: none"> Recommendation in favor of treatment or procedure being useful/effective Some conflicting evidence from multiple randomized trials or meta-analyses 	<ul style="list-style-type: none"> Recommendation's usefulness/efficacy less well established Greater conflicting evidence from multiple randomized trials or meta-analyses 	<ul style="list-style-type: none"> Recommendation that procedure or treatment is not useful/effective and may be harmful Sufficient evidence from multiple randomized trials or meta-analyses 	
LEVEL B Limited populations evaluated* Data derived from a single randomized trial or nonrandomized studies	<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective Evidence from single randomized trial or nonrandomized studies 	<ul style="list-style-type: none"> Recommendation in favor of treatment or procedure being useful/effective Some conflicting evidence from single randomized trial or nonrandomized studies 	<ul style="list-style-type: none"> Recommendation's usefulness/efficacy less well established Greater conflicting evidence from single randomized trial or nonrandomized studies 	<ul style="list-style-type: none"> Recommendation that procedure or treatment is not useful/effective and may be harmful Evidence from single randomized trial or nonrandomized studies 	
LEVEL C Very limited populations evaluated* Only consensus opinion of experts, case studies, or standard of care	<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective Only expert opinion, case studies, or standard of care 	<ul style="list-style-type: none"> Recommendation in favor of treatment or procedure being useful/effective Only diverging expert opinion, case studies, or standard of care 	<ul style="list-style-type: none"> Recommendation's usefulness/efficacy less well established Only diverging expert opinion, case studies, or standard of care 	<ul style="list-style-type: none"> Recommendation that procedure or treatment is not useful/effective and may be harmful Only expert opinion, case studies, or standard of care 	
Suggested phrases for writing recommendations	should is recommended is indicated is useful/effective/beneficial	is reasonable can be useful/effective/beneficial is probably recommended or indicated	may/might be considered may/might be reasonable usefulness/effectiveness is unknown/unclear/uncertain or not well established	COR III: No Benefit is not recommended is not indicated should not be performed/ administered/ other is not useful/ beneficial/ effective	COR III: Harm potentially harmful causes harm associated with excess morbid- ity/mortality should not be performed/ administered/ other
Comparative effectiveness phrases†	treatment/strategy A is recommended/indicated in preference to treatment B treatment A should be chosen over treatment B	treatment/strategy A is probably recommended/indicated in preference to treatment B it is reasonable to choose treatment A over treatment B			

A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use.

†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

were compared with those that used magnetic resonance angiography (MRA), there was no difference in prevalence, but prevalence was significantly lower in studies that used MRI and remained lower after adjustment for age and sex.¹¹ When the studies that primarily used MRI were excluded, the overall prevalence was 3.5% (95% CI, 2.7%–4.7%).¹¹ Although the crude prevalence of UIAs was higher in studies using imaging versus autopsy definitions, there was no difference in prevalence estimates after adjustment for sex, age, and comorbidities.¹¹ Women had a higher prevalence of UIAs than men, even after adjustment for age and comorbidities.¹¹ Prevalence overall was higher in people aged ≥30 years. In comparisons made

between the United States and other countries, after adjustment for sex and age, a similar prevalence was noted, but no data by race/ethnicity have been reported.¹¹ Another report that summarized the literature before this systematic review suggested that the prevalence of UIAs in the population >30 years of age is ≈3.6% to 6.0%, with higher prevalence in women and an increased prevalence with age.¹² A recent cross-sectional study from China of 4813 adults aged 35 to 75 years found a prevalence of 7.0% based on MRA, also with a higher prevalence in women than men.¹³

In the population-based Rotterdam Study, in which 2000 patients (mean age 63 years; range, 45.7–96.7 years)

Table 2. Definition of Classes and Levels of Evidence Used in AHA/ASA Recommendations

Class I	Conditions for which there is evidence for and/or general agreement that the procedure or treatment is useful and effective
Class II	Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment
Class IIa	The weight of evidence or opinion is in favor of the procedure or treatment
Class IIb	Usefulness/efficacy is less well established by evidence or opinion
Class III	Conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful
Therapeutic recommendations	
Level of Evidence A	Data derived from multiple randomized clinical trials or meta-analyses
Level of Evidence B	Data derived from a single randomized trial or nonrandomized studies
Level of Evidence C	Consensus opinion of experts, case studies, or standard of care
Diagnostic recommendations	
Level of Evidence A	Data derived from multiple prospective cohort studies using a reference standard applied by a masked evaluator
Level of Evidence B	Data derived from a single grade A study or one or more case-control studies, or studies using a reference standard applied by an unmasked evaluator
Level of Evidence C	Consensus opinion of experts
AHA/ASA indicates American Heart Association/American Stroke Association.	

underwent protocol-driven high-resolution structural brain MRI, the prevalence of incidental intracranial aneurysms (IAs) was found to be 1.8%, with no change in prevalence by age¹⁴; however, in another systematic review and meta-analysis of other population-based observational studies of incidental findings on MRI (including the Rotterdam Study), the prevalence of IAs was only 0.35% (95% CI, 0.13%–0.67%), but age data were not complete, and only cross-sectional MRI was available.¹⁵ In the large population-based Norwegian Nord-Trøndelag Health (HUNT) cohort study, based on MRA, the prevalence in the 1006 volunteers aged 50 to 65 years was 1.9%.¹⁶ Data from the US National Hospital Discharge Survey indicate an increase in the number of patients admitted with UIAs from 1996 to 2001 compared with earlier years of 1986 to 1995.¹⁷ This may be related to increased availability and use of brain imaging over the period. The mean age of patients included from 1986 to 1990 was lower than for patients included from 1990 to 1995.¹⁷

Mortality associated with UIAs may best be described in relation to natural history and the treatment studies discussed below. Mortality in patients with UIAs has not been well studied. In a Finnish study of 140 patients with

178 UIAs who were hospitalized between 1989 and 1999, during a mean follow-up of 13 years, patients had a 50% excess mortality compared with the general population.¹⁸ Rates of in-hospital mortality in acute care hospitals in the United States for UIAs were 5.9% in 1986 to 1990, which increased to 6.3% (1991–1995), then decreased to 1.4% (1996–2001).¹⁷

Risk Factors

IA risk can be divided into factors associated with 3 phases: (1) risk for aneurysm development; (2) risk for growth or morphological change; and (3) risk for rupture.¹⁹ Aneurysm risk can be assessed through image-based screening on a population basis, of high-risk populations, clinical populations, or registries of patients.

IAs are acquired lesions and are the cause of most cases (80%–85%) of nontraumatic SAH^{2,20}; however, the proportion of IAs that rupture is unknown. There is also substantial discrepancy between unruptured aneurysm annual prevalence (2000–4000 per 100 000) and SAH annual incidence (10 per 100 000).²¹ This ratio suggests that only ≈1 rupture occurs among 200 to 400 patients per year. There are no studies of SAH that delineate a documented history of a prior unruptured aneurysm diagnosis.

The frequency of identification of UIAs depends on the selection of patients for imaging.^{12,14,22–29} In a meta-analysis of UIA prevalence studies, the detection rate was 0.4% (95% CI, 0.4%–0.5%) in retrospective autopsy studies, 3.6% (95% CI, 3.1%–4.1%) in prospective autopsy studies, 3.7% (95% CI, 3.0%–4.4%) in retrospective angiography studies, and 6.0% (95% CI, 5.3%–6.8%) in prospective angiography studies.³ Larger UIAs may present with mass effect, cranial nerve deficits (most commonly a third nerve palsy), seizures, motor deficit, or sensory deficit, or they may be detected after imaging performed for headaches, ischemic disease, ill-defined transient spells, or other reasons.³⁰ Small aneurysms, <7 mm in diameter, uncommonly cause aneurysmal symptoms and are the most frequently detected. They are labeled as incidental or asymptomatic.^{12,23}

Most risk factors for aneurysm occurrence that have been identified were from patients with SAH, clinical retrospective or prospective series, and screening of at-risk populations. Autopsy and imaging screening offer information on detection (prevalence) but little information on risk factors other than age and sex.^{4,5,14,25–29,31–35} Few population-based studies or controlled comparative studies exist.¹⁴ Only a few large registries of patients, obtained either retrospectively or prospectively, have been compiled.^{3–5,32–35} Also, there is variation in these studies of clinical, inheritable, and modifiable risk factors.

Nonmodifiable Risk Factors

Most studies, regardless of design, show similar age and sex trends. Prevalence studies have demonstrated an increasing frequency by age, with a peak in the fifth and sixth decade of age (Table 3).^{4,5,14,25–29,31–35} Cases reported in children usually are associated with other conditions or genetic risk.^{36,37} There

Table 3. Detection of Intracranial Saccular Aneurysm by Age and Sex in Olmsted County, Minnesota, 1965–1995²⁶

Age Group, y	Counts			Rates*					
	Actual Number of Cases Detected			All Cases			All Cases Excluding Asymptomatic Cases Diagnosed at Autopsy		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
≤34	11	10	21	1.3	1.1	1.2	1.3	1.1	1.2
35–44	20	14	34	10.5	7.1	8.8	9.9	7.1	8.5
45–54	20	35	55	14.4	24.5	19.5	13.0	24.5	18.8
55–64	21	23	44	21.0	21.0	21.0	17.0	20.1	18.6
65–74	21	45	66	33.4	52.6	44.5	15.9	44.4	32.3
75–84	11	26	37	35.3	44.7	41.4	16.0	31.0	25.8
≥85	1	12	13	12.0	49.0	39.6	0.0	16.3	12.2
Total	105	165	270	9.3†	12.2†	11.1‡	6.7†	10.7†	9.0‡

*Crude age- and sex-specific detection rate for Olmsted County, Minnesota population.

†Age-adjusted incidence rate per 100 000 per year adjusted to the 1980 US white population.

‡Age- and sex-adjusted incidence rate per 100 000 per year adjusted to the 1980 US white population.

is an increased frequency of IAs in women compared with men, with aneurysms occurring more frequently in women across the age spectrum.^{4,5,22,24,31–35}

At-Risk Disorders

There is substantial evidence from autopsy clinical series and imaging studies of specific clinical groups that there is an increased risk of aneurysm formation in disorders such as polycystic kidney disease, type IV Ehlers-Danlos syndrome, Marfan syndrome, coarctation of the aorta, bicuspid aortic valve, pseudoxanthoma elasticum, hereditary hemorrhagic telangiectasia, neurofibromatosis type 1, α_1 -antitrypsin deficiency, fibromuscular dysplasia, pheochromocytoma, Klinefelter syndrome, tuberous sclerosis, Noonan syndrome, α -glucosidase deficiency, microcephalic osteodysplastic primordial dwarfism, and intracranial arteriovenous malformations.^{24,38–47} For autosomal dominant polycystic kidney disease, the increased risk may be 3- to 14-fold.¹¹ However, when examined in a large clinical cohort, all of these conditions constituted <10% of patients presenting with unruptured aneurysms, which left the majority attributable to other risk factors.⁴

Family History and Genetics

Estimates of the frequency of familial occurrence of IAs range from 7% to 20%.^{48–56} This variation is largely a result of the various methods of family history ascertainment. The prevalence ratios (prevalence adjusted for comorbidity, age, and sex) indicate an increased risk between 1.9% and 5.9%.¹¹ There may be a slightly higher frequency of aneurysm detection in first-degree relatives of those with a history of SAH. In a study using MRA screening, 4% (95% CI, 2.6%–5.8%) of such first-degree relatives were found to have a UIA. Siblings had a higher likelihood of detection than children of those affected.^{54,57} Factors that increased the likelihood of aneurysm detection in those with familial risk included other risk factors, such as older age, female sex, cigarette smoking, history of hypertension, higher lipid levels, higher fasting glucose, family history of polycystic kidney disease, and family history of SAH or aneurysm in ≥ 2

relatives.⁵⁷ There is also an increased risk of detection if ≥ 2 members of a family have a history of SAH or UIA. In 1 study of 438 people from 85 families, 38 first-degree relatives (8.7%) had a UIA on screening imaging.⁵² In the Familial Intracranial Aneurysm (FIA) Study, first-degree relatives of those affected with brain aneurysm who were >30 years old and had a history of either smoking or hypertension were screened with MRA. Among the first 304 patients screened, 58 (19.1%) had at least 1 IA.⁵⁵ In long-term serial MRA or computerized tomographic angiography (CTA) screening of people with ≥ 2 first-degree relatives with a history of aneurysmal SAH (aSAH) or UIA, aneurysms were identified in 11% of 458 subjects at first screening, 8% of 261 at second screening, 5% of 128 at third screening, and 5% of 63 at fourth screening, which represents a substantial risk of UIA with up to 10 years of follow-up, even after 2 initial negative screenings.⁵⁸ In this study, significant risk factors for UIA at first screening were smoking, history of previous aneurysm, and family history of aneurysm. In the follow-up screening, the only significant risk factor was history of previous aneurysm.

The inheritance patterns of IAs are unclear, but autosomal dominance transmission is suspected to be the most common mode of inheritance. A variety of genes or chromosomal regions have been identified in both familial and sporadic cases of IAs.^{59–73} In linkage studies, regions on chromosomes 1p34.3-p36.13, 7q11, 19q13.3, and Xp22 have been associated with IAs. Genome-wide association studies identified replicated associations on chromosome 4q31.23 (*EDNRA*), 8q12.1 (*SOX17*), 9p213 (*CDKN2A/CDKN2B/CDKN2BAS*), 10q24.32 (*CNNM2*), 12q22, 13q13.1 (*KL/STARD13*), 18q11.2 (*RBBP8*), and 20p12.1, with the strongest evidence for the *CDKN2BAS* and *SOX17* genes.⁷⁴ A meta-analysis of ruptured IAs (RIAs) and UIAs identified the gene IL 6 G572C to have an elevated risk; however, no predominant genetic risk factor has been identified.⁶⁰ In another meta-analysis, 19 single-nucleotide polymorphisms were associated with aneurysm occurrence.⁷⁵ Single-nucleotide polymorphisms with the strongest association to IA occurrence include chromosome 9 within the *CDKN2B* antisense inhibitor gene, chromosome 8 near the

SOX17 transcription regulator gene, and on chromosome 4 near the *EDNRA* gene.

Modifiable Risk Factors

As with aSAH, an increased prevalence of smoking among patients with UIAs has been demonstrated in several controlled studies.^{4,5,32–35,76–80} For UIAs, in the large, prospective clinical registry of the ISUIA of patients with UIA, 44% of patients in the prospective cohort were current smokers and 33% were former smokers.⁴ The retrospective component of the ISUIA had a rate of 61% smokers and 19% former smokers.³⁴ In the Finland prospective series, 36% were current smokers and 24% were former smokers.³³ In the Japanese cohort, the prevalence of former and current smokers combined was only 17%.⁵ Hence, the role of smoking as a risk factor appears differential. Smoking cessation studies have shown a modified risk of aSAH,^{77,81} but no studies in patients with UIAs have been reported. In reference to hypertension, no prospective studies of blood pressure control have been performed that demonstrate prevention of aneurysm development. There was indirect evidence of the effectiveness of antihypertensive medication in prevention in a recent study from Kuopio, Finland; antihypertensive medication use was more frequent in the UIA incident group, and untreated hypertension was more frequent in the ruptured aneurysm group.⁸² Excessive alcohol use may also be a risk factor for aneurysm development.⁸³ The role of oral contraceptives has been controversial in aSAH, with some data suggesting a potential association of high-dose estrogen oral contraceptives with SAH; there are few studies to demonstrate an association with aneurysm development.^{84–86} In summary, the increased prevalence of cigarette smoking and hypertension in some UIA cohorts supports the concept that IAs may be subject to risk factor modification, but there are limited data available regarding the impact of risk factor modification and the occurrence of UIA.

Multiplicity

Two or more aneurysms are found in 15% to 30% of patients.^{4,87–91} Risk factors for multiple aneurysms have been evaluated primarily in mixed UIA and SAH populations. Risk factors include female sex, cigarette smoking, hypertension, a family history of cerebrovascular disease, and postmenopausal hormone replacement therapy.^{84–86}

Risk Factors for Aneurysmal Change

Growth

The incidence of growth has been widely variable depending on the definition of growth and the population studied.⁹² Factors attributed to growth have been increased blood pressure, hemodynamic stress based on location and shape of the aneurysm, and inflammation. Most research has been limited to experimental settings. Most epidemiological studies have been retrospective, with only a few prospective studies with short follow-up periods. A variety of factors for growth that have been identified include female sex, cigarette smoking, younger age, excessive alcohol consumption, aneurysm location, multiplicity of aneurysms, history of stroke, and history

of transient ischemic attack.^{93–95} Recent findings indicate the propensity for growing aneurysms to rupture and indicate that risk factors for growth were initial aneurysm size, arterial branch-related aneurysms, hypertension, tobacco smoking, and female sex.^{96–98} More prospective studies with either imaging or biomarkers are needed, and intervention studies with blood pressure or inflammation control would be of interest.

Ruptured Versus Unruptured

Few studies have simultaneously collected data on ruptured and unruptured aneurysms. Most of these have concentrated on size and location differences. Anterior communicating artery aneurysms and pericallosal artery aneurysms may be overrepresented in the rupture cohort.^{99,100} Middle cerebral artery aneurysms are less likely to be in the ruptured cohort. The likelihood of detection after rupture is higher with larger size. In addition, sex differences in rupture status may vary by location. Several characteristics of aneurysm morphology, such as a bottleneck shape and the ratio of size of aneurysm to parent vessel, have been associated with rupture status, but how these might be applied to individual patients to predict future aneurysmal rupture is still unclear.^{99–102} There is interest in the relationship of morphology (maximum diameter, complex spatial geometry, high aspect ratio [maximum aneurysm height/neck diameter]) and hemodynamics (complex flow pattern, low wall shear stress, high oscillatory shear index) to aneurysm rupture. Recent studies have demonstrated the combination is discriminatory between ruptured and unruptured aneurysms.^{103–109}

In a prospective Finnish cohort of 118 UIA patients aged 22.6 to 60.7 years followed up from diagnosis (1956–1978) to SAH or death, 29% had SAH during their lifetime, and the annual rupture rate per patient was 1.6%. Risk factors for lifetime SAH were female sex, current smoking, and aneurysm diameter >7 mm.¹¹⁰ In the HUNT longitudinal cohort study, with linkage to hospital and death records, the overall rupture risk in people with UIAs aged 50 to 65 years was 0.87% per year.¹⁶

Comparison of risk factors at the patient level was evaluated in the retrospective and prospective cohorts of patients of the ISUIA classified by prior SAH or no prior SAH. Those without an SAH history were older, had more hypertension, more cardiac disease, less alcohol use, less current smoking, and more oral contraceptive use.³⁴

Predictors

Prospective studies of the risk of rupture in previously unruptured aneurysms have consistently recognized the role of aneurysm size and location.^{4,5,31–35} Potential but not universally demonstrated risk factors for rupture include younger age, cigarette smoking, hypertension, aneurysmal growth, morphology, female sex, prior SAH, and family history of SAH.^{111,112} In annual follow-up of 384 UIAs, significant independent predictors of rupture were hypertension and age <50 years.¹¹³ Inflammation may play an important role in the pathogenesis and growth of IAs.^{114,115} The role of anti-inflammatory medications in prevention of growth and rupture has been hypothesized but needs controlled, prospective confirmation.¹¹⁴ Comparative and prospective cohort studies

of aspirin use have shown fewer SAH events in patients with routine aspirin use.¹¹⁶ Other interventions, such as the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and calcium channel blockers, may retard aneurysm formation through the inhibition of nuclear factor- κ B and other pathways, but observational findings are not supportive of the use of statins for prevention.¹¹⁵

Similarities With aSAH Risk Factors

Demographic risk factors associated with aSAH include age, sex, and race. A familial history of aSAH and evidence of familial aneurysms (at least 1 first-degree family member with an IA) increase the risk of aSAH in an individual.¹¹⁷ Certain genetic syndromes, such as autosomal dominant polycystic kidney disease, type IV Ehlers-Danlos syndrome, and microcephalic osteodysplastic primordial dwarfism (autosomal recessive inheritance), have an association with aSAH. Modifiable risk factors for aSAH include hypertension, smoking, and alcohol abuse. Elevated aSAH risk associated with the use of sympathomimetic drugs (eg, cocaine) and decreased risk among those with diabetes mellitus and those with elevated body weight have not been shown in subjects with unruptured aneurysms.^{2,12,20}

Summary

The prevalence of UIAs increases with age. Aneurysms are thought to be acquired, although there is evidence of genetic and familial risk in some patients. There is increased risk in patients with selected other vascular abnormalities. There are several heritable conditions associated with an increased occurrence of a UIA, including autosomal dominant polycystic kidney disease, but UIAs associated with these conditions are very uncommon in clinical practice. Women appear to be at increased risk, but the role of oral contraceptives and estrogen loss or prevention of estrogen loss after menopause is inconclusive. The substantial increase in prevalence among smokers and people with hypertension indicates that both are likely modifiable factors for aneurysm development. Factors related to hemodynamic stress and inflammation may accelerate the rate of rapid aneurysm development and rupture and need to be elucidated. A combination of risk factor prevention and management may be necessary to reduce the prevalence of unruptured aneurysms and the precursor for SAH in the majority of cases.

Risk Factors for Aneurysm Development, Growth, and Rupture: Recommendations

1. Given that smoking appears to increase the risk of UIA formation, patients with UIA should be counseled regarding the importance of smoking cessation (*Class I; Level of Evidence B*).
2. Given that hypertension may play a role in growth and rupture of IAs, patients with UIA should monitor blood pressure and undergo treatment for hypertension (*Class I; Level of Evidence B*).
3. Aneurysmal growth may increase the risk of rupture, and intermittent imaging studies to follow those UIAs managed conservatively should be considered (*Class I; Level of Evidence B*).

Clinical Presentation

UIAs are most commonly identified after hemorrhage from another aneurysm, or incidentally during evaluation of neurological symptoms other than from a hemorrhage, or a sudden severe or “different” headache. In the ISUIA, the diagnosis of the target unruptured aneurysm was made during evaluation of hemorrhage from another aneurysm (30.4%), headache (23.7%), ischemic cerebrovascular disease or transient ischemic attack (10.6% and 10.5%, respectively), cranial nerve palsy (8.0%), seizures (2.9%), symptoms of mass effect (2.7%), subdural or intracerebral hemorrhage (1.2%), brain tumor (0.8%), central nervous system degenerative disorders (0.4%), and undefined “spells” (7.1%).⁴ In another prospective observational study that excluded patients presenting with SAH from another source, the combination of cerebrovascular disease, transient ischemic attack, and nonspecific spells was the most common indication for evaluation leading to aneurysm discovery (43.4%), whereas headache accounted for 16%.¹¹⁸ The results of ISUIA support the use of aneurysm size and location in the consideration of optimal management after UIA detection. The manner of presentation may also influence the natural history of the aneurysm or the decision to treat. Wermer et al⁹⁹ found a 4-fold increased risk of rupture with symptomatic unruptured aneurysms.

ISUIA assessed the prospective risk of spontaneous hemorrhage from UIAs identified in patients after presentation with a ruptured aneurysm. The ruptured aneurysm was treated, and the UIA was then followed up. In these patients, during a 5-year period, the risk of hemorrhage for aneurysms <7 mm in diameter was significantly greater than for patients with similarly sized unruptured aneurysms and no prior history of hemorrhage.⁴ The rate of rupture was not significantly different between these groups for aneurysms >7 mm.

In the absence of hemorrhage, the most common indication for diagnostic evaluation leading to the discovery of an unruptured aneurysm is headache.^{4,118} In the ISUIA, patients presenting with headache were more likely to undergo treatment of their unruptured aneurysm, but no data were provided regarding the risk of spontaneous hemorrhage. Several small observational studies have reported improvement in headache frequency or severity after aneurysm treatment in those patients presenting with headache attributed to the aneurysm.^{119–122} No studies, however, have sufficiently correlated presentation with headache with a change in the risk of spontaneous hemorrhage, and it remains likely that most headaches in patients with UIA are not directly related to the aneurysm.

UIAs may be discovered in the evaluation of cranial nerve palsy. Patients whose aneurysm was identified in the presence of cranial nerve palsy were more likely to undergo treatment than observation in ISUIA, and no data were provided regarding the risk of subsequent rupture.⁴ Several small observational studies have reported improvement in cranial nerve function after aneurysm treatment in those patients presenting with cranial nerve palsy, but no randomized trials have evaluated this practice.^{123–127} For patients presenting with oculomotor palsy secondary to posterior communicating aneurysms, several retrospective studies have indicated better resolution with surgery than endovascular therapy^{128–130} or conservative

management.¹²⁸ Sudden onset of third nerve palsy in this setting is generally considered an indication of expansion and concern for imminent rupture, necessitating rapid workup and intervention.

Evaluation after presentation with ischemic cerebrovascular disease may lead to the discovery of a UIA.^{4,118} A small minority of these aneurysms are found proximal to the ischemic territory, and particularly when a given aneurysm has an intra-aneurysmal thrombus, it may be considered a potential source of the ischemic event.¹³¹ No prospective randomized trial has compared the risk of subsequent ischemic events, rupture, death, or disability after treatment or medical management. Although the practice of leaving a symptomatic aneurysm unsecured or treating the patient with antiplatelet or anticoagulation therapy remains controversial, there are insufficient data to evaluate and support the treatment of UIAs for the prevention of ischemic cerebrovascular disease. Aneurysms found after presentation with stroke or transient ischemic attack and that have clearly defined intrasaccular thrombus proximal to the ischemic territory on imaging may warrant consideration for treatment, but a lack of prospective data makes it uncertain as to whether such treatment will reduce the risk of subsequent ischemia.

Clinical Presentation: Recommendations

1. **Patients with an aSAH should undergo careful assessment for a coexistent UIA (Class I; Level of Evidence B).**
2. **Early treatment is generally indicated for patients presenting with cranial nerve palsy caused by a UIA (Class I; Level of Evidence C).**
3. **The effectiveness of the routine treatment of UIAs for the prevention of ischemic cerebrovascular disease is uncertain (Class IIb; Level of Evidence C).**

Diagnosis/Imaging

The methods of imaging of aneurysms have expanded greatly, with advanced MRA, CTA, and DSA techniques. Each has advantages and disadvantages, and each is used variably by individual practitioners at various stages in the evaluation of cerebral aneurysms. Initial imaging diagnosis, full evaluation of the anatomy of the aneurysm and the relationship to the parent vessel(s), and follow-up imaging evaluation for UIAs are covered in this section.

After the diagnosis of an aneurysm, the specific anatomic (and perhaps in the future, dynamic) details of the aneurysm(s) both initially and in follow-up are necessary to adequately categorize the lesion to select appropriate management and assess the outcomes of that management.^{132–134}

Digital Subtraction Angiography

DSA continues to be the “gold standard” of aneurysm diagnosis; however, with the advent of 3-dimensional (3D) rotational angiography, even more detailed imaging can be performed than with 2-dimensional planar imaging. Studies have shown greater sensitivity of DSA, especially in aneurysms smaller than 3 mm.^{135–138} In addition, the resolution provided by DSA is greater for the smallest of vessels, such as perforators.^{139–144}

Although DSA remains the gold standard, it should be recognized that catheter arteriography does have risks, albeit small. Possible complications include contrast-related events, cerebral infarction, aneurysmal rupture, arterial injury, and others.^{145,146} In patients with renal insufficiency or Ehlers-Danlos syndrome, in whom the risk of catheter angiography is higher, clinicians may favor noninvasive imaging; however, in general, the risks are low, with most contemporary data indicating permanent neurological complications in patients with cerebral aneurysms, SAH, and arteriovenous malformation occurring at a rate of 0.07%.¹⁴⁷ There is also the potential for radiation risks, but in the setting of diagnostic angiography, these risks are small. The invasiveness and the cumulative radiation make it less frequently used for follow-up¹⁴⁸; however, selective DSA follow-up for treated aneurysms carries a low risk.^{149,150}

Computed Tomography

With the development of multidetector scanners, CTA is frequently added to the noncontrast computed tomography (CT) to assist diagnosis. There are multiple generations of scanners, but in general, the sensitivity, specificity, and accuracy of aneurysm detection with modern-generation scanners is very high compared with DSA with 3D rotational acquisition, with 1 report indicating values of 96.3%, 100%, and 94.6%, respectively. However, in that same report, there was lesser sensitivity for smaller aneurysms (typically characterized as those <3 mm), of 81.8%, 100%, and 93.3%, respectively.¹⁵¹

In 2003, a meta-analysis of 21 studies that included 1251 patients resulted in a sensitivity of 93.3% and specificity of 87.8% for CTA compared with DSA.¹⁵² In addition, CT is very useful in identifying mural calcification and thrombus, which can have a significant impact on treatment decisions.¹⁵³ However, the reconstruction methods may not accurately depict the true neck/dome/adjacent small vessel anatomy, which can be important determinates of the type of treatment rendered.¹³⁹ Despite this shortcoming, with its high sensitivity and specificity, even in smaller aneurysms, CTA can be considered as an initial diagnostic test for aneurysm detection and screening.

CTA may be limited by artifact from bone and metal (coils, stents, and clips), thereby reducing its usefulness as an alternative to DSA as a follow-up technique for noninvasive imaging in treated aneurysms. The associated exposure to radiation is another issue in its use in long-term follow-up.^{154–157}

Magnetic Resonance Imaging

Imaging of aneurysms with MRA typically uses time-of-flight (TOF) or contrast methods. It is unclear which method is most useful, but generally, MRA has been reported to have a detection sensitivity ranging from 74% to 98%.¹⁵⁸ However, 1 study showed that overall, sensitivity was 79% with the most experienced readers, and aneurysm size greatly affected the results. Aneurysms >3 mm were detected with a sensitivity of 89% by the most experienced readers.^{159–161} These data suggest that as a primary method of screening for UIAs, magnetic resonance can be very useful for aneurysms larger than 3 mm. A recent analysis of small aneurysms (≤5 mm) with 3T TOF

MRA with volume rendering versus DSA showed very high accuracy (96.4%–97.3% for the readers), with the continued caveats regarding small-vessel detection (infundibula versus aneurysm) and contrast merging because of vessel tortuosity yielding false-positive and false-negative results. However, with this level of accuracy, using appropriate protocols, even small aneurysms should be detected.¹⁶²

For follow-up after interventional treatment, although susceptibility artifacts occur at the skull base and surrounding metallic implants such as stents, coils, and clips, MRA remains an effective alternative for noninvasive follow-up of both treated and untreated aneurysms.^{163–168} A meta-analysis of contrast-enhanced MRA in postcoiled aneurysms showed that contrast-enhanced MRA had an overall sensitivity of 92% and a specificity of 96% in detecting residual aneurysm compared with DSA.¹⁶⁹ However, with treated aneurysms, the resulting susceptibility artifacts on MRA can cause an underestimation of the size of the residual or recurrent aneurysm, and formal DSA may be necessary to determine the need for retreatment.^{166,167} As is always the case for MRI, care should be taken to ensure that the metallic implants are compatible with the magnetic environment of the MRI scanner.^{170–172}

In the follow-up of treated UIAs, magnetic resonance is a reasonable option given the high sensitivity for a residual aneurysm, lack of beam-hardening artifacts seen with CT, and invasiveness of DSA. For untreated UIAs already diagnosed, the lack of ionizing radiation or contrast (for TOF MRA) would make it the option of choice in those patients with renal compromise or in whom radiation exposure risks are relevant.

Analysis and Reporting

Whatever aneurysm imaging method is chosen, certain aspects of the anatomy require appropriate analysis and documentation to be useful for management and follow-up of UIAs. For determination of the method of treatment, including conservative management, endovascular, surgical, or combined therapy, accurate measurement of the neck size, a neck-to-dome ratio descriptor, measures of the aneurysm in 3 dimensions, and the relationship of the aneurysm to the surrounding vessels are essential.¹³² For treated aneurysms, the presence, measurements, and descriptors of residuals and any parent vessel changes are necessary, along with identification of any new aneurysm development.¹³²

The follow-up requirements for treated aneurysms remain uncertain. Long-term follow-up in treated UIAs has not been studied in randomized trials, so much of the general practices have been extrapolated from ruptured aneurysm trials. In general practice with adequate clipping, often no follow-up imaging is performed, or it may be limited to immediate perioperative angiography.¹⁵⁶ In ISAT, there was a slightly higher risk of recurrent hemorrhage from a coiled aneurysm than from those treated with surgical clipping, but the risks in both groups were very small.

For endovascularly treated aneurysms, because a residual or recurrent aneurysm is more common, imaging is often performed at 6 months to 1 year after treatment.^{161,163–168,173} Timing of the later follow-ups is variable and depends on the occlusion status of the initial and early follow-up, as well as the

condition of the patient. However, with residual aneurysms after coiling, long-term follow-up is indicated because there are late hemorrhages and aneurysm recurrences. For example, annual rates of hemorrhage in large and giant aneurysms (the most difficult group to treat with coiling) are up to 1.9%.¹⁷⁴ There is evidence that certain characteristics, such as wider neck diameters, larger aneurysms, and partial treatment, have a greater association with recurrence.^{175,176}

With unruptured aneurysms, follow-up is indicated. This is discussed further in the section regarding follow-up of untreated aneurysms.

Diagnosing/Imaging: Recommendations

1. DSA can be useful compared with noninvasive imaging for identification and evaluation of cerebral aneurysms if surgical or endovascular treatment is being considered (*Class IIa; Level of Evidence B*).
2. DSA is reasonable as the most sensitive imaging for follow-up of treated aneurysms (*Class IIa; Level of Evidence C*).
3. CTA and MRA are useful for detection and follow-up of UIA (*Class I; Level of Evidence B*).
4. It is reasonable to perform MRA as an alternative for follow-up for treated aneurysms, with DSA used as necessary when deciding on therapy (*Class IIa; Level of Evidence C*).
5. Coiled aneurysms, especially those with wider neck or dome diameters or those that have residual filling, should have follow-up evaluation (*Class I; Level of Evidence B*). The timing and duration of follow-up is uncertain, and additional investigation is necessary.
6. The importance of surveillance imaging after endovascular treatment of UIAs lacking high-risk features for recurrence remains unclear, but surveillance imaging is probably indicated (*Class IIa; Level of Evidence C*).

Screening

The decision to screen for unruptured aneurysms by noninvasive CTA or MRA depends on the patient under consideration. Clinicians should consider aneurysmal prevalence associated with a given trait (such as prevalence in selected inherited disorders), projected disease morbidity, accessibility of a cost-effective screening test, the likely availability of an acceptably low-risk and effective treatment, and the patients' understanding of the potential implications of detecting an intracranial finding on imaging (such as future obtainment of life insurance), as well as the stress and anxiety that can be associated with UIA detection. Screening for unruptured aneurysms is appropriate in families with >1 affected person with an IA; in patients with a family history of IA and evidence of autosomal dominant polycystic kidney disease, type IV Ehlers-Danlos (vascular subtype), or the extremely rare microcephalic osteodysplastic primordial dwarfism¹⁷⁷; and in those with selected conditions associated with an increased occurrence of IAs, such as coarctation of the aorta or bicuspid aortic valve.^{178–181} The likelihood of aneurysm detection among first-degree relatives of those with sporadic SAH is

≈4% (95% CI, 2.6%–5.8%),⁵⁴ with somewhat higher risk among siblings than among children of those affected.⁵⁷ An AHA guideline regarding management of SAH suggested that it might be reasonable to offer noninvasive screening to first-degree relatives of those with SAH, but the risks and benefits of this approach are uncertain.²⁰

Populations at Increased Risk of Harboring an IA

Certain genetic syndromes have been associated with an increased risk of aSAH, such as autosomal dominant polycystic kidney disease, type IV Ehlers-Danlos syndrome, and microcephalic osteodysplastic primordial dwarfism.¹⁷⁷ These syndromes also support the theory of an inherited susceptibility to aneurysm formation. Patients who have clinical evidence of polycystic kidney disease and are without a family history of IA/hemorrhagic stroke have a reported 6% to 11% risk of harboring a UIA compared with 16% to 23% of those who also have a family history of IA/hemorrhagic stroke.^{179,181} In the latter group, noninvasive screening should be strongly considered, although the aneurysms are often small, and the risk of rupture is generally low in the small series reported previously.^{179,181} In addition, first-degree family members of patients who have type IV Ehlers-Danlos syndrome (including a family history of IA) should also be strongly considered for screening.¹⁷⁸ In a neurovascular screening program of patients with microcephalic osteodysplastic primordial dwarfism,¹⁷⁷ 13 of the patients (52%) were found to have cerebral neurovascular abnormalities, including moyamoya angiopathy and IAs. Finally, of 117 consecutive patients with coarctation who were >16 years of age who underwent screening with brain MRA, 10.3% had a UIA.¹⁸² Screening for UIA in these latter 2 groups of patients is also appropriate.

In addition to rare but well-defined genetic causes of IAs, such as polycystic kidney disease, population studies of aSAH have demonstrated that 9% to 14% of patients with an SAH have a family history of SAH in a first-degree relative.^{80,117,183,184} It is in these families that screening for UIA should be most strongly considered.

The National Institute of Neurological Disorders and Stroke–funded FIA Study was designed to find genetic risk factors for IA and, as part of its design, included screening by MRA for UIA.^{74,185,186} Eligible families included those with at least 2 affected siblings or ≥3 affected family members. The first-degree relatives of those affected with IA were offered screening if they were previously unaffected, were >30 years of age, and had a history of smoking or hypertension. The MRA screening was performed in 303 patients, and of these, 58 (19.1%) had at least 1 aneurysm. In a multivariate analysis, independent predictors of detection of IA included female sex (odds ratio [OR], 2.46), pack-years of cigarette smoking (OR 3.24 for 20 pack-years of cigarette smoking compared with never having smoked), and duration of hypertension (OR 1.26 when comparing those with 10 years of hypertension to those with no hypertension).^{55,187} Most of the detected aneurysms were small: 2 IAs were ≥7 mm in maximal diameter; 19 were 4 to 6 mm; and 50 were 2 to 3 mm. Both of the aneurysms that were ≥7 mm in maximal diameter were treated.¹⁸⁷

In another earlier screening study for IAs but with less aggregation of familial aneurysms, first-degree family

members of patients with an IA were screened if they were at least 30 years of age and if there was no history of polycystic kidney disease. Among 438 individuals from 85 families, 38 (8.7%) had an IA.⁵² As was the case in the FIA Study, most of the aneurysms detected were small. Large screening studies have also been performed in patients with sporadic SAH (those without any family history of IA). Among 626 first-degree relatives of 160 patients with sporadic SAH, 4% had aneurysms (25 of 626).⁵⁷ Thus, screening for IAs among unaffected family members in FIA families with multiple members with IA, particularly in smokers and those with hypertension, has strong justification, whereas screening among family members of patients with sporadic IA is not justified at present.

Cost-Effectiveness of Screening

In evaluation of the cost-effectiveness of screening for asymptomatic IAs, the monetary costs of screening should be weighed against the risks, consequences, and costs of an untreated ruptured aneurysm. Several assumptions must be made to estimate cost-effectiveness: likelihood of aneurysm detection by noninvasive imaging in the population studied, the sensitivity and specificity of noninvasive imaging, risk of intra-arterial angiography, risk of rupture in patients with detected aneurysms who are managed medically, the aggressiveness of medical management (example, smoking cessation), the morbidity and mortality associated with clipping or coiling of an unruptured aneurysm in cases in which the aneurysm is deemed treatable by either method, and the risk of subsequent rupture after intervention.

Although none of the models of cost-effectiveness include data for all of these variables, recent studies provide reasonable estimates of the utility of screening. One study provided evidence for recommendations to screen individuals with ≥2 first-degree relatives with SAH. The optimal screening strategy according to the authors' model is screening every 7 years from age 20 years until 80 years given a cost-effectiveness threshold of \$20 000 per quality-adjusted life-year (QALY) (\$29 200/QALY).¹⁸⁸ In another reported model of families with ≥2 affected first-degree relatives, screening compared with no screening had an incremental cost-effectiveness ratio of \$37 400 per QALY. With screening, life expectancy increased from 39.44 to 39.55 years. The incremental cost-effectiveness ratio of screening was >\$50 000 per QALY if age at screening was ≥50 years. In family members with 1 affected first-degree relative, screening compared with no screening had an incremental cost-effectiveness ratio of \$56 500 per QALY.¹⁸⁹ Finally, Li and colleagues¹⁹⁰ examined various screening models of the asymptomatic general population. Overall, screening resulted in a QALY loss, which equated to a negative clinical impact. The threshold for 5-year risk of rupture at which screening resulted in a gain in QALYs was 13%. This held true for any prevalence of IA between 1% and 25%. Risk of rupture had a greater impact on outcome than prevalence. Halving the risk of intervention (either surgery or coiling) reduced the threshold 5-year risk of rupture at which screening resulted in gain of QALYs to 6%. Thus, noninvasive screening for IA is beneficial only in populations with a higher expected prevalence and higher risk of rupture.¹⁹⁰

Table 4. Five-Year Cumulative Rupture Rates (%) According to Size and Location of Unruptured Aneurysm*

	<7 mm		7–12 mm	13–24 mm	≥25 mm
	Group 1	Group 2			
Cavernous carotid artery (n=210)	0	0	0	3.0	6.4
AC/MC/IC (n=1037)	0	1.5	2.6	14.5	40
Post-P comm (n=445)	2.5	3.4	14.5	18.4	50

AC indicates anterior communicating or anterior cerebral artery; IC, internal carotid artery (not cavernous carotid artery); MC, middle cerebral artery; and Post-P comm, vertebrobasilar, posterior cerebral arterial system, or the posterior communicating artery.

*Reprinted from *The Lancet*,⁴ with permission from Elsevier. Copyright © 2003, Elsevier Ltd.

Screening: Recommendations

1. **Patients with ≥2 family members with IA or SAH should be offered aneurysmal screening by CTA or MRA. Risk factors that predict a particularly high risk of aneurysm occurrence in such families include history of hypertension, smoking, and female sex (Class I; Level of Evidence B).**
2. **Patients with a history of autosomal dominant polycystic kidney disease, particularly those with a family history of IA, should be offered screening by CTA or MRA (Class I; Level of Evidence B), and it is reasonable to offer CTA or MRA to patients with coarctation of the aorta and patients with microcephalic osteodysplastic primordial dwarfism (Class IIa; Level of Evidence B).**

Natural History of UIAs

A large number of studies of varying quality have evaluated rupture risk of UIAs. The ISUIA and the Unruptured Cerebral Aneurysm Study Japan (UCAS Japan) study are the most carefully designed large studies.^{4,5,34} In its first phase, ISUIA obtained retrospective natural history data on 1449 patients with 1937 unruptured aneurysms seen at 63 centers in North America and Europe.³⁴ Among patients with no history of SAH, the rupture risk was 0.05% per year for aneurysms <10 mm in diameter and ≈1% per year for larger aneurysms; aneurysm size (relative risk, [RR] 11.6 for 10–24 mm and 59 for >25 mm compared with <10 mm) and location in the posterior circulation (RR 13.8 for basilar tip and RR 13.6 for vertebrobasilar or posterior cerebral versus anterior circulation) or posterior communicating artery (RR, 8.0) were predictors of rupture risk in this group. Among those with a history of SAH from a different aneurysm, the rupture risk was 0.5% per year for those <10 mm and ≈0.7% per year for larger aneurysms; basilar tip aneurysms (RR, 5.1) and older age were predictors of rupture risk in this group.

Phase 2 of the ISUIA included a prospective natural history study of 1692 patients with 2686 unruptured aneurysms followed up for a mean of 4.1 years at 61 centers in North America and Europe.⁴ After the results were analyzed, aneurysm rupture rates were stratified by group (with a new cut point of <7 mm to define the smallest group of aneurysms), history of SAH from a different aneurysm, and location (cavernous carotid, anterior circulation except posterior communicating artery, or posterior circulation plus posterior communicating

artery). For patients with no history of SAH and aneurysms <7 mm in diameter, there were no ruptures among aneurysms in the anterior circulation, and the risk was 2.5% per year in those with aneurysms in the posterior circulation or posterior communicating artery (Table 4). Among those with a history of SAH and an aneurysm <7 mm, the risk of rupture was 1.5% per year in the anterior circulation and 3.4% per year in the posterior circulation. History of SAH was not a predictor of rupture for aneurysms >7 mm, and rupture risks were higher with larger aneurysms.⁴

The natural history data from the ISUIA have been criticized for several reasons. First, the number of patients in certain categories is small, so some of the estimates of rupture risk in the strata shown in Table 4 are imprecise. Second, although some predictors of rupture were confirmed in the second phase of the study, some were not. For example, a smaller cut point for size (<7 versus <10 mm) was defined in the second phase of ISUIA, identifying a group at extremely low risk of rupture. When cut points are optimized, findings are less likely to be validated in independent studies. Third, although the proportion of patients undergoing an interventional procedure varied tremendously from center to center in this nonrandomized study, in general, the surgeon or radiologist evaluating the patient would only have conservatively managed those patients who were deemed to be at low risk of rupture, and therefore, selection biases could change the risk profile of included participants. Fourth, differential follow-up and detection biases could alter apparent rates, and some outcome events may have been missed. In spite of these and other limitations, ISUIA remains one of the most rigorous and largest studies of the natural history of UIAs that includes patients of European descent.

Many other studies of the natural history of unruptured aneurysms have been published. The most recent meta-analysis of these included 19 studies with 6556 unruptured aneurysms and 4705 patients³⁹; >70% of the patient-years of observation in the meta-analysis were contributed by the ISUIA. Together, these 19 studies published between 1966 and 2005 varied dramatically in size and duration of follow-up, and they included both prospective and retrospective designs. Overall, the annual rupture rates were 1.2% for studies with mean follow-up <5 years, 0.6% for those with mean follow-up of 5 to 10 years, and 1.3% for those with mean follow-up >10 years. Several risk factors for rupture were identified, including age >60 years (RR, 2.0; 95% CI, 1.1–3.7), female sex (RR, 1.6; 95% CI, 1.1–2.4), Japanese or Finish descent (RR, 3.4;

95% CI, 2.6–4.4), symptomatic aneurysm (RR, 4.4; 95% CI, 2.8–6.8), diameter >5 mm (RR, 2.3; 95% CI, 1.0–5.2), and posterior circulation aneurysm (RR, 2.5; 95% CI, 1.6–4.1). The overall annual rupture rate for aneurysms <7 mm was 0.4%. Published data were limited, so the meta-analysis could not evaluate more than 1 risk factor at a time.

Several studies of natural history have been published since this meta-analysis. The large, prospective UCAS Japan study included 6697 patients followed up for a mean of 1.7 years and found an annual rupture rate of 0.95%.⁵ The annual risk of rupture varied dramatically by size, ranging from 0.36% for 3- to 4-mm aneurysms, 0.50% for 5- to 6-mm aneurysms, 1.69% for 7- to 9-mm aneurysms, 4.37% for 10- to 24-mm aneurysms, and 33.4% for aneurysms ≥25 mm. Location in the anterior or posterior communicating arteries (hazard ratio 1.90 and 2.02, respectively, versus location in the middle cerebral artery) and aneurysms with daughter sacs (hazard ratio, 1.63) were also at greater risk of rupture. A daughter sac was defined as an irregular protrusion from the aneurysmal wall. Family history and history of SAH from a different aneurysm were not identified as risk factors for rupture. The authors noted that rates of rupture in Japan were higher, and results might not be generalizable to other populations.

Another recent small prospective study from Japan followed 374 patients with 448 unruptured aneurysms <5 mm in diameter for a mean of 41 months.¹⁹¹ The overall risk of rupture was 0.5% per year, with younger age, larger aneurysm size, hypertension, and aneurysm multiplicity being predictors of rupture. All ruptures occurred in those with anterior circulation aneurysms, and most occurred in those without a history of SAH or family history, thus failing to confirm the extremely low risk of rupture in these groups in ISUIA. However, the patients were of Japanese descent, and it is unclear whether the data can be validly compared with studies evaluating patients of principally European descent. A second small study from Japan included 419 patients with 529 unruptured aneurysms followed up for a mean of 2.5 years and found a rupture rate of 1.4% per year.¹⁹² Larger aneurysm size, posterior circulation location, and a history of SAH were all independent risk factors for rupture. The rupture rate of those with no history of SAH and an aneurysm <5 mm in diameter was 0.6% per year. However, 5 of the 19 ruptures occurred in patients with <7-mm diameter anterior circulation aneurysms and no history of SAH; the annualized rupture risk in this group was not reported but was higher than the comparable group in ISUIA. It is unclear whether the failure to confirm the extremely low risk of rupture in this subgroup in these 3 Japanese studies reflects differences in aneurysm characteristics and risk of SAH in people of Japanese descent or whether it represents a failure of validation of ISUIA more broadly. A limitation of the Japanese cohort studies and ISUIA is the relatively short mean follow-up; all 3 studies have a mean follow-up of ≤4.1 years.

A prospective study of 319 aneurysms <7 mm in diameter in US patients with no history of SAH followed patients for a mean of 2.4 years with serial CTA and MRA of intracranial vessels.¹¹¹ They did not report any aneurysm ruptures during follow-up, confirming the low risk in this subgroup of

unruptured aneurysms identified from ISUIA. However, aneurysm growth of at least 0.75 mm was observed at an annual rate of 5.4%. Given that the threshold for growth was the resolution of imaging, the authors acknowledged that some assessments of growth may have been false-positive results.

A prospective study of patients enrolled in the large FIA study followed 113 patients with 148 unruptured aneurysms, nearly all <7 mm and none with a history of SAH, for a mean of 1.5 years.¹⁸⁷ Among these patients, there were 2 SAHs in patients with 3- and 5-mm anterior communicating artery aneurysms, respectively, for a rupture rate of 1.2% per year (95% CI, 0.14%–4.3%), 17-fold higher than that seen in patients with comparably sized and positioned aneurysms in ISUIA. The small number of ruptures and large CI lead to ongoing uncertainty regarding the relative rupture risks in patients with familial aneurysm.

Although ISUIA provides evidence for stratifying that risk by aneurysm size and location at the time of discovery, it cannot address the risk of aneurysms that may change in size over time, because repeat imaging was not required. Multiple studies have reported an increased risk of spontaneous hemorrhage from aneurysms with documented growth over time.^{25,95} A recently published prospective observational study reported a dramatically increased risk of spontaneous hemorrhage from aneurysms with documented growth on serial magnetic resonance angiography.¹⁹³ The authors of this study evaluated 1002 patients with 1325 aneurysms followed up by routine serial MRA which identified 18 patients with interval aneurysm growth. They reported an annual hemorrhage rate of 18.5% for those patients with documented growth and estimated that 90.3% of growing aneurysms would be detected before hemorrhage with screening performed at 6-month intervals. A second, smaller study of 258 aneurysms showed 18% of aneurysms grew. When compared with the nongrowing group, the per year rate of hemorrhage was 2.4% in the growing aneurysm group versus 0.2% in the nongrowing group. As with the other study, some growing aneurysms were treated before rupture, so the rate could be higher.⁹⁸ Therefore, routine screening by noninvasive vascular imaging techniques to detect aneurysm growth is probably indicated, and treatment of aneurysms with documented growth may be reasonable.

Patients with aneurysms in the setting of autosomal dominant polycystic kidney disease do not appear to be at increased risk of aneurysm rupture, but experience is limited.¹⁹⁴ Several other recent studies have reported rupture rates and their risk factors but have had methodological limitations that reduced the reliability of their conclusions.

Natural History: Recommendations

1. Prior history of aSAH may be considered to be an independent risk factor for future hemorrhage secondary to a different small unruptured aneurysm (*Class IIb; Level of Evidence B*).
2. Patients with aneurysms with documented enlargement during follow-up should be offered treatment in the absence of prohibitive comorbidities (*Class I; Level of Evidence B*).

3. Treatment of UIAs in patients with a family history of IA is reasonable even in aneurysms at smaller sizes than spontaneously occurring IAs (Class IIa; Level of Evidence B).

Surgical Clipping

Outcomes

Surgical treatment for UIAs comprises primarily direct surgical clipping, although other options such as occlusion with bypass and wrapping have also been used in treatment of more complex aneurysms. The majority of studies examining treatment outcomes related to UIA surgery have been single-center retrospective case series. These reports frequently lack features of high-quality studies, such as independent assessment of outcome, adequate specification of patient and lesion characteristics, reporting of occlusion rates and methods of determination, periprocedural complication data, and standardized time frame of follow-up.

Despite these shortcomings, several meta-analyses have analyzed data regarding outcome of surgery for UIAs. The first¹⁹⁵ included patients with only asymptomatic UIAs, totaling 733 patients from 28 studies published between 1966 and 1993 and reported a 1% mortality and 4.1% morbidity rate. Morbidity was defined as permanent significant deficit or was based on individual study authors' assessment without defined criteria and at variable follow-up time points. Subsequently, Raaymakers et al¹⁹⁶ analyzed 2460 patients from 61 studies published between 1966 and 1996 and reported 2.6% mortality and 10.9% morbidity (defined as all permanent deficit not present before operation and all outcomes other than the best category). Of note, the generally poor quality of studies was reflected by the fact that only half of the studies used clearly defined outcome measures, and fewer than half specified the time point of outcome determination, which itself varied from evaluation at discharge to a median of 24 weeks. More recently, Kotowski et al¹⁹⁷ reported on 9845 patients from 60 studies published in a more contemporary time frame spanning 1990 to 2011. They found an overall mortality rate of 1.7% and morbidity rate of 5%, for a total unfavorable outcome estimate of 6.7% up to 1 year after surgery. Morbidity was defined as nonindependence (modified Rankin Scale [mRS] score >2, Glasgow Outcome Scale score <4) or "fair"/"poor" on qualitative scores. It is notable that the majority of included studies (85%) were rated as poor quality based on STROBE (Strengthening the Reporting of Observational Studies in Epidemiology)¹⁹⁸ reporting criteria.

The combined estimates of morbidity show the most variability among these meta-analyses, potentially reflecting the definition of morbidity used and the case mix of aneurysms and patients represented in the studies included. For example, the analysis by King et al¹⁹⁵ included only asymptomatic UIA and a predominance of small and anterior circulation lesions, whereas these lower-risk features represented a smaller proportion in the other reviews.^{196,197} The highest morbidity, exceeding 10%, was reported in the meta-analysis by Raaymakers et al¹⁹⁶; however, 112 of 268 patients categorized as experiencing morbidity were independent in daily life despite signs

or symptoms and likely would not have met the definition of unfavorable outcome used in the other meta-analyses. With variability in reporting and a lack of high quality of the studies, these meta-analyses serve best to help identify potential risk factors rather than to definitively set the benchmark for surgical outcomes or conclusively identify predictors.

Regional or population-based data extracted from administrative data sets, such as the National (Nationwide) Inpatient Sample (NIS), have also been used as an estimation of "real-world" UIA treatment outcomes. These retrospective database studies have reported mortality from surgical treatment ranging from 0.7% to 3.5% and morbidity ranging from 13.5% to 27.6%.^{199–208} Because of the lack of specific outcome information available in such databases, morbidity has generally been defined as discharge status to a facility other than home (including rehabilitation facilities). No longer-term outcome data past the time of discharge can be assessed, and assumptions that discharge status is a reliable surrogate for longer-term outcome are not well validated. Furthermore, because of a lack of information within these databases related to specific aneurysm features such as location and size, a robust determination or adjustment of risk factors for poor outcomes cannot generally be performed. Thus, despite large sample sizes, the inherent limitations to hospital-based administrative data sets, including their retrospective nature and potential for miscoding of complications, limit interpretation of outcomes. A review by Lee et al²⁰⁹ performed an aggregate analysis of 30 studies, combining case series and database studies to arrive at an overall unfavorable outcome of 17.8% with surgical clipping of UIAs; however, the heterogeneity of the study designs and the lack of uniformity in the definition of morbidity limit the utility of this analysis.

Prospective registries that include patient- and aneurysm-specific parameters, as well as specified outcome determinations at predefined intervals after discharge, are likely to offer more reliable data. The prospective arm of the ISUIA followed 1917 patients after clipping for UIA and reported an overall mortality of 2.3%.⁴ One-year morbidity, defined as mRS score >2 or impaired cognition (measured by Mini-Mental State Examination or telephone survey of cognitive status) was present in 12.1% at 1 year after treatment. Importantly, several risk factors strongly predictive of outcome were evident, as outlined in the sections below.

Beyond morbidity related to functional outcomes, the potential cognitive impact of surgical treatment for UIA has also been a topic of interest. As noted, ISUIA included cognition in its determination of postoperative morbidity and found that impaired cognition alone accounted for 55% of the overall reported morbidity. Subsequent small, prospective, single-center series examining cognitive function before and after clipping have not borne out the same conclusion, demonstrating no cognitive dysfunction on Mini-Mental State Examination at 1 month after surgery.^{210,211} There have been contradictory results in series that used more comprehensive neuropsychological batteries.^{210,212,213} Nonetheless, it appears that standard outcomes instruments such as the mRS and the Glasgow Outcome Scale do not correlate with results of the Mini-Mental State Examination after aneurysm surgery,²¹⁴ and

thus, the incorporation of cognitive assessment of patients can provide additional useful outcomes information.

A number of small series have also examined quality of life using health outcome scales such as the Short Form-36 and the Hospital Anxiety and Depression Scale (HADS). These have generally indicated that there may be a short-term negative impact on quality of life but largely with full recovery to baseline or to reference population values by 1 to 3 years after treatment.^{215,216}

In terms of specific complications after UIA surgery, the rate of seizure after craniotomy for UIA is poorly defined. Analyses of administrative data sets have reported a very low incidence of 0.1% for status epilepticus¹⁹⁹ and as high as 9.2% when reporting any seizures,²¹⁷ although these studies do not account for preexisting seizures or use of anticonvulsant drugs. For example, in the ISUIA cohort, 4.4% of patients with surgically treated UIAs had a preexisting convulsive disorder.⁴ For postoperative stroke, administrative database studies have reported ischemic complications in 6.7% to 10%^{199,207} and hemorrhagic complications in 2.4% to 4.1%^{199,207} of patients undergoing UIA clipping. In ISUIA, the incidence of cerebral infarction was reported to be 11%, with a 4% incidence of intracranial hemorrhage. One small prospective series of 51 aneurysms (UIAs and RIAs) using diffusion-weighted imaging MRI before and after clipping found silent ischemia in 9.8% but only an 2% incidence of symptomatic stroke despite complex aneurysms by size and location.²¹⁸

Efficacy and Durability

Although surgical clipping is believed to provide definitive and long-term treatment of aneurysms, data on efficacy of treatment in terms of complete obliteration have not been reported consistently. In addition, the mode of imaging and timing of postoperative examination may not be clear. In the meta-analysis by Raaymakers et al,¹⁹⁶ only 10 of 61 studies reported postoperative angiography to verify the clipping, and results were only available in 5 studies that demonstrated 11 incomplete clippings among 158 patients, for a 93% complete obliteration rate. Kotowski et al¹⁹⁷ similarly found that information on occlusion rates was missing for the majority of studies examined, but based on 1969 postoperative examinations, 91.8% were completely occluded, 3.9% had neck remnants, and 4.3% were incompletely occluded.

There are limited data available regarding the long-term risk of intracranial hemorrhage after UIA clipping. Kotowski et al¹⁹⁷ found data available in only 9 of 60 publications, representing 773 patients; 3 hemorrhages (0.38%) were reported during an average 1.2-year follow-up. The retrospective studies that used large-scale administrative databases provided no data on the success of the intervention in regard to aneurysm obliteration or risk of subsequent hemorrhage. Single-center long-term follow-up studies have typically included both UIA and RIAs. In a study that evaluated the long-term efficacy of clip ligation in 147 ruptured and unruptured aneurysms,²¹⁹ immediate postoperative angiography confirmed complete occlusion in 135 aneurysms (91.8%) and a residual neck in 12 (8.2%). The residual necks were defined as “dog ear” versus “broad-based.” Of the completely occluded aneurysms,

angiography at 3 years demonstrated 2 recurrent aneurysms (1.5%) without new SAH. Of the 12 aneurysms with a known residual neck, 2 of the 8 dog-ear residua enlarged, compared with 3 of the 4 broad-based. These data confirm both the immediate and long-term efficacy of clip obliteration and also highlight the need for continued follow-up in patients with known residua.

Another study of 140 aneurysms followed up for a mean of 9.3 years reported a regrowth rate of 0.26% per year for completely clipped aneurysms and a 0.89% per year risk of de novo aneurysm formation.²²⁰ Similarly, the incidence of regrowth was higher in incompletely clipped lesions (7.1% versus 2.4%). In a previous study, the same authors noted a cumulative risk of SAH from de novo and recurrent aneurysms of 1.4% in 10 years and 12.4% in 20 years.²²¹ A recent study reported a lower incidence of hemorrhage, with only 2 patients (0.2%) having SAH and a total of 9 patients (0.9%) having recurrent aneurysms among 1016 aneurysms clipped over a 15-year period; however, follow-up was not routinely performed in this series, and thus, the true incidence of recurrence is unclear.²²²

Given the inclusion of both UIA and RIA, these results may not be generalizable to UIA alone. Although overall reported rates of recurrence appear to be very low, the limited available data suggest that recurrence rates may increase with incompletely clipped aneurysms and longer lengths of follow-up. Along with the reported risk of de novo aneurysms, these findings warrant consideration for repeat imaging within a 5- to 10-year time frame, and even up to 20 years in younger patients.

Risk Factors: Lesion Specific

The size and location of aneurysms have been most consistently associated with surgical risk.^{196,197} In the prospective ISUIA cohort, aneurysm size >12 mm was a significant predictor of poor outcome, with an RR of 2.6.⁴ In the recent meta-analysis by Kotowski et al,¹⁹⁷ unfavorable outcome (including death) was noted in 4.0%, 12.1%, and 26.5% of patients with small (<10 mm), large (10–24 mm), and giant (≥25 mm) aneurysms respectively, with an RR of 3.5 for aneurysms >10 mm. Increasing aneurysm size conferred an OR of 1.13 per 1-mm increase in a prospective cohort of 603 UIAs.²²³ The same cohort study also noted an OR of 2.9 for anterior versus posterior circulation aneurysms. Location (anterior versus posterior) was associated with an RR of 4.1 in the meta-analysis by Kotowski et al,¹⁹⁷ and in the ISUIA cohort, posterior circulation location was an independent predictor of poor outcome, with an RR of 1.6.

The interaction of size and location appears to be particularly pertinent. In the meta-analysis by Raaymakers et al,¹⁹⁶ non-giant (<25 mm) anterior circulation aneurysms carried the lowest mortality estimate of 0.8% (1.9% morbidity) compared with non-giant posterior circulation aneurysms at 3% (12.9% morbidity), giant anterior circulation aneurysms at 7.4% (26.9% morbidity), and giant posterior circulation aneurysms at 9.6% (37.9% morbidity). Giant aneurysms can pose a dilemma, given their higher surgical risk yet poor natural history. Overall favorable results can be achieved in younger

patients²²⁴ and for all patients with regard to mortality, but at a cost in terms of morbidity: In a series of 39 patients with giant UIAs, Nakase et al²²⁵ noted that mortality was markedly reduced by surgical intervention (4% versus 31%), but morbidity affected 19% compared with 8% of untreated patients.

Other aneurysm features, such as atheroma/calcification, thrombus, nonsaccular morphology, and multiplicity, pose additional challenges and have been reported to adversely affect surgical outcome in small case series. Atherosclerosis and calcifications have typically been noted in single-center retrospective series to be associated with worse outcomes,^{226–228} although 1 study of 51 aneurysms did not identify extent of aneurysmal atherosclerotic plaques to be a risk for postoperative stroke.²¹⁸ Calcifications appear to be correlated with aneurysm size,²²⁶ and atherosclerotic burden is typically higher in elderly patients. Although it is generally presumed that worse outcomes with age reflect increased medical comorbidities, an increased incidence of atherosclerosis may also be a factor. Presence of intra-aneurysmal thrombus has also been a factor associated with increased risk of stroke.²¹⁸ Multiple UIAs have been reported to be associated with worse outcomes in some^{227,229} but not all²³⁰ studies.

Risk Factors: Patient Specific

Age has emerged as an important risk factor influencing outcomes after surgical clipping. In ISUIA, multivariate analysis demonstrated age as a powerful predictor of poor surgical outcome, with an RR of 2.4 for age ≥ 50 years.⁴ In 1 large prospective series of >600 UIAs, age was associated with an OR of 1.03 for morbidity and mortality per year of increased age.²²³ Administrative database studies have also identified age as a factor that affects outcome,^{199,200,231} with mortality ranging from as low as 0.6% to 0.9% in patients <50 years old and averaging $\approx 2\%$ thereafter, and as high as 21.4% in those ≥ 80 years old.^{199,231} The published meta-analyses of case series have not been able to identify an age effect, but this likely reflects insufficient power given that information regarding outcome with respect to age was reported in the minority of patients in the included studies.^{195–197} Presentation of patients with symptoms other than rupture, as opposed to those with incidentally found UIAs, appears to carry a higher surgical risk,⁴ particularly for those presenting with ischemic symptoms (whether directly attributable to the aneurysm or otherwise).^{232,233} In the ISUIA cohort, a history of prior ischemic cerebrovascular disease was associated with a significantly higher risk for adverse events after clipping, at an RR of 1.9.⁴ This could relate to ischemia serving as a marker for atheroma or intraluminal thrombus, features that can increase surgical risk as noted above. Patients presenting with symptoms of mass effect from compression of cranial nerves or surrounding brain structures can be treated effectively with surgical clipping/decompression for relief of symptoms.¹²³ Higher overall surgical risks in this setting may be primarily a reflection of aneurysm size, given the tendency of lesions presenting in this manner to be large.^{230,231} A new deficit related to the finding of an aneurysm, such as new-onset oculomotor nerve palsy, is considered an urgent indication for treatment, because it implies growth of the aneurysm with attendant risk

of hemorrhage; prognosis for recovery of deficit in this setting is high with early surgical management.¹²⁸

Direct evidence for the presumed negative impact of general medical comorbidities in surgical outcome is difficult to document. Published studies have the selection bias of including patients already chosen for intervention, with the likelihood that the status of medical comorbidities contributed to that decision making. However, it is reasonable to presume that medical comorbidities negatively influence outcomes in UIA clipping, as in any other surgery.

Surgical Experience and Hospital Volume

A number of studies have demonstrated a strong volume-outcome relationship related to outcomes after aneurysm surgery for both UIA and RIA in the United States.^{202,234,235} For UIAs specifically, 3498 patients with UIA treated at 463 hospitals by 585 surgeons in the NIS were assessed.²⁰¹ Hospitals with >20 cases compared with those with <4 cases per year had better discharge disposition (84.4% versus 76.2% discharged to home) and lower mortality (1.6% versus 2.2%).²⁰¹ In a study of 2200 admissions for UIA from the New York State database and for clipped aneurysms found lower morbidity (OR, 0.85) and mortality (OR, 0.94) for each additional 10 cases per year in total procedural volume.²⁰² Surgeon experience, in addition to overall hospital volume, may also be pertinent; individual surgeon volume was also a strong predictor of better functional outcome in a review of 449 aneurysms treated by 10 different surgeons at the same institution.²³⁶

Other Considerations: Intraoperative Factors/Technical Advances

Surgical technique in aneurysm surgery continues to evolve, in addition to advances in intraoperative tools to maximize the safety of surgical clipping. The use of intraoperative angiography to verify complete aneurysm obliteration at the time of surgery and verify the patency of branch vessels has become more widespread, especially at tertiary centers.^{237–241} Case series have demonstrated unexpected findings (such as vessel occlusions or residual aneurysms) in $\approx 7\%$ to 12% of cases,^{237,239,242} leading to alterations in clipping and thus providing an indirect validation of its value. Because of the time, expertise, and expense associated with intraoperative angiography, other tools have also emerged that can provide more immediate feedback related particularly to vessel compromise. Both intraoperative Doppler sonography²⁴³ and ultrasonic flowmetry²⁴⁴ have demonstrated utility in assessing the patency of vessel branches associated with the aneurysm after clipping. The introduction of intravenous indocyanine green video angiography has been a further advance, providing the ability to quickly visualize the patency of perforators and larger branch vessels associated with the aneurysm. This technique uses a rapid intravenous injection of dye, which is then visualized through the operating microscope.^{245,246} Each modality has strengths and limitations, and although there are no prospective controlled studies examining the benefits of these intraoperative adjuncts, the prevailing belief is that the use of these tools, alone or in combination, is beneficial in reducing surgical risk and optimizing successful aneurysm

obliteration. Physiological brain monitoring with intraoperative somatosensory or motor evoked potentials to predict adverse ischemic sequelae during surgery has also demonstrated some value.^{247,248} The use of judicious temporary clipping of vessels to facilitate aneurysm dissection and clipping, or of adenosine for temporary cardiac arrest, especially in large aneurysms, offers additional techniques to enhance surgical safety.^{249,250}

Neuroprotection with intraoperative hypothermia has been assessed as a strategy to reduce the risk of surgical clipping. A pilot randomized study of intraoperative hypothermia demonstrated no outcome advantage in patients with UIAs.²⁵¹ Subsequent randomized trials have also failed to demonstrate an overall benefit for RIAs.²⁵² However, both hypothermia and intraoperative burst suppression to reduce metabolic demand are still used selectively by neurosurgeons and neuroanesthesiologists for cerebral protection during aneurysm surgery, especially in the setting of anticipated temporary vessel occlusion.²⁵³

Surgical technique has also evolved, with increased emphasis on avoiding the use of fixed brain retractors during surgery.^{254,255} Additionally, smaller, less invasive surgical exposures are becoming more commonplace, including “key-hole” approaches, through small calvarial openings and incisions that minimize soft tissue disruption and brain manipulation/retraction.²⁵⁶ Interestingly, in the larger reported meta-analyses, unfavorable outcomes were found to decrease in more recent publication years.^{196,197} Even in the large-scale database studies, unfavorable outcomes, particularly mortality, are generally lower in the more contemporary studies,²⁰⁷ which could be construed as reflecting improvements in surgical paradigms, although other factors such as centralization of care or changes in patient selection may also be invoked.

Surgical Clipping: Recommendations

1. Several factors, including patient age and aneurysm location and size, should be taken into account when considering surgical clipping as the mode of treatment for a UIA (*Class I; Level of Evidence B*).
2. Imaging after surgical intervention, to document aneurysm obliteration, is recommended given the differential risk of growth and hemorrhage for completely versus incompletely obliterated aneurysms (*Class I; Level of Evidence B*).
3. Long-term follow-up imaging may be considered after surgical clipping given the combined risk of aneurysm recurrence and de novo aneurysm formation. Long-term follow-up may be particularly important for those aneurysms that are incompletely obliterated during initial treatment (*Class IIb; Level of Evidence B*).
4. Surgical treatment of UIA is recommended to be performed at higher-volume centers (eg, performing >20 cases annually) (*Class I; Level of Evidence B*).
5. The use of specialized intraoperative tools and techniques for avoiding vessel compromise or residual aneurysms may be considered to reduce the adverse outcomes seen with operative management of UIAs (*Class IIb; Level of Evidence C*).

Endovascular Treatment

In 1995, the US Food and Drug Administration approved the Guglielmi detachable coil for the treatment of nonsurgical cerebral aneurysms based on a study of 150 patients, 67 of whom had unruptured aneurysms.²⁵⁷ Over the next 20 years, various permutations of this seminal adaptation of the endoluminal aneurysm occlusion coil have been applied to increasing numbers of ruptured and unruptured cerebral aneurysms worldwide, making endovascular aneurysm repair the preferred treatment in many medical centers.

During the 1990s, some authors noted improving endovascular results while surgical complications were increasing despite the practice of reserving endovascular treatment for higher-risk surgical patients.^{4,206,258} Event rates declined in endovascular coil series from 1990 to 2000, but differences in study design made direct comparison difficult.²⁰⁹ This occurred despite the fact that most aneurysm patients were prescreened for surgical clipping during the 1990s before referral for endovascular treatment.⁴

Since the publication of ISAT, which showed better outcomes for endovascular coil occlusion of ruptured aneurysms than for surgical clipping in selected cases,⁸ there has been a steady increase in the relative proportion of patients with ruptured and unruptured aneurysms undergoing endovascular procedures. From 1998 to 2003, the proportion of unruptured aneurysms alone undergoing endovascular treatment increased from 11% to 43%.²⁵⁹ Increased use of endovascular techniques, increased awareness of high-risk surgical indications, and the sensitivity of modern brain imaging, including CT and MRI, to identify unruptured aneurysms resulted in more endovascular procedures.^{48,52,55,260} Increasing proportions of patients undergoing endovascular procedures have been identified in developed countries.^{199,208,231,261} Still, most reports on the endovascular treatment of unruptured aneurysms remain small, single-center series.^{262–267} Technical failure rates range between 0% and 10%.^{268–270} Complications occur in 5% to 10% of cases.^{265,271–274} Meanwhile, researchers identified significant potential for bias in the literature on unruptured aneurysm.^{209,275}

The prospective ISUIA aimed not only to evaluate the natural history of unruptured aneurysms but also to measure the risk of treatment.⁴ Among treated patients, 1917 patients underwent craniotomy and surgical clipping, and 451 underwent coil occlusion of their aneurysms. The combined surgical morbidity and mortality at 1 year was 10.1% for patients without prior SAH and 12.6% for patients with prior SAH versus 7.1% and 9.8%, respectively, for the endovascular group. Endovascular treatment in patients older than 50 years appeared safer than surgical clipping, but the difference was not statistically significant. Because the endovascular group was relatively small, wide CIs and variance limited comparability.⁴ Nevertheless, until recently, ISUIA remained among the best data available on the natural history of untreated aneurysms in relation to treatment outcomes.

Two publications analyzed endovascular aneurysm series in aggregate or through meta-analysis. Lanterna et al²⁷⁶ performed a systematic review of English, French, and Italian literature from 1990 to 2002 and identified 1379 patients,

including a case fatality rate of 0.6%, permanent morbidity rate of 7%, and hemorrhage rate of 0.9%. Procedural morbidity decreased from 8.6% to 4.5% in studies after 1995, which suggests improvement in operator skills and experience, as well as improved devices and technology. Naggara et al²⁷⁷ performed a systematic review of the medical literature on endovascular treatment of unruptured aneurysms from 2003 to 2008. Seventy-one publications were included in this review, which identified procedural complications in 4.8% of cases, satisfactory aneurysm occlusion in 86.1%, and aneurysm regrowth or recurrence in 24.4% over 0.4 to 3.2 years of surveillance, as well as retreatment in these cases in 9.1%. The annual risk of bleeding in treated patients was 0.2%, although clinical follow-up was often brief, only 6 months in 76.7% of reported cases. The authors concluded that endovascular aneurysm coil occlusion appears to be relatively safe, although the efficacy of these procedures had not been rigorously documented.²⁷⁷

Because of perceived limitations in the available data on unruptured aneurysm occlusion, Pierot et al²⁷⁸ performed the Analysis of Treatment by Endovascular Approach of Non-ruptured Aneurysms (ATENA) to determine risk and clinical outcomes of endovascular treatment. In this study sponsored by the French Society of Neuroradiology, 649 patients with 1100 unruptured aneurysms ≤ 15 mm were prospectively and consecutively treated by a multidisciplinary team of physicians at 27 French and Canadian neurointerventional centers. Aneurysms were discovered incidentally in 65% of patients, after rupture from another aneurysm in 20%, because of neurological symptoms in 13%, and during screening for familial disease in 2.5%. A balloon-remodeling technique was used in 37%, stent-assisted coil occlusion was used in 7.8%, and 98.4% of aneurysms were treated with coils. Aneurysm occlusion was deemed complete by the treating physician in 59%, with neck remnant in 21.7% and an aneurysm remnant in 19.3%. Systemic anticoagulation was used in all cases during treatment, and antithrombotic medications were used during or after treatment in up to 57% of patients. Inability to treat the aneurysm occurred in 4.3%, most commonly at the middle cerebral bifurcation, and failure was more common in smaller (1–6 mm) than larger (7–15 mm) aneurysms. Treatment-related adverse events occurred in 15.4%, including thromboembolic events. Aneurysm rupture during the procedure occurred in 2.6%, which was asymptomatic in 50% of such cases but fatal in 3 patients (16.7% of occurrences.). Neurological complications predominantly caused by thromboembolic complications occurred in 5.4%, were permanent in 2.6%, and led to death in 0.9%. For patients who were neurologically normal before treatment (mRS=0), 96% continued to have an mRS score of 0, 3.4% had an mRS of 1, 0.4% had an mRS of 2, and 0.2% had an mRS of 3. Complications were higher in patients >60 years of age. The authors concluded that there was a high rate of procedural success and a low rate of permanent complications, seemingly better than reported outcomes of surgical clipping.²⁷⁸

The durability of aneurysm occlusion when endovascular coils are used remains problematic, and a number of measures have been applied in an effort to improve this issue. In ISAT,

the risk of aneurysm recanalization after endovascular occlusion was associated with recurrent hemorrhage, although that risk was small, with 10 episodes after 1 year in 1073 patients (8447 person-years).²⁷⁹ The likelihood of aneurysm recanalization appears greater in previously ruptured aneurysms than in unruptured aneurysms²⁸⁰; however, if recanalization of an unruptured aneurysm occurs, then the benefit of endovascular coil occlusion may be called into question, which has led some authors to suggest preferential clipping of anterior circulation aneurysms, especially in patients <40 years old, when possible.^{279,281,282} For unruptured aneurysms, recanalization of bifurcation aneurysms after endovascular coil occlusion remains a problem, especially at the middle cerebral bifurcation and at the carotid and basilar artery termini, although recanalization can also occur with clipped aneurysms at lower rates.^{99,220,283} Attempts to improve the durability of occlusion by adding coatings such as polyglycolic acid, polyglycolic-lactic acid, and hydrogel (acrylamide:sodium acrylate gel) to platinum coils in an effort to augment aneurysm healing and fibrosis have not proved beneficial despite increased cost.^{284–291} Other studies have also suggested that the risk of permanent disability or death attributable to treatment of aneurysm recurrence after prior endovascular coiling is quite low, which supports the practice of regular surveillance and prophylactic treatment of recurrences.²⁹²

Adjunctive methods such as balloon remodeling and stent-assisted occlusion are commonly reported, although the potential added value to accomplish superior aneurysm occlusion is not clearly defined. It is generally recognized that these techniques allow for the treatment of more aneurysms and with higher packing density than was possible with endosaccular coil occlusion alone.²⁹³ In the ATENA study, balloon remodeling was commonly used and resulted in no excess morbidity.²⁷⁸ However, other authors have identified increased rates of cerebral ischemia when using a balloon-remodeling technique, especially when assessed with advanced imaging techniques such as MRI with diffusion.^{264,294} Endovascular stents represent a departure from the endosaccular occlusion paradigm, because prosthetic material now lies in the normal vessel adjacent to the aneurysm. A number of single-center retrospective studies have reported increased rates of progressive aneurysm occlusion with the use of stents.^{295–298} However, stents were allowed in the Matrix and Platinum Science (MAPS)²⁹⁹ and Hydrocoil Endovascular Aneurysm Occlusion and Packing (HELPS)²⁸⁵ trials, but not in the Cerecyte Coil Trial,²⁸⁴ and no greater rates of aneurysm occlusion were observed in the studies in which stents were used. The morbidity and mortality associated with the adjunctive use of balloon remodeling or endovascular stents have not been systematically assessed.

Some single-center studies are available regarding the use of stent-assisted endovascular therapy for aneurysm morphology and locations that are otherwise highly risky or impossible to treat, and in these cases, chronic double-antiplatelet therapy is advocated. However, to date, the efficacy of such treatment remains unproven.

From a cost-effectiveness perspective, early analysis suggested that coil embolization of cerebral aneurysm was efficacious. Kallmes et al³⁰⁰ found that the cost-effectiveness of

endovascular aneurysm occlusion depended primarily on the natural history of untreated cerebral aneurysms, and less so the morbidity of treatment and patient life expectancy at the time of Guglielmi detachable coil treatment. Johnston et al,²⁰⁵ using empirical data, showed that treatment of large (≥ 10 mm) or symptomatic aneurysms or of a patient with prior SAH was cost-effective, possibly more effective and more cost-effective than surgical clipping.³⁰¹ Similarly, a retrospective analysis of 2484 aneurysm cases in a 12-state database revealed more adverse outcomes, more in-hospital deaths, longer hospital stays, and greater total charges in the surgical group than in the endovascular group.³⁰²

Outside of any trial or registry, recent administrative database studies show increased rates of use of endovascular coils for treatment of unruptured aneurysms, with increasing cost of treatment procedures, but no definite outcome benefit through use of endovascular techniques.³⁰³ Huang et al³⁰³ reviewed >100 000 records from the US NIS from 1997 through 2006, which showed a 75% increase in the number of hospital admissions for the treatment of unruptured cerebral aneurysms. Inflation-adjusted charges increased 60% during this time period, but the total national bill increased by 200%. Length of hospital stay decreased by 37%, and in-hospital mortality was reduced by 54%, but endovascular aneurysm intervention had become the major driving force behind increasing overall national charges.³⁰³ In Europe, the cost of the procedure and associated hospitalization for endovascular coil occlusion for ruptured cerebral aneurysms remained similar to the cost of surgical clipping, whereas the cost of endovascular treatment in the United States was generally higher than in Europe but less than the cost of surgical clipping in the United States.³⁰⁴

Some studies suggest that treatment of cerebral artery aneurysms should be performed at centers of excellence with both surgical and endovascular capabilities.^{305,306} This dilution of experience has led some to argue for a moratorium on the training of neurointerventionalists to prevent further dilution of operator experience, training, and competence.³⁰⁷

Emerging technologies may lead to further evolutions in the endovascular treatment of unruptured cerebral aneurysms, even before the existing coil-based technology is completely understood. Low-porosity stent devices have the capability to channel or divert blood flow away from the aneurysm and provide a scaffold on which neointima can grow across the orifice of the aneurysm. In the Pipeline for Uncoilable or Failed Aneurysms (PUFS) trial, 106 of 107 patients underwent successful implantation of the Pipeline (Covidien) device with promising results, which led to approval by the US Food and Drug Administration for very limited (proximal intradural carotid circulation–cavernous, paraclinoid–ophthalmic segment) aneurysms.³⁰⁸ High rates of use suggest application beyond the confines of its indication for use in the United States. In other countries, Pipeline has been applied successfully to a variety of aneurysms at different locations.³⁰⁹ A liquid embolic agent (Onyx HD-500, Covidien) has been adapted to the treatment of cerebral aneurysms. During balloon occlusion of the parent artery, high density ethylene vinyl copolymer is injected into the aneurysm through a microcatheter. Molyneux et al³¹⁰ reported results of the Cerebral Aneurysm

Multicenter Onyx (CAMEO) trial, in which 97 patients with 100 aneurysms, mostly large or giant, underwent treatment. A majority of the aneurysms treated were large or giant. Serious adverse events occurred in 26.8% of patients. Permanent morbidity and mortality occurred in 8.2% and 2.0%, respectively. Complete aneurysm occlusion was achieved in 79%.

Endovascular treatment of cerebral aneurysms requires the use of x-ray fluoroscopy, and this type of radiation is carcinogenic. It is assumed that the radiation exposure to the patient and medical staff is justified by the disease state for which the patient is undergoing treatment, so long as it is kept “as low as reasonably achievable.”^{311,312} Neurointerventional procedures commonly fall into the category of high-exposure fluoroscopic procedures. It is possible that the radiation exposure would become so significant that alternative surgical procedures should be considered, especially for patients with unruptured aneurysms who have a long potential life expectancy with appropriate treatment. Although radiation exposure has not commonly been accounted for during neurointerventional procedures, some authors have considered radiation dose and exposure.^{311,313–315} Significant radiation exposure may occur from 30 minutes of fluoroscopy or a series of DSA acquisitions.³¹⁶ When a kerma area product, or dose-area product, of at least 500 Gy cm² has been reached, follow-up evaluation for signs of radiation injury may be necessary.³¹⁶ According to National Council on Radiation Protection guidelines, each procedure should be justified according to the medical goal accomplished, and specific patient follow-up for radiation injury is necessary.³¹⁷ In the future, trials and registries used to assess cerebral aneurysm treatment should include measures of patient radiation exposure. Finally, the procedural risks of radiation exposure encountered in endovascular aneurysm treatment should be included and specifically reviewed in any procedural consent.³¹¹

Endovascular Treatment: Recommendations

An AHA scientific statement published in 2009, “Indications for the Performance of Intracranial Endovascular Neurointerventional Procedures,” provided a summary of indications and recommendations for the endovascular treatment of unruptured cerebral aneurysms.³¹⁸ Moreover, a set of imaging reporting standards for the endovascular treatment of cerebral aneurysms were published in the AHA journal *Stroke*.¹³² On the basis of the available evidence, the existing recommendations have not changed and are summarized below in “Comparative Efficacy of Clipping Versus Coiling”; there is 1 new recommendation to address emerging technologies.

1. **Endoluminal flow diversion represents a new treatment strategy that may be considered in carefully selected cases (Class IIb; Level of Evidence B). Other emerging technologies to treat unruptured cerebral aneurysms, such as liquid embolic agents, represent new treatment strategies that may be considered in carefully selected cases (Class IIb; Level of Evidence C). The long-term effects of these newer approaches remain largely unknown. Strict adherence to the US Food and Drug Administration’s indications for use is probably indicated until additional trial data**

demonstrate an incremental improvement in safety and efficacy over existing technologies (*Class IIa; Level of Evidence C*).

2. Use of coated coils is not beneficial compared with bare-metal coils (*Class III; Level of Evidence A*).
3. Endovascular treatment of UIAs is recommended to be performed at high-volume centers (*Class I; Level of Evidence B*).
4. The procedural risk of radiation exposure should be explicitly reviewed in the consent process for endovascular procedures (*Class I; Level of Evidence C*).

Comparative Efficacy of Clipping Versus Coiling

Treatment paradigms for UIAs have shifted dramatically over the past 2 decades, in large part as a result of the increasing role of endovascular therapy. Historically, the primary indication for endovascular coiling of a UIA was in patients for whom surgery was deemed high risk. Over the past decade, however, advances in endovascular technology have revolutionized UIA treatment methods, and in fact, the number of patients with UIAs treated with endovascular coiling surpassed the number treated with surgical clipping (34 054 versus 29 866, respectively) between 2001 and 2008, according to the NIS.²³¹ Given the growth in popularity of endovascular coiling for the treatment of UIAs, several large-scale prospective and retrospective clinical studies have been conducted to compare the long-term efficacy of surgical clipping to endovascular coiling.

The ISUIA provided important natural history data on UIAs and information related to the risk of surgical repair.³⁴ A follow-up analysis in 2003 further reviewed outcomes after surgical clipping or endovascular coiling.⁴ Of the 4060 eligible patients, 1917 were treated surgically and 451 were treated endovascularly. Overall morbidity and mortality (defined as death and mRS 3–5 or impaired cognitive status) at 1 year was 12.6% (if no prior history of SAH) and 10.1% (if prior history of SAH) for surgical clipping and 9.8% (if no prior history of SAH) and 7.1% (if prior history of SAH) for endovascular coiling. In the endovascular group, periprocedural hemorrhage was found in 2% and cerebral infarction in 5%. Within this cohort, complete obliteration was accomplished in 55% of patients, incomplete obliteration in 24%, and no obliteration in 3%. In the surgical cohort, intraprocedural rupture was noted in 6% of patients, intracranial hemorrhage in 4%, and cerebral infarction in 11%. The degree of aneurysmal obliteration is not routinely assessed after surgical clipping, whereas this analysis is readily available after endovascular coiling. Finally, as opposed to the surgical arm, rates of morbidity and mortality in the endovascular group were less dependent on patient age, which perhaps indicates that this treatment modality may be better suited for older patients. These endovascular data represent an early epoch in the use of endovascular coiling for UIAs.

Over the past decade, analyses of several large-scale national databases have provided important outcome data related to surgical clipping and endovascular coiling of UIAs. Table 5 summarizes these data, which indicate that patients

Table 5. Outcome Data From Large-Scale Analyses of Surgical Clipping and Coil Embolization of UIAs

First Author, Year	Database	No. of Patients	Adverse Outcomes/ Morbidity, %		Ischemic or Hemorrhagic Complications, %		Mortality, %		Mean Length of Stay, d		Discharge to Long-Term Care Facility, %	
			Clipping	Coiling	Clipping	Coiling	Clipping	Coiling	Clipping	Coiling	Clipping	Coiling
Barker, 2004 ²⁰⁰	NIS	3919	OR 1.9/4.1*		OR 2.0		2.1	1.7	5	2	3.3	2.4
Higashida, 2007 ²⁰⁴	Publicly available, nonfederal hospital records (18 states)	2535	13.2	6.6	2.5	0.9	7.4	4.5
Hoh, 2010 ³¹⁹	NIS	9174 (hospitalizations)	9	4.5
Alshekhlee, 2010 ¹⁹⁹	NIS	3738	8.4	3.7	6.7 (ischemic), 2.4 (hemorrhagic)	2.9 (ischemic), 1.4 (hemorrhagic)	1.6	0.5	4 (median)	1 (median)
Brinjikji, 2011 ^{231†}	NIS	63 940	13.7	4.0	1.1	0.5	6.6	3.0	13.7	4.0
Brinjikji, 2011 ²⁰³	NIS	64 043	14.8	7.6	1.2	0.6	14	4.9
McDonald, 2013 ²⁰⁷	Perspective	4899	OR 2.2		0.7	0.5	OR 4.8	

NIS indicates National (Nationwide) Inpatient Sample; OR, odds ratio; and UIAs, unruptured intracranial aneurysms.

*Age ≤65 years, OR 1.9; age >65 years, OR 4.1.

†Data represent ages 50 to 64 years; additional data for age <50 years, ages 65 to 79 years, and age ≥80 years demonstrate decreased morbidity, mortality (except equal mortality for age <50 years), length of stay, and discharge to a long-term care facility for endovascular coiling compared with surgical clipping.

with endovascularly coiled UIAs have fewer adverse outcomes and ischemic and hemorrhagic events, a lower overall mortality rate, shorter lengths of hospital stay, and fewer discharges to a long-term care facility. However, retrospective comparative data based on administrative data sets must be viewed with caution. Outcome assessment is often limited to discharge status to facilities other than home, including rehabilitation facilities, and is not an indication of longer-term outcome. Furthermore, adjustment for confounding factors is limited because of the lack of information within such data sets, including specific aneurysm features such as location and size.

Despite the focus on RIAs, important information can be learned from the ISAT⁸ and Cerebral Aneurysm Rerupture After Treatment (CARAT)³²⁰ studies. Long-term follow-up data (mean, 9 years) on 2004 treated patients from the initial ISAT report reveal 24 rehemorrhages, 13 of which were from the treated aneurysm (10 treated by coiling and 3 by clipping).²⁷⁹ Long-term data from the CARAT study concluded that the degree of aneurysm occlusion after initial treatment is a strong predictor of the risk of rehemorrhage.³²¹ Overall, treated aneurysms with complete occlusion had a 1.1% risk of rehemorrhage compared with a 2.9% risk for 91% to 99% occlusion (small residual neck), a 5.9% risk for 70% to 90% occlusion (residual neck), and a 17.6% risk for <70% occlusion (partial). This trend was reflected in both the coil embolization and surgical clipping arms. For the 1001 patients in the study, there were 19 reruptures during 4 years of follow-up, with a 3.4% risk of rerupture for coil embolization and 1.3% for surgical clipping.

Higashida et al²⁰⁴ performed a retrospective cohort study of 2535 patients with UIAs based on information in a publicly available database in 18 American states. Of these patients, 1881 were treated with surgical clipping and 654 with endovascular coiling. Overall, endovascular therapy was associated with fewer adverse outcomes at discharge (6.6% versus 13.2%) and decreased mortality (0.9% versus 2.5%) compared with surgical clipping. In addition, patients treated with endovascular coiling had an average hospital length of stay of 4.5 days compared with 7.4 days in the surgical cohort. This finding was echoed by Hoh et al,³¹⁹ who identified in an analysis of the NIS that surgically managed patients had an average length of stay 1.8 times that of patients treated with endovascular coiling. Similar conclusions were drawn from a review of the NIS by Alshekhlee et al,¹⁹⁹ in which clipped patients experienced increased hospital length of stay, higher hospital charges, and greater morbidity and mortality compared with the coiled population.

Brinjikji et al^{203,231} have published several reports based on information gathered from 2001 to 2008 from the NIS. In 1 report, patients were stratified by age: <50 years of age, 50 to 64 years of age, 65 to 79 years of age, and ≥80 years of age.²³¹ In patients <50 years of age, endovascular coiling was associated with lower morbidity rates (3.5% versus 8.1%) than surgical clipping, but there was no difference in mortality (0.6% versus 0.6%). For the remaining age groups, endovascular coiling had decreased morbidity and mortality compared with surgical clipping. These data differ slightly from an analysis

of the NIS by Barker et al²⁰⁰ from 1996 to 2000, in which there was no difference in overall mortality rates after clipping or coiling of UIAs. In this same study, for patients ≥65 years of age, there was a trend toward worse outcomes for surgical patients with respect to death and discharge to a long-term facility, although this trend was not observed in patients <65 years of age. In another study by Brinjikji et al,²⁰³ surgical clipping was associated with a 14% incidence of discharge to a long-term care facility and a 1.2% mortality rate, whereas endovascular coiling was associated with a 4.9% discharge rate to a long-term facility and a 0.6% mortality rate.

The Perspective database (Premier Inc, Charlotte, NC) is represented by >600 American hospitals and accounts for ≈15% of the hospitalizations nationwide. An examination of this database by McDonald et al²⁰⁷ identified 4899 patients with UIAs between 2006 and 2011. In-hospital mortality was similar between the 1388 patients who underwent surgical clipping and the 3551 patients who underwent endovascular coiling; however, endovascular coiling was associated with a lower likelihood of discharges to long-term care facilities, ischemic complications, and hemorrhagic complications.

Since the emergence of coil embolization for the treatment of UIAs in 1990, this treatment modality has progressively become the dominant treatment method, as evidenced by analyses from the NIS. Prospective and retrospective data from national and international studies indicate that coil embolization may be superior to surgical clipping with respect to procedural morbidity and mortality, length of hospital stay, and associated hospital costs. On the basis of these prospective and retrospective data, it is reasonable to favor endovascular coiling over surgical clipping in the treatment of select UIAs, especially in cases in which surgical clipping is predicted to carry excess morbidity (ie, posterior circulation, elderly population) and aneurysm anatomy is likely to result in near-complete coil obliteration. Despite these observations, however, other data indicate that coil embolization may carry a higher risk of aneurysmal rerupture after treatment, likely as a result of incomplete aneurysm obliteration. Moving forward, large-scale prospective studies that incorporate not simply treatment modality but also aneurysm size and location as important predictors of outcome will be instrumental in guiding treatment paradigms for UIAs in the coming years.

Comparative Efficacy of Clipping Versus Coiling: Recommendations

1. Surgical clipping is an effective treatment for UIAs that are considered for treatment (*Class I; Level of Evidence B*).
2. Endovascular coiling is an effective treatment for select UIAs that are considered for treatment (*Class IIa; Level of Evidence B*).
3. Patients with UIAs who are considered for treatment should be fully informed about the risks and benefits of both endovascular and microsurgical aneurysm clipping (*Class I; Level of Evidence B*).
4. Endovascular coiling is associated with a reduction in procedural morbidity and mortality over surgical

clipping in selected cases but has an overall higher risk of recurrence (Class IIb; Level of Evidence B).

Aneurysm Follow-Up (Patients Treated Without Surgery or Coiling)

For patients with UIAs that are managed noninvasively without either surgical or endovascular intervention, some form of radiographic follow-up is usually recommended. Various studies have documented aneurysm growth over time,^{95,194,322–327} and interval growth has been believed to be a risk factor for hemorrhage. Unfortunately, there are no studies specifically addressing the appropriate imaging modality or interval for follow-up. Most published work indicates a preference for first follow-up imaging 6 to 12 months after initial discovery.^{24,118,192,328,329} Continued follow-up is then generally recommended yearly or every 2 years once stability is documented.³²⁹ Certainly, at some point a patient's age or medical comorbidities may become such that invasive intervention will become inordinately high risk or of no significant benefit, whereby it may be reasonable to discontinue further scheduled follow-up. Both CTA and MRA have been used for follow-up.^{95,195,322–327} However, various CT and magnetic resonance protocols are available, and the question as to which modality is most appropriate is unresolved. In general, because a TOF MRA does not require intravenous contrast and does not involve x-ray radiation, this may be the most appropriate first-line method for repeated imaging follow-up. For patients with contraindications to MRA or whose aneurysm(s) cannot be suitably visualized with this technique, CTA remains a viable alternative.

Aneurysm Follow-Up (Patients Treated Without Surgery or Endovascular Coiling): Recommendations

1. For patients with UIAs that are managed noninvasively without either surgical or endovascular intervention, radiographic follow-up with MRA or CTA at regular intervals is indicated. The optimal interval and duration of recommended follow-up are uncertain (Class I; Level of Evidence B).
2. For patients with UIAs that are managed noninvasively without either surgical or endovascular intervention, a first follow-up study at 6 to 12 months after initial discovery, followed by subsequent yearly or every other year follow-up, may be reasonable (Class IIb; Level of Evidence C).
3. For patients with UIAs that are managed noninvasively and in whom there are no contraindications to MRI, it may be reasonable to consider TOF MRA rather than CTA for repeated long-term follow-up (Class IIb; Level of Evidence C).

Conclusions

The overall prevalence of UIAs remains somewhat variable depending on the population studied and the analytical methods used. Nonetheless, it appears that older individuals and females tend to be more affected. Other nonmodifiable risk factors include a variety of inherited syndromes, such as

polycystic kidney disease. Nonsyndromic familial cases are also well documented and account for roughly 10% of cases. Recent genome-wide association studies have indicated areas of intense genomic interest for further study in both familial and nonfamilial cases. The most important modifiable risk factors are cigarette smoking and hypertension, with excessive alcohol intake and oral contraceptive use being far less important. No studies have prospectively evaluated the impact of successful risk factor modification on either the development of UIA or the rupture of a previously asymptomatic UIA.

In any given year, only a minority of UIA patients will present with SAH, and many of the aneurysms that rupture may not be the same as those found incidentally. Although recent studies confirm that larger UIA size portends a worse prognosis in terms of bleeding, newer data suggest that strict size cutoffs may be less helpful than previously thought. The available data also continue to suggest that UIAs in certain locations, with certain morphological characteristics, are more likely to rupture. It also appears that growth of a UIA is associated with rupture, and several factors associated with growth on serial imaging have been identified. Unfortunately, no prospective data exist on whether modification of these factors will alter the risk of growth or rupture. Finally, we still lack high-quality data on whether any of the treatments available—surgical, endovascular, or medical (ie, anti-inflammatory medications, statins, antihypertensive medications, smoking cessation)—afford even a subset of UIA patients a better outcome than the natural history without such treatment.

Given these issues, it is reasonable to more strongly consider a patient for repair (1) when the UIA is discovered as a result of a prior SAH from a different lesion, (2) if the aneurysm is symptomatic, causing compressive symptoms, or a likely source of otherwise unexplained embolic stroke, or (3) if the patient has a family history of IA. Nonetheless, the risks, benefits, and alternatives to repair must be considered carefully in each individual case.

Although UIAs that are clearly growing or are causing a neurological deficit typically require an endovascular or surgical treatment, in a small minority of those cases, these lesions might reasonably be managed conservatively for several reasons, including very short or low-quality life expectancy. Routine serial imaging of aneurysms treated conservatively is reasonable, but the optimal interval between imaging studies and the mode of that imaging remain uncertain. When treatment is elected, it appears that in most instances, DSA is the best method to plan repair, and immediately after treatment, it is typically used to define whether the aneurysm has been excluded definitively and whether there is a need for repeat treatment. By contrast, routine delayed follow-up imaging of a treated lesion is usually performed noninvasively by either CTA or MRA, and the timing and frequency of that follow-up are dictated by the completeness and method of the original repair, as well as the documented duration of imaging stability and a host of other patient- and aneurysm-specific factors.

In part because decisions regarding UIA treatment remain so individualized, there is significant uncertainty as to which populations should undergo noninvasive MRA or CTA screening for these lesions. If screening is undertaken, it is critical

to screen populations at higher risk of aneurysm formation than the general population and those in whom treatment would likely be elected if an aneurysm were identified. Two populations that might be considered to meet these criteria are patients with autosomal dominant polycystic kidney disease (especially those with a family history of IA) and individuals with a strong family history of aneurysms or SAH. Although others may benefit, neither the cost-effectiveness nor the clinical utility of any screening program has been evaluated prospectively.

When a patient is considered for repair of an aneurysm, patient age, presence of medical comorbidities, and aneurysm location and size should be taken into careful consideration, because these are strong predictors of perioperative morbidity and rupture risk. The treating physicians should consider the risk of treatment not only on the basis of published reports and trial results but also on the basis of their own personal results. This is of particular importance in low-volume (<20 cases annually) centers, where the results of UIA treatment appear to be inferior. At such centers, referral to a high-volume center makes intuitive sense and is more than reasonable. Although not true for all aneurysms, microsurgical repair is generally associated with higher perioperative morbidity than endovascular repair but is also associated with higher rates of aneurysm obliteration and lower rates of recurrence. In older patients (more than ≈ 60 years of age), the benefit of coiling compared with that of surgery appears to be greater for most lesions, because the risk of recurrence is less of a concern and the rates of perioperative microsurgical complications are higher. At least with current technology, there also appears to be an advantage to microsurgery in the treatment of most middle cerebral artery aneurysms and for endovascular repair in the treatment of most basilar apex and vertebrobasilar confluence aneurysms. Emerging technologies to treat unruptured cerebral aneurysms, particularly flow-diverting low-porosity stents, and the use of stent-assisted coiling procedures represent compelling new treatment strategies that may be considered in carefully selected cases. Because their long-term effects remain largely unknown, strict adherence to the US Food and Drug Administration's indications for use is recommended until additional trial data demonstrate an incremental improvement in safety and efficacy over existing technologies. After clipping, coiling, or stenting, assessment of cognitive outcome, in addition to standard measures of outcome, is reasonable. Early documentation of the degree of aneurysm obliteration after any repair technique is necessary to guide the

frequency of further follow-up for the detection of recurrence and de novo aneurysm formation. Although the frequency of long-term imaging is uncertain, it is reasonable to increase the frequency for those with aneurysms that are incompletely obliterated during initial treatment.

Conclusions: Recommendations

1. Several factors should be considered in selection of the optimal management of a UIA, including the size, location, and other morphological characteristics of the aneurysm; documented growth on serial imaging; the age of the patient; a history of prior aSAH; family history of cerebral aneurysm; the presence of multiple aneurysms; or the presence of concurrent pathology such as an arteriovenous malformation or other cerebrovascular or inherited pathology that may predispose to a higher risk of hemorrhage (*Class I; Level of Evidence C*).
2. Patients with unruptured cerebral aneurysms who are considered for treatment should be fully informed about the risks and benefits of both endovascular and microsurgical treatment as alternatives to secure the UIAs and prevent bleeding (*Class I; Level of Evidence B*).
3. The results of UIA treatment are inferior at low-volume centers, and hence treatment is recommended to be performed at higher-volume centers (*Class I; Level of Evidence B*).
4. Data from prospective and retrospective studies from multiple national and international investigations indicate that microsurgical clip ligation may confer more durable protection against aneurysm regrowth, but coil embolization may be superior to surgical clipping with respect to procedural morbidity and mortality, length of stay, and hospital costs, so it may be reasonable to choose endovascular therapy over surgical clipping in the treatment of select UIAs, particularly in cases for which surgical morbidity is high, such as at the basilar apex and in the elderly (*Class IIb; Level of Evidence B*).
5. The treatment risk of patients with UIAs is related to advancing age, medical comorbidities, and aneurysm location and size, so in older patients (>65 years of age) and those with associated medical comorbidities with small asymptomatic UIAs and low hemorrhage risk by location, size, morphology, family history, and other relevant factors, observation is a reasonable alternative (*Class IIa; Level of Evidence B*).

Disclosures

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
B. Gregory Thompson	University of Michigan	None	None	None	None	None	None	None
Robert D. Brown, Jr	Mayo Clinic	NIH†	None	None	None	None	None	None
Sepideh Amin-Hanjani	University of Illinois at Chicago	None	None	None	None	None	None	None
Joseph P. Broderick	University of Cincinnati	NINDS†	None	None	None	None	None	None
Kevin M. Cockroft	Penn State Hershey Medical Center	None	None	None	None	None	Covidien†	None
E. Sander Connolly, Jr	Columbia University	None	None	None	None	None	None	None
Gary R. Duckwiler	University of California at Los Angeles	None	None	None	None	Sequent Medical (personally purchased stock)*	Sequent Medical*; EV3/Covidien Medical*; Concentric Medical (Stryker)*	UC Regents (employer) receives patent royalties from Guglielmi and Matrix; author receives no direct payments†
Catherine C. Harris	Jefferson University	None	None	None	None	None	None	None
Virginia J. Howard	University of Alabama at Birmingham	NIH†	None	None	None	None	None	None
S. Claiborne (Clay) Johnston	University of Texas, Dell Medical School	None	Stryker† (payment issued to employer/UCSF in October 2012; no direct payment to author)	None	None	None	None	None
Philip M. Meyers	Columbia University	None	None	None	None	None	Stryker (co-PI, SCENT trial, no financial interest)*	None
Andrew Molyneux	Oxford University	None	None	None	Medical expert witness in aneurysm cases†	None	Sequent Medical Inc; Case adjudication and study design advice†	None
Christopher S. Ogilvy	Beth Israel Deaconess Medical Center	None	None	None	None	None	None	None
Andrew J. Ringer	University of Cincinnati, Mayfield Clinic	None	None	None	None	None	EV3/Covidien Medical*; Stryker*; MicroVention*	None
James Torner	University of Iowa	CDC†; NIH/NINDS†; NIH/NIA†; VA†	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Thomas Bleck	Rush University Medical Center	None	None	None	None	None	None	None
Ketan Bulsara	Yale University	None	None	None	None	None	None	None
J. Mocco	Mount Sinai Hospital	FEAT: randomized trial (PI for a prospective randomized trial of 2 different methods of aneurysm treatment)†; POSITIVE: randomized trial of flow diversion vs coil embolization (co-PI for a prospective randomized trial of 2 different methods of aneurysm treatment)*	None	None	None	Blockade Medical†	Codman Neurovascular*	None
Alejandro Rabinstein	Mayo Clinic	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

References

- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. *Circulation*. 2014;129:e28–e292. doi: 10.1161/01.cir.0000441139.02102.80.
- Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G; European Stroke Organization. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. *Cerebrovasc Dis*. 2013;35:93–112. doi: 10.1159/000346087.
- Rinkel GJ, Djibuti M, Algra A, van Gijn J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. *Stroke*. 1998;29:251–256.
- Wiebers DO, Whisnant JP, Huston J 3rd, Meissner I, Brown RD Jr, Piegras DG, Forbes GS, Thielens K, Nichols D, O'Fallon WM, Peacock J, Jaeger L, Kassell NF, Kongable-Beckman GL, Torner JC; International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. *Lancet*. 2003;362:103–110.
- UCAS Japan Investigators; Morita A, Kirino T, Hashi K, Aoki N, Fukuhara S, Hashimoto N, Nakayama T, Sakai M, Teramoto A, Tominari S, Yoshimoto T. The natural course of unruptured cerebral aneurysms in a Japanese cohort. *N Engl J Med*. 2012;366:2474–2482. doi: 10.1056/NEJMoa1113260.
- Raymond J, Roy D, Weill A, Guilbert F, Nguyen T, Molyneux AJ, Fox AJ, Johnston SC, Collet JP, Rouleau I; Trial on Endovascular Aneurysm Management (TEAM) collaborative group. Unruptured intracranial aneurysms and the Trial on Endovascular Aneurysm Management (TEAM): the principles behind the protocol. *J Vasc Interv Neurol*. 2008;1:22–26.
- The Canadian UnRuptured Endovascular Versus Surgery Trial (CURES). <http://clinicaltrials.gov/ct2/show/NCT01139892>. Accessed May 15, 2013.
- Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, Holman R; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. *Lancet*. 2002;360:1267–1274.
- Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, Sandercock P; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. *Lancet*. 2005;366:809–817.
- Bederson JB, Awad IA, Wiebers DO, Piegras D, Haley EC Jr, Brott T, Hademenos G, Chyatte D, Rosenwasser R, Caroselli C. Recommendations for the management of patients with unruptured intracranial aneurysms: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke*. 2000;31:2742–2750.
- Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. *Lancet Neurol*. 2011;10:626–636. doi: 10.1016/S1474-4422(11)70109-0.
- Wardlaw JM, White PM. The detection and management of unruptured intracranial aneurysms. *Brain*. 2000;123(pt 2):205–221.
- Li MH, Chen SW, Li YD, Chen YC, Cheng YS, Hu DJ, Tan HQ, Wu Q, Wang W, Sun ZK, Wei XE, Zhang JY, Qiao RH, Zong WH, Zhang Y, Lou W, Chen ZY, Zhu Y, Peng DR, Ding SX, Xu XF, Hou XH, Jia WP. Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: a cross-sectional study. *Ann Intern Med*. 2013;159:514–521. doi: 10.7326/0003-4819-159-8-201310150-00004.
- Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, Niessen WJ, Breteler MM, van der Lugt A. Incidental findings on brain MRI in the general population. *N Engl J Med*. 2007;357:1821–1828. doi: 10.1056/NEJMoa070972.
- Morris Z, Whiteley WN, Longstreth WT Jr, Weber F, Lee YC, Tsushima Y, Alphas H, Ladd SC, Warlow C, Wardlaw JM, Al-Shahi Salman R. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. 2009;339:b3016. doi: 10.1136/bmj.b3016.



16. Müller TB, Sandvei MS, Kvistad KA, Rydland J, Håberg A, Vik A, Gårseth M, Stovner LJ. Unruptured intracranial aneurysms in the Norwegian Nord-Trøndelag Health Study (HUNT): risk of rupture calculated from data in a population-based cohort study. *Neurosurgery*. 2013;73:256–261. doi: 10.1227/01.neu.0000430295.23799.16.
17. Qureshi AI, Suri MF, Nasar A, Kirmani JF, Divani AA, He W, Hopkins LN. Trends in hospitalization and mortality for subarachnoid hemorrhage and unruptured aneurysms in the United States. *Neurosurgery*. 2005;57:1–8.
18. Pyysalo L, Luostarinen T, Keski-Nisula L, Öhman J. Long-term excess mortality of patients with treated and untreated unruptured intracranial aneurysms. *J Neurol Neurosurg Psychiatry*. 2013;84:888–892. doi: 10.1136/jnnp-2012-303073.
19. Stehbens WE. *Pathology of the Cerebral Blood Vessels*. St. Louis, MO: Mosby; 1972:351–470.
20. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, Hoh BL, Kirkness CJ, Naidech AM, Ogilvy CS, Patel AB, Thompson BG, Vespa P; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2012;43:1711–1737. doi: 10.1161/STR.0b013e3182587839.
21. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. *J Neurol Neurosurg Psychiatry*. 2007;78:1365–1372. doi: 10.1136/jnnp.2007.117655.
22. Ronkainen A, Miettinen H, Karkola K, Papinaho S, Vanninen R, Puranen M, Hernesniemi J. Risk of harboring an unruptured intracranial aneurysm. *Stroke*. 1998;29:359–362.
23. Wiebers DO, Whisnant JP, Sundt TM Jr, O'Fallon WM. The significance of unruptured intracranial saccular aneurysms. *J Neurosurg*. 1987;66:23–29. doi: 10.3171/jns.1987.66.1.0023.
24. Brown RD. Unruptured intracranial aneurysms. *Semin Neurol*. 2010;30:537–544. doi: 10.1055/s-0030-1268858.
25. Phan TG, Huston J 3rd, Brown RD Jr, Wiebers DO, Piepgras DG. Intracranial saccular aneurysm enlargement determined using serial magnetic resonance angiography. *J Neurosurg*. 2002;97:1023–1028. doi: 10.3171/jns.2002.97.5.1023.
26. Menghini VV, Brown RD Jr, Sicks JD, O'Fallon WM, Wiebers DO. Incidence and prevalence of intracranial aneurysms and hemorrhage in Olmsted County, Minnesota, 1965 to 1995. *Neurology*. 1998;51:405–411.
27. Jeon TY, Jeon P, Kim KH. Prevalence of unruptured intracranial aneurysm on MR angiography. *Korean J Radiol*. 2011;12:547–553. doi: 10.3348/kjr.2011.12.5.547.
28. Horikoshi T, Akiyama I, Yamagata Z, Nukui H. Retrospective analysis of the prevalence of asymptomatic cerebral aneurysm in 4518 patients undergoing magnetic resonance angiography: when does cerebral aneurysm develop? *Neurol Med Chir (Tokyo)*. 2002;42:105–112.
29. Nakagawa T, Hashi K. The incidence and treatment of asymptomatic, unruptured cerebral aneurysms. *J Neurosurg*. 1994;80:217–223. doi: 10.3171/jns.1994.80.2.0217.
30. Raps EC, Rogers JD, Galetta SL, Solomon RA, Lennihan L, Klebanoff LM, Fink ME. The clinical spectrum of unruptured intracranial aneurysms. *Arch Neurol*. 1993;50:265–268.
31. Brinjikji W, Rabinstein AA, Lanzino G, Cloft HJ. Racial and ethnic disparities in the treatment of unruptured intracranial aneurysms: a study of the Nationwide Inpatient Sample 2001–2009. *Stroke*. 2012;43:3200–3206. doi: 10.1161/STROKEAHA.112.671214.
32. Juvela S, Porras M, Heiskanen O. Natural history of unruptured intracranial aneurysms: a long-term follow-up study. *J Neurosurg*. 1993;79:174–182. doi: 10.3171/jns.1993.79.2.0174.
33. Juvela S, Porras M, Poussa K. Natural history of unruptured intracranial aneurysms: probability of and risk factors for aneurysm rupture. *J Neurosurg*. 2000;93:379–387. doi: 10.3171/jns.2000.93.3.0379.
34. International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms: risk of rupture and risks of surgical intervention [published correction appears in *N Engl J Med*. 1999;340:744]. *N Engl J Med*. 1998;339:1725–1733.
35. Wiebers DO, Whisnant JP, O'Fallon WM. The natural history of unruptured intracranial aneurysms. *N Engl J Med*. 1981;304:696–698. doi: 10.1056/NEJM198103193041203.
36. Meyer FB, Sundt TM Jr, Fode NC, Morgan MK, Forbes GS, Mellinger JF. Cerebral aneurysms in childhood and adolescence. *J Neurosurg*. 1989;70:420–425. doi: 10.3171/jns.1989.70.3.0420.
37. Storrs BB, Humphreys RP, Hendrick EB, Hoffman HJ. Intracranial aneurysms in the pediatric age-group. *Childs Brain*. 1982;9:358–361.
38. Badani KK, Hemal AK, Menon M. Autosomal dominant polycystic kidney disease and pain: a review of the disease from aetiology, evaluation, past surgical treatment options to current practice. *J Postgrad Med*. 2004;50:222–226.
39. Chapman AB, Rubinstein D, Hughes R, Stears JC, Earnest MP, Johnson AM, Gabow PA, Kaehny WD. Intracranial aneurysms in autosomal dominant polycystic kidney disease. *N Engl J Med*. 1992;327:916–920. doi: 10.1056/NEJM199209243271303.
40. Germain DP. Clinical and genetic features of vascular Ehlers-Danlos syndrome. *Ann Vasc Surg*. 2002;16:391–397. doi: 10.1007/s10016-001-0229-y.
41. DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency, 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. *Thorax*. 2004;59:259–264.
42. Schievink WI, Katzmman JA, Piepgras DG, Schaid DJ. Alpha-1-antitrypsin phenotypes among patients with intracranial aneurysms. *J Neurosurg*. 1996;84:781–784. doi: 10.3171/jns.1996.84.5.0781.
43. Yoneyama T, Kasuya H, Akagawa H, Onda H, Nakajima T, Hori T, Inoue I, Lee JC, Yang TK, Kim CJ. Absence of alpha-1 antitrypsin deficiency alleles (S and Z) in Japanese and Korean patients with aneurysmal subarachnoid hemorrhage. *Stroke*. 2004;35:e376–e378. doi: 10.1161/01.STR.0000147966.81215.be.
44. Conway JE, Hutchins GM, Tamargo RJ. Marfan syndrome is not associated with intracranial aneurysms. *Stroke*. 1999;30:1632–1636.
45. van den Berg JS, Hennekam RC, Cruysberg JR, Steijlen PM, Swart J, Tijmes N, Limburg M. Prevalence of symptomatic intracranial aneurysm and ischaemic stroke in pseudoxanthoma elasticum. *Cerebrovasc Dis*. 2000;10:315–319. doi: 10.1007/s00033-000-0010-0.
46. Schievink WI, Raissi SS, Maya MM, Velebir A. Screening for intracranial aneurysms in patients with bicuspid aortic valve. *Neurology*. 2010;74:1430–1433. doi: 10.1212/WNL.0b013e3181d1c1ac.
47. Waldron JS, Hettis SW, Armstrong-Wells J, Dowd CF, Fullerton HJ, Gupta N, Lawton MT. Multiple intracranial aneurysms and moyamoya disease associated with microcephalic osteodysplastic primordial dwarfism type II: surgical considerations. *J Neurosurg Pediatr*. 2009;4:439–444. doi: 10.3171/2009.6.PEDS08137.
48. Lozano AM, Leblanc R. Familial intracranial aneurysms. *J Neurosurg*. 1987;66:522–528. doi: 10.3171/jns.1987.66.4.0522.
49. Schievink WI. Genetics of intracranial aneurysms. In: Winn HR, ed. *Yousmans Neurological Surgery*. 5th ed. Philadelphia, PA: Saunders; 2004:1769–1779.
50. Schievink WI, Schaid DJ, Michels VV, Piepgras DG. Familial aneurysmal subarachnoid hemorrhage: a community-based study. *J Neurosurg*. 1995;83:426–429. doi: 10.3171/jns.1995.83.3.0426.
51. Ruigrok YM, Rinkel GJ, Algra A, Raaymakers TW, Van Gijn J. Characteristics of intracranial aneurysms in patients with familial subarachnoid hemorrhage. *Neurology*. 2004;62:891–894.
52. Ronkainen A, Hernesniemi J, Puranen M, Niemitukia L, Vanninen R, Ryyänänen M, Kuivaniemi H, Tromp G. Familial intracranial aneurysms. *Lancet*. 1997;349:380–384. doi: 10.1016/S0140-6736(97)80009-8.
53. Ronkainen A, Puranen MI, Hernesniemi JA, Vanninen RL, Partanen PL, Saari JT, Vainio PA, Ryyänänen M. Intracranial aneurysms: MR angiographic screening in 400 asymptomatic individuals with increased familial risk. *Radiology*. 1995;195:35–40. doi: 10.1148/radiology.195.1.7892491.
54. The Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group. Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage. *N Engl J Med*. 1999;341:1344–1350.
55. Brown RD Jr, Huston J, Hornung R, Foroud T, Kallmes DF, Kleindorfer D, Meissner I, Woo D, Sauerbeck L, Broderick J. Screening for brain aneurysm in the Familial Intracranial Aneurysm study: frequency and predictors of lesion detection. *J Neurosurg*. 2008;108:1132–1138. doi: 10.3171/JNS/2008/108/6/1132.
56. Mackey J, Brown RD Jr, Moomaw CJ, Sauerbeck L, Hornung R, Gandhi D, Woo D, Kleindorfer D, Flaherty ML, Meissner I, Anderson C, Connolly ES, Rouleau G, Kallmes DF, Torner J, Huston J 3rd, Broderick JP; FIA and ISUIA Investigators. Unruptured intracranial aneurysms in the Familial Intracranial Aneurysm and International Study of Unruptured Intracranial Aneurysms cohorts: differences in multiplicity and

- location [published correction appears in *J Neurosurg*. 2012;117:192]. *J Neurosurg*. 2012;117:60–64. doi: 10.3171/2012.4.JNS111822.
57. Raaymakers TW; MARS Study Group: Magnetic Resonance Angiography in Relatives of patients with Subarachnoid hemorrhage. Aneurysms in relatives of patients with subarachnoid hemorrhage: frequency and risk factors. *Neurology*. 1999;53:982–988.
 58. Bor AS, Rinkel GJ, van Norden J, Wermer MJ. Long-term, serial screening for intracranial aneurysms in individuals with a family history of aneurysmal subarachnoid haemorrhage: a cohort study. *Lancet Neurol*. 2014;13:385–392. doi: 10.1016/S1474-4422(14)70021-3.
 59. van 't Hof FN, Ruigrok YM, Baas AF, Kiemeny LA, Vermeulen SH, Uitterlinden AG, Hofman A, Rivadeneira F, Rinkel GJ, de Bakker PI. Impact of inherited genetic variants associated with lipid profile, hypertension, and coronary artery disease on the risk of intracranial and abdominal aortic aneurysms. *Circ Cardiovasc Genet*. 2013;6:264–270. doi: 10.1161/CIRCGENETICS.113.000022.
 60. Caranci F, Briganti F, Cirillo L, Leonardi M, Muto M. Epidemiology and genetics of intracranial aneurysms. *Eur J Radiol*. 2013;82:1598–1605. doi: 10.1016/j.ejrad.2012.12.026.
 61. Cebal JR, Raschi M. Suggested connections between risk factors of intracranial aneurysms: a review. *Ann Biomed Eng*. 2013;41:1366–1383. doi: 10.1007/s10439-012-0723-0.
 62. Low SK, Takahashi A, Cha PC, Zembutsu H, Kamatani N, Kubo M, Nakamura Y. Genome-wide association study for intracranial aneurysm in the Japanese population identifies three candidate susceptible loci and a functional genetic variant at EDNRA. *Hum Mol Genet*. 2012;21:2102–2110. doi: 10.1093/hmg/dds020.
 63. Kanematsu Y, Kanematsu M, Kurihara C, Tada Y, Tsou TL, van Rooijen N, Lawton MT, Young WL, Liang EI, Nuki Y, Hashimoto T. Critical roles of macrophages in the formation of intracranial aneurysm. *Stroke*. 2011;42:173–178. doi: 10.1161/STROKEAHA.110.590976.
 64. Akiyama K, Narita A, Nakaoka H, Cui T, Takahashi T, Yasuno K, Tajima A, Krischek B, Yamamoto K, Kasuya H, Hata A, Inoue I. Genome-wide association study to identify genetic variants present in Japanese patients harboring intracranial aneurysms. *J Hum Genet*. 2010;55:656–661. doi: 10.1038/jhg.2010.82.
 65. McColgan P, Thant KZ, Sharma P. The genetics of sporadic ruptured and unruptured intracranial aneurysms: a genetic meta-analysis of 8 genes and 13 polymorphisms in approximately 20,000 individuals. *J Neurosurg*. 2010;112:714–721. doi: 10.3171/2009.8.JNS092.
 66. Zhang J, Clatterbuck RE. Molecular genetics of human intracranial aneurysms. *Int J Stroke*. 2008;3:272–287. doi: 10.1111/j.1747-4949.2008.00224.x.
 67. Ruigrok YM, Rinkel GJ. Genetics of intracranial aneurysms. *Stroke*. 2008;39:1049–1055. doi: 10.1161/STROKEAHA.107.497305.
 68. Biros E, Golledge J. Meta-analysis of whole-genome linkage scans for intracranial aneurysm. *Neurosci Lett*. 2008;431:31–35. doi: 10.1016/j.neulet.2007.11.014.
 69. Woo D, Broderick J. Genetics of intracranial aneurysm. *J Stroke Cerebrovasc Dis*. 2002;11:230–240. doi: 10.1053/jscd.2002.129598.
 70. Nahed BV, Bydon M, Ozturk AK, Bilguvar K, Bayrakli F, Gunel M. Genetics of intracranial aneurysms. *Neurosurgery*. 2007;60:213–225. doi: 10.1227/01.NEU.0000249270.18698.BB.
 71. Yamada S, Utsunomiya M, Inoue K, Nozaki K, Inoue S, Takenaka K, Hashimoto N, Koizumi A. Genome-wide scan for Japanese familial intracranial aneurysms: linkage to several chromosomal regions. *Circulation*. 2004;110:3727–3733. doi: 10.1161/01.CIR.0000143077.23367.18.
 72. Ruigrok YM, Seitz U, Wolterink S, Rinkel GJ, Wijmenga C, Urbán Z. Association of polymorphisms and haplotypes in the elastin gene in Dutch patients with sporadic aneurysmal subarachnoid hemorrhage. *Stroke*. 2004;35:2064–2068. doi: 10.1161/01.STR.0000139380.50649.5c.
 73. Korja M, Silventoinen K, McCarron P, Zdravkovic S, Skytté A, Haapanen A, de Faire U, Pedersen NL, Christensen K, Koskenvuo M, Kaprio J; GenomEUtwin Project. Genetic epidemiology of spontaneous subarachnoid hemorrhage: Nordic Twin Study. *Stroke*. 2010;41:2458–2462. doi: 10.1161/STROKEAHA.110.586420.
 74. Foroud T, Koller DL, Lai D, Sauerbeck L, Anderson C, Ko N, Deka R, Mosley TH, Fornage M, Woo D, Moosaw CJ, Hornung R, Huston J, Meissner I, Bailey-Wilson JE, Langefeld C, Rouleau G, Connolly ES, Worrall BB, Kleindorfer D, Flaherty ML, Martini S, Mackey J, De Los Rios La Rosa F, Brown RD Jr, Broderick JP; FIA Study Investigators. Genome-wide association study of intracranial aneurysms confirms role of ANRIL and SOX17 in disease risk. *Stroke*. 2012;43:2846–2852. doi: 10.1161/STROKEAHA.112.656397.
 75. Alg VS, Sofat R, Houlden H, Werring DJ. Genetic risk factors for intracranial aneurysms: a meta-analysis in more than 116,000 individuals. *Neurology*. 2013;80:2154–2165. doi: 10.1212/WNL.0b013e318295d751.
 76. Patterson JM, Eberly LE, Ding Y, Hargreaves M. Associations of smoking prevalence with individual and area level social cohesion. *J Epidemiol Community Health*. 2004;58:692–697. doi: 10.1136/jech.2003.009167.
 77. Juvela S, Hillbom M, Numminen H, Koskinen P. Cigarette smoking and alcohol consumption as risk factors for aneurysmal subarachnoid hemorrhage. *Stroke*. 1993;24:639–646.
 78. Bonita R. Cigarette smoking, hypertension and the risk of subarachnoid hemorrhage: a population-based case-control study. *Stroke*. 1986;17:831–835. doi: 10.1161/01.STR.17.5.831.
 79. Knekt P, Reunanen A, Aho K, Heliövaara M, Rissanen A, Aromaa A, Impivaara O. Risk factors for subarachnoid hemorrhage in a longitudinal population study. *J Clin Epidemiol*. 1991;44:933–939.
 80. Longstreth WT Jr, Nelson LM, Koepsell TD, van Belle G. Cigarette smoking, alcohol use, and subarachnoid hemorrhage. *Stroke*. 1992;23:1242–1249. doi: 10.1161/01.STR.23.9.1242.
 81. Shiue I, Arima H, Hankey GJ, Anderson CS; ACROSS Group. Modifiable lifestyle behaviours account for most cases of subarachnoid haemorrhage: a population-based case-control study in Australasia. *J Neurol Sci*. 2012;313:92–94. doi: 10.1016/j.jns.2011.09.017.
 82. Lindgren AE, Kurki MI, Riihinen A, Koivisto T, Ronkainen A, Rinne J, Hernesniemi J, Eriksson JG, Jääskeläinen JE, von und zu Fraunberg M. Hypertension predisposes to the formation of saccular intracranial aneurysms in 467 unruptured and 1053 ruptured patients in Eastern Finland. *Ann Med*. 2014;46:169–176. doi: 10.3109/07853890.2014.883168.
 83. Klatsky AL, Armstrong MA, Friedman GD. Alcohol use and subsequent cerebrovascular disease hospitalizations. *Stroke*. 1989;20:741–746. doi: 10.1161/01.STR.20.6.741.
 84. Chen M, Ouyang B, Goldstein-Smith L, Feldman L. Oral contraceptive and hormone replacement therapy in women with cerebral aneurysms. *J Neurointerv Surg*. 2011;3:163–166. doi: 10.1136/jnis.2010.003855.
 85. Lindegård B, Hillbom M, Brody S. High-dose estrogen-progestagen oral contraceptives: a risk factor for aneurysmal subarachnoid hemorrhage? *Acta Neurol Scand*. 1987;76:33–45.
 86. Johnston SC, Colford JM Jr, Gress DR. Oral contraceptives and the risk of subarachnoid hemorrhage: a meta-analysis. *Neurology*. 1998;51:411–418.
 87. Qureshi AI, Suarez JJ, Parekh PD, Sung G, Geocadin R, Bhardwaj A, Tamargo RJ, Ulatowski JA. Risk factors for multiple intracranial aneurysms. *Neurosurgery*. 1998;43:22–26.
 88. Ellamushi HE, Grieve JB, Jäger HR, Kitchen ND. Risk factors for the formation of multiple intracranial aneurysms. *J Neurosurg*. 2001;94:728–732. doi: 10.3171/jns.2001.94.5.0728.
 89. Juvela S. Risk factors for multiple intracranial aneurysms. *Stroke*. 2000;31:392–397. doi: 10.1161/01.STR.31.2.392.
 90. Kaminogo M, Yonekura M, Shibata S. Incidence and outcome of multiple intracranial aneurysms in a defined population. *Stroke*. 2003;34:16–21. doi: 10.1161/01.STR.0000046763.48330.AD.
 91. Nehls DG, Flom RA, Carter LP, Spetzler RF. Multiple intracranial aneurysms: determining the site of rupture. *J Neurosurg*. 1985;63:342–348. doi: 10.3171/jns.1985.63.3.0342.
 92. Marshman LA, Ward PJ, Walter PH, Dossetor RS. The progression of an infundibulum to aneurysm formation and rupture: case report and literature review. *Neurosurgery*. 1998;43:1445–1448.
 93. Juvela S. Natural history of unruptured intracranial aneurysms: risks for aneurysm formation, growth, and rupture. *Acta Neurochir Suppl*. 2002;82:27–30.
 94. So TY, Dowling R, Mitchell PJ, Laidlaw J, Yan B. Risk of growth in unruptured intracranial aneurysms: a retrospective analysis. *J Clin Neurosci*. 2010;17:29–33. doi: 10.1016/j.jocn.2009.04.010.
 95. Matsubara S, Hadeishi H, Suzuki A, Yasui N, Nishimura H. Incidence and risk factors for the growth of unruptured cerebral aneurysms: observation using serial computerized tomography angiography. *J Neurosurg*. 2004;101:908–914. doi: 10.3171/jns.2004.101.6.0908.
 96. Jeon JS, Ahn JH, Huh W, Son YJ, Bang JS, Kang HS, Sohn CH, Oh CW, Kwon OK, Kim JE. A retrospective analysis on the natural history of incidental small paraclinoid unruptured aneurysm. *J Neural Neurosurg Psychiatry*. 2014;85:289–294. doi: 10.1136/jnnp-2013-305019.
 97. Kubo Y, Koji T, Kashimura H, Otawara Y, Ogawa A, Ogasawara K. Female sex as a risk factor for the growth of asymptomatic unruptured cerebral saccular aneurysms in elderly patients. *J Neurosurg*. 2014;121:599–604. doi: 10.3171/2014.5.JNS132048.
 98. Villablanca JP, Duckwiler GR, Jahan R, Tateshima S, Martin NA, Frazee J, Gonzalez NR, Sayre J, Vinuela FV. Natural history of asymptomatic

- unruptured cerebral aneurysms evaluated at CT angiography: growth and rupture incidence and correlation with epidemiologic risk factors. *Radiology*. 2013;269:258–265. doi: 10.1148/radiol.13121188.
99. Wermer MJ, van der Schaaf IC, Algra A, Rinkel GJ. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics: an updated meta-analysis. *Stroke*. 2007;38:1404–1410. doi: 10.1161/01.STR.0000260955.51401.cd.
 100. You SH, Kong DS, Kim JS, Jeon P, Kim KH, Roh HK, Kim GM, Lee KH, Hong SC. Characteristic features of unruptured intracranial aneurysms: predictive risk factors for aneurysm rupture. *J Neurol Neurosurg Psychiatry*. 2010;81:479–484. doi: 10.1136/jnnp.2008.169573.
 101. Sato K, Yoshimoto Y. Risk profile of intracranial aneurysms: rupture rate is not constant after formation. *Stroke*. 2011;42:3376–3381. doi: 10.1161/STROKEAHA.111.625871.
 102. Lall RR, Eddleman CS, Bendok BR, Batjer HH. Unruptured intracranial aneurysms and the assessment of rupture risk based on anatomical and morphological factors: sifting through the sands of data. *Neurosurg Focus*. 2009;26:E2. doi: 10.3171/2009.2.FOCUS0921.
 103. Xiang J, Yu J, Choi H, Dolan Fox JM, Snyder KV, Levy EI, Siddiqui AH, Meng H. Rupture Resemblance Score (RRS): toward risk stratification of unruptured intracranial aneurysms using hemodynamic-morphological discriminants [published online ahead of print May 7, 2014]. *J Neurointerv Surg*. doi: 10.1136/neurintsurg-2014-011218. <http://jn.is.bmj.com/content/early/2014/05/07/neurintsurg-2014-011218.long>. Accessed June 9, 2015.
 104. Dhar S, Tremmel M, Mocco J, Kim M, Yamamoto J, Siddiqui AH, Hopkins LN, Meng H. Morphology parameters for intracranial aneurysm rupture risk assessment. *Neurosurgery*. 2008;63:185–196. doi: 10.1227/01.NEU.0000316847.64140.81.
 105. Xiang J, Natarajan SK, Tremmel M, Ma D, Mocco J, Hopkins LN, Siddiqui AH, Levy EI, Meng H. Hemodynamic-morphologic discriminants for intracranial aneurysm rupture. *Stroke*. 2011;42:144–152. doi: 10.1161/STROKEAHA.110.592923.
 106. Cebal JR, Mut F, Weir J, Putman C. Quantitative characterization of the hemodynamic environment in ruptured and unruptured brain aneurysms. *AJNR Am J Neuroradiol*. 2011;32:145–151. doi: 10.3174/ajnr.A2419.
 107. Jou LD, Lee DH, Morsi H, Mawad ME. Wall shear stress on ruptured and unruptured intracranial aneurysms at the internal carotid artery. *AJNR Am J Neuroradiol*. 2008;29:1761–1767. doi: 10.3174/ajnr.A1180.
 108. Shojima M, Oshima M, Takagi K, Torii R, Hayakawa M, Katada K, Morita A, Kirino T. Magnitude and role of wall shear stress on cerebral aneurysm: computational fluid dynamic study of 20 middle cerebral artery aneurysms. *Stroke*. 2004;35:2500–2505. doi: 10.1161/01.STR.0000144648.89172.0f.
 109. Liu J, Xiang J, Zhang Y, Wang Y, Li H, Meng H, Yang X. Morphologic and hemodynamic analysis of paraclinoid aneurysms: ruptured versus unruptured. *J Neurointerv Surg*. 2014;6:658–663. doi: 10.1136/neurintsurg-2013-010946.
 110. Korja M, Lehto H, Juvela S. Lifelong rupture risk of intracranial aneurysms depends on risk factors: a prospective Finnish cohort study. *Stroke*. 2014;45:1958–1963. doi: 10.1161/STROKEAHA.114.005318.
 111. Chien A, Liang F, Sayre J, Salamon N, Villablanca P, Viñuela F. Enlargement of small, asymptomatic, unruptured intracranial aneurysms in patients with no history of subarachnoid hemorrhage: the different factors related to the growth of single and multiple aneurysms. *J Neurosurg*. 2013;119:190–197. doi: 10.3171/2013.3.JNS121469.
 112. Mehan WA Jr, Romero JM, Hirsch JA, Sabbag DJ, Gonzalez RG, Heit JJ, Schaefer PW. Unruptured intracranial aneurysms conservatively followed with serial CT angiography: could morphology and growth predict rupture? *J Neurointerv Surg*. 2014;6:761–766. doi: 10.1136/neurintsurg-2013-010944.
 113. Güresir E, Vatter H, Schuss P, Platz J, Konczalla J, de Rochement Rdu M, Berkefeld J, Seifert V. Natural history of small unruptured anterior circulation aneurysms: a prospective cohort study. *Stroke*. 2013;44:3027–3031. doi: 10.1161/STROKEAHA.113.001107.
 114. Hasan DM, Mahaney KB, Brown RD Jr, Meissner I, Piepgras DG, Huston J, Capuano AW, Torner JC; International Study of Unruptured Intracranial Aneurysms Investigators. Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. *Stroke*. 2011;42:3156–3162. doi: 10.1161/STROKEAHA.111.619411.
 115. Marbacher S, Schläppli JA, Fung C, Hüsler J, Beck J, Raabe A. Do statins reduce the risk of aneurysm development? A case-control study. *J Neurosurg*. 2012;116:638–642. doi: 10.3171/2011.10.JNS11153.
 116. Gross BA, Rosalind Lai PM, Frerichs KU, Du R. Aspirin and aneurysmal subarachnoid hemorrhage. *World Neurosurg*. 2014;82:1127–1130. doi: 10.1016/j.wneu.2013.03.072.
 117. Kissela BM, Sauerbeck L, Woo D, Khoury J, Carrozzella J, Pancioli A, Jauch E, Moomaw CJ, Shukla R, Gebel J, Fontaine R, Broderick J. Subarachnoid hemorrhage: a preventable disease with a heritable component. *Stroke*. 2002;33:1321–1326. doi: 10.1161/01.STR.0000014773.5773.
 118. Loumiosis I, Wagenbach A, Brown RD Jr, Lanzino G. Small (< 10-mm) incidentally found intracranial aneurysms, part 1: reasons for detection, demographics, location, and risk factors in 212 consecutive patients. *Neurosurg Focus*. 2011;31:E3. doi: 10.3171/2011.9.FOCUS11234.
 119. Choxi AA, Durrani AK, Mericle RA. Both surgical clipping and endovascular embolization of unruptured intracranial aneurysms are associated with long-term improvement in self-reported quantitative headache scores. *Neurosurgery*. 2011;69:128–133. doi: 10.1227/NEU.0b013e318213437d.
 120. Kong DS, Hong SC, Jung YJ, Kim JS. Improvement of chronic headache after treatment of unruptured intracranial aneurysms. *Headache*. 2007;47:693–697. doi: 10.1111/j.1526-4610.2006.00630.x.
 121. Qureshi AI, Suri MF, Kim SH, Olson K, Siddiqui AM, Yahia AM, Guterman LR, Hopkins LN. Effect of endovascular treatment on headaches in patients with unruptured intracranial aneurysms. *Headache*. 2003;43:1090–1096.
 122. Schwedt TJ, Gereau RW, Frey K, Kharasch ED. Headache outcomes following treatment of unruptured intracranial aneurysms: a prospective analysis. *Cephalalgia*. 2011;31:1082–1089. doi: 10.1177/0333102411398155.
 123. Güresir E, Schuss P, Seifert V, Vatter H. Oculomotor nerve palsy by posterior communicating artery aneurysms: influence of surgical strategy on recovery. *J Neurosurg*. 2012;117:904–910. doi: 10.3171/2012.8.JNS111239.
 124. Hassan T, Hamimi A. Successful endovascular management of brain aneurysms presenting with mass effect and cranial nerve palsy. *Neurosurg Rev*. 2013;36:87–97. doi: 10.1007/s10143-012-0404-3.
 125. Lv X, Jiang C, Li Y, Wu Z. Clinical outcomes of lower cranial nerve palsies caused by vertebral artery-posterior inferior cerebellar artery aneurysms after endovascular embolization. *Neurol Res*. 2010;32:796–800. doi: 10.1179/016164109X12478302362455.
 126. Panagiotopoulos V, Ladd SC, Gizewski E, Asgari S, Sandalcioğlu EI, Forsting M, Wanke I. Recovery of ophthalmoplegia after endovascular treatment of intracranial aneurysms. *AJNR Am J Neuroradiol*. 2011;32:276–282. doi: 10.3174/ajnr.A2281.
 127. Zhang SH, Pei W, Cai XS, Cheng G. Endovascular management and recovery from oculomotor nerve palsy associated with aneurysms of the posterior communicating artery. *World Neurosurg*. 2010;74:316–319. doi: 10.1016/j.wneu.2010.05.036.
 128. Güresir E, Schuss P, Setzer M, Platz J, Seifert V, Vatter H. Posterior communicating artery aneurysm-related oculomotor nerve palsy: influence of surgical and endovascular treatment on recovery: single-center series and systematic review. *Neurosurgery*. 2011;68:1527–1533. doi: 10.1227/NEU.0b013e31820edd82.
 129. Chen PR, Amin-Hanjani S, Albuquerque FC, McDougall C, Zabramski JM, Spetzler RF. Outcome of oculomotor nerve palsy from posterior communicating artery aneurysms: comparison of clipping and coiling. *Neurosurgery*. 2006;58:1040–1046. doi: 10.1227/01.NEU.0000215853.95187.5E.
 130. Bulsara KR, Jackson D, Galvan GM. Rate of third nerve palsy recovery following endovascular management of cerebral aneurysms. *Neurosurg Rev*. 2007;30:307–310. doi: 10.1007/s10143-007-0089-1.
 131. Qureshi AI, Mohammad Y, Yahia AM, Luft AR, Sharma M, Tamargo RJ, Frankel MR. Ischemic events associated with unruptured intracranial aneurysms: multicenter clinical study and review of the literature. *Neurosurgery*. 2000;46:282–289.
 132. Meyers PM, Schumacher HC, Higashida RT, Derdeyn CP, Nesbit GM, Sacks D, Wechsler LR, Bederson JB, Lavine SD, Rasmussen P. Reporting standards for endovascular repair of saccular intracranial cerebral aneurysms. *Stroke*. 2009;40:e366–e379. doi: 10.1161/STROKEAHA.108.527572.
 133. Delgado Almandoz JE, Jagadeesan BD, Refai D, Moran CJ, Cross DT 3rd, Chicoine MR, Rich KM, Diringner MN, Dacey RG Jr, Derdeyn CP, Zipfel GJ. Diagnostic yield of computed tomography angiography and magnetic resonance angiography in patients with catheter angiography-negative subarachnoid hemorrhage. *J Neurosurg*. 2012;117:309–315. doi: 10.3171/2012.4.JNS112306.
 134. Yu DW, Jung YJ, Choi BY, Chang CH. Subarachnoid hemorrhage with negative baseline digital subtraction angiography: is repeat digital subtraction angiography necessary? *J Cerebrovasc Endovasc Neurosurg*. 2012;14:210–215. doi: 10.7461/jcen.2012.14.3.210.
 135. Yoon DY, Lim KJ, Choi CS, Cho BM, Oh SM, Chang SK. Detection and characterization of intracranial aneurysms with 16-channel multidetector

- row CT angiography: a prospective comparison of volume-rendered images and digital subtraction angiography. *AJNR Am J Neuroradiol*. 2007;28:60–67.
136. Teksam M, McKinney A, Casey S, Asis M, Kieffer S, Truwit CL. Multi-section CT angiography for detection of cerebral aneurysms. *AJNR Am J Neuroradiol*. 2004;25:1485–1492.
 137. Dammert S, Krings T, Moller-Hartmann W, Ueffing E, Hans FJ, Willmes K, Mull M, Thron A. Detection of intracranial aneurysms with multislice CT: comparison with conventional angiography. *Neuroradiology*. 2004;46:427–434. doi: 10.1007/s00234-003-1155-1.
 138. McKinney AM, Palmer CS, Truwit CL, Karagulle A, Teksam M. Detection of aneurysms by 64-section multidetector CT angiography in patients acutely suspected of having an intracranial aneurysm and comparison with digital subtraction and 3D rotational angiography. *AJNR Am J Neuroradiol*. 2008;29:594–602. doi: 10.3174/ajnr.A0848.
 139. Hirai T, Korogi Y, Ono K, Murata Y, Suginoara K, Omori T, Uemura S, Takahashi M. Preoperative evaluation of intracranial aneurysms: usefulness of intraarterial 3D CT angiography and conventional angiography with a combined unit: initial experience. *Radiology*. 2001;220:499–505. doi: 10.1148/radiology.220.2.r01au20499.
 140. Kucukay F, Okten RS, Tekiner A, Dagli M, Gocek C, Bayar MA, Cumhur T. Three-dimensional volume rendering digital subtraction angiography in comparison with two-dimensional digital subtraction angiography and rotational angiography for detecting aneurysms and their morphological properties in patients with subarachnoid hemorrhage. *Eur J Radiol*. 2012;81:2794–2800. doi: 10.1016/j.ejrad.2011.10.006.
 141. Sugahara T, Korogi Y, Nakashima K, Hamatake S, Honda S, Takahashi M. Comparison of 2D and 3D digital subtraction angiography in evaluation of intracranial aneurysms. *AJNR Am J Neuroradiol*. 2002;23:1545–1552.
 142. van Rooij WJ, Peluso JP, Sluzewski M, Beute GN. Additional value of 3D rotational angiography in angiographically negative aneurysmal subarachnoid hemorrhage: how negative is negative? *AJNR Am J Neuroradiol*. 2008;29:962–966. doi: 10.3174/ajnr.A0972.
 143. van Rooij WJ, Sprengers ME, de Gast AN, Peluso JP, Sluzewski M. 3D rotational angiography: the new gold standard in the detection of additional intracranial aneurysms. *AJNR Am J Neuroradiol*. 2008;29:976–979. doi: 10.3174/ajnr.A0964.
 144. Wong SC, Nawawi O, Ramli N, Abd Kadir KA. Benefits of 3D rotational DSA compared with 2D DSA in the evaluation of intracranial aneurysm. *Acad Radiol*. 2012;19:701–707. doi: 10.1016/j.acra.2012.02.012.
 145. Jackson A, Stewart G, Wood A, Gillespie JE. Transient global amnesia and cortical blindness after vertebral angiography: further evidence for the role of arterial spasm. *AJNR Am J Neuroradiol*. 1995;16(suppl):955–959.
 146. Saitoh H, Hayakawa K, Nishimura K, Okuno Y, Teraura T, Yumitori K, Okumura A. Rupture of cerebral aneurysms during angiography. *AJNR Am J Neuroradiol*. 1995;16:539–542. 320. doi: 10.1161/01.STR.30.2.317.
 147. Cloft HJ, Joseph GJ, Dion JE. Risk of cerebral angiography in patients with subarachnoid hemorrhage, cerebral aneurysm, and arteriovenous malformation: a meta-analysis. *Stroke*. 1999;30:317–320. doi: 10.1161/01.STR.30.2.317.
 148. Serafin Z, Strzeńiewski P, Lasek W, Beuth W. Follow-up after embolization of ruptured intracranial aneurysms: a prospective comparison of two-dimensional digital subtraction angiography, three-dimensional digital subtraction angiography, and time-of-flight magnetic resonance angiography. *Neuroradiology*. 2012;54:1253–1260. doi: 10.1007/s00234-012-1030-z.
 149. Ferns SP, Majoie CB, Sluzewski M, van Rooij WJ. Late adverse events in coiled ruptured aneurysms with incomplete occlusion at 6-month angiographic follow-up. *AJNR Am J Neuroradiol*. 2010;31:464–469. doi: 10.3174/ajnr.A1841.
 150. Ringer AJ, Lanzino G, Veznedaroglu E, Rodriguez R, Mericle RA, Levy EI, Hanel RA, Lopes DK, Boulous AS. Does angiographic surveillance pose a risk in the management of coiled intracranial aneurysms? A multicenter study of 2243 patients. *Neurosurgery*. 2008;63:845–849. doi: 10.1227/01.NEU.0000333261.63818.9C.
 151. Wang H, Li W, He H, Luo L, Chen C, Guo Y. 320-Detector row CT angiography for detection and evaluation of intracranial aneurysms: comparison with conventional digital subtraction angiography. *Clin Radiol*. 2013;68:e15–e20. doi: 10.1016/j.crad.2012.09.001.
 152. Chappell ET, Moure FC, Good MC. Comparison of computed tomographic angiography with digital subtraction angiography in the diagnosis of cerebral aneurysms: a meta-analysis. *Neurosurgery*. 2003;52:624–631.
 153. Villablanca JP, Martin N, Jahan R, Gobin YP, Frazee, Duckwiler G, Benton J, Hardart M, Coiteiro D, Sayre J, Vinuela F. Volume-rendered helical computerized tomography angiography in the detection and characterization of intracranial aneurysms. *J Neurosurg*. 2000;93:254–264. doi: 10.3171/jns.2000.93.2.0254.
 154. Pechlivanis I, Koenen D, Engelhardt M, Scholz M, Koenig M, Heuser L, Harders A, Schmieder K. Computed tomographic angiography in the evaluation of clip placement for intracranial aneurysm. *Acta Neurochir (Wien)*. 2008;150:669–676. doi: 10.1007/s00701-008-1515-z.
 155. Sagara Y, Kiyosue H, Hori Y, Sainoo M, Nagatomi H, Mori H. Limitations of three-dimensional reconstructed computerized tomography angiography after clip placement for intracranial aneurysms. *J Neurosurg*. 2005;103:656–661. doi: 10.3171/jns.2005.103.4.0656.
 156. Uysal E, Ozel A, Erturk SM, Kirdar O, Basak M. Comparison of multislice computed tomography angiography and digital subtraction angiography in the detection of residual or recurrent aneurysm after surgical clipping with titanium clips. *Acta Neurochir (Wien)*. 2009;151:131–135. doi: 10.1007/s00701-009-0184-x.
 157. Wallace RC, Karis JP, Partovi S, Fiorella D. Noninvasive imaging of treated cerebral aneurysms, part II: CT angiographic follow-up of surgically clipped aneurysms. *AJNR Am J Neuroradiol*. 2007;28:1207–1212. doi: 10.3174/ajnr.A0664.
 158. Sailer AM, Wagemans BA, Nelemans PJ, de Graaf R, van Zwam WH. Diagnosing intracranial aneurysms with MR angiography: systematic review and meta-analysis. *Stroke*. 2014;45:119–126. doi: 10.1161/STROKEAHA.113.003133.
 159. Li MH, Cheng YS, Li YD, Fang C, Chen SW, Wang W, Hu DJ, Xu HW. Large-cohort comparison between three-dimensional time-of-flight magnetic resonance and rotational digital subtraction angiographies in intracranial aneurysm detection. *Stroke*. 2009;40:3127–3129. doi: 10.1161/STROKEAHA.109.553800.
 160. Okahara M, Kiyosue H, Yamashita M, Nagatomi H, Hata H, Saginoya T, Sagara Y, Mori H. Diagnostic accuracy of magnetic resonance angiography for cerebral aneurysms in correlation with 3D-digital subtraction angiographic images: a study of 133 aneurysms. *Stroke*. 2002;33:1803–1808. doi: 10.1161/01.STR.0000019510.32145.A9.
 161. Pierot L, Portefaix C, Boulain A, Gauvrit JY. Follow-up of coiled intracranial aneurysms: comparison of 3D time-of-flight and contrast-enhanced magnetic resonance angiography at 3T in a large, prospective series [published correction appears in *Eur Radiol*. 2012;22:2282]. *Eur Radiol*. 2012;22:2255–2263. doi: 10.1007/s00330-012-2466-6.
 162. Li MH, Li YD, Gu BX, Cheng YS, Wang W, Tan HQ, Chen YC. Accurate diagnosis of small cerebral aneurysms ≤5 mm in diameter with 3.0-T MR angiography. *Radiology*. 2014;271:553–560. doi: 10.1148/radiol.14122770.
 163. Agid R, Schaaf M, Farb R. CE-MRA for follow-up of aneurysms post stent-assisted coiling. *Interv Neuroradiol*. 2012;18:275–283.
 164. Anzalone N, Scomazzoni F, Cirillo M, Cadioli M, Iadanza A, Kirchin MA, Scotti G. Follow-up of coiled cerebral aneurysms: comparison of three-dimensional time-of-flight magnetic resonance angiography at 3 Tesla with three-dimensional time-of-flight magnetic resonance angiography and contrast-enhanced magnetic resonance angiography at 1.5 Tesla. *Invest Radiol*. 2008;43:559–567. doi: 10.1097/RLI.0b013e31817e9b0b.
 165. Anzalone N, Scomazzoni F, Cirillo M, Righi C, Simonato F, Cadioli M, Iadanza A, Kirchin MA, Scotti G. Follow-up of coiled cerebral aneurysms at 3T: comparison of 3D time-of-flight MR angiography and contrast-enhanced MR angiography. *AJNR Am J Neuroradiol*. 2008;29:1530–1536. doi: 10.3174/ajnr.A1166.
 166. Lavoie P, Gariépy JL, Milot G, Jodoin S, Bédard F, Trotier F, Verreault R. Residual flow after cerebral aneurysm coil occlusion: diagnostic accuracy of MR angiography. *Stroke*. 2012;43:740–746. doi: 10.1161/STROKEAHA.111.635300.
 167. Serafin Z, Strzeńiewski P, Lasek W, Beuth W. Comparison of remnant size in embolized intracranial aneurysms measured at follow-up with DSA and MRA. *Neuroradiology*. 2012;54:1381–1388. doi: 10.1007/s00234-012-1063-3.
 168. Takayama K, Taoka T, Nakagawa H, Myouchin K, Wada T, Sakamoto M, Fukusumi A, Iwasaki S, Kurokawa S, Kichikawa K. Usefulness of contrast-enhanced magnetic resonance angiography for follow-up of coil embolization with the enterprise stent for cerebral aneurysms. *J Comput Assist Tomogr*. 2011;35:568–572. doi: 10.1097/RCT.0b013e3182bd498.
 169. Weng HH, Jao SY, Yang CY, Tsai YH. Meta-analysis on diagnostic accuracy of MR angiography in the follow-up of residual intracranial aneurysms treated with Guglielmi detachable coils. *Interv Neuroradiol*. 2008;14(suppl 2):53–63.
 170. Kakizawa Y, Seguchi T, Horiuchi T, Hongo K. Cerebral aneurysm clips in the 3-Tesla magnetic field: laboratory investigation. *J Neurosurg*. 2010;113:859–869. doi: 10.3171/2010.3.JNS091346.

171. Pride GL Jr, Kowal J, Mendelsohn DB, Chason DP, Fleckenstein JL. Safety of MR scanning in patients with nonferromagnetic aneurysm clips. *J Magn Reson Imaging*. 2000;12:198–200.
172. Shellock FG, Detrick MS, Brant-Zawadski MN. MR compatibility of Guglielmi detachable coils. *Radiology*. 1997;203:568–570. doi: 10.1148/radiology.203.2.9114123.
173. Serafin Z, Strzeńskiński P, Lasek W, Beuth W. Methods and time schedule for follow-up of intracranial aneurysms treated with endovascular embolization: a systematic review. *Neurol Neurochir Pol*. 2011;45:421–430.
174. Chalouhi N, Tjoumakaris S, Gonzalez LF, Dumont AS, Starke RM, Hasan D, Wu C, Singhal S, Moukartzel LA, Rosenwasser R, Jabbour P. Coiling of large and giant aneurysms: complications and long-term results of 334 cases. *AJNR Am J Neuroradiol*. 2014;35:546–552. doi: 10.3174/ajnr.A3696.
175. Bruneau M, Rynkowski M, Smida-Rynkowska K, Brothi J, De Witte O, Lubicz B. Long-term follow-up survey reveals a high yield, up to 30% of patients presenting newly detected aneurysms more than 10 years after ruptured intracranial aneurysms clipping. *Neurosurg Rev*. 2011;34:485–496. doi: 10.1007/s10143-011-0332-7.
176. Taki W, PRESAT Group. Factors predicting retreatment and residual aneurysms at 1 year after endovascular coiling for ruptured cerebral aneurysms: Prospective Registry of Subarachnoid Aneurysms Treatment (PRESAT) in Japan. *Neuroradiology*. 2012;54:597–606. doi: 10.1007/s00234-011-0945-0.
177. Bober MB, Khan N, Kaplan J, Lewis K, Feinstein JA, Scott CI Jr, Steinberg GK. Majewski osteodysplastic primordial dwarfism type II (MOPD II): expanding the vascular phenotype. *Am J Med Genet A*. 2010;152A:960–965. doi: 10.1002/ajmg.a.33252.
178. Germain DP, Herrera-Guzman Y. Vascular Ehlers-Danlos syndrome. *Ann Genet*. 2004;47:1–9.
179. Ong AC. Screening for intracranial aneurysms in ADPKD [published correction appears in *BMJ*. 2009;339:b4204]. *BMJ*. 2009;339:b3763.
180. Ring T, Spiegelhalter D. Risk of intracranial aneurysm bleeding in autosomal-dominant polycystic kidney disease. *Kidney Int*. 2007;72:1400–1402. doi: 10.1038/sj.ki.5002488.
181. Xu HW, Yu SQ, Mei CL, Li MH. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. *Stroke*. 2011;42:204–206. doi: 10.1161/STROKEAHA.110.578740.
182. Connolly HM, Huston J 3rd, Brown RD Jr, Warnes CA, Ammash NM, Tajik AJ. Intracranial aneurysms in patients with coarctation of the aorta: a prospective magnetic resonance angiographic study of 100 patients. *Mayo Clin Proc*. 2003;78:1491–1499. doi: 10.4065/78.12.1491.
183. Wang PS, Longstreth WT Jr, Koepsell TD. Subarachnoid hemorrhage and family history: a population-based case-control study. *Arch Neurol*. 1995;52:202–204.
184. Woo D, Khoury J, Haverbusch MM, Sekar P, Flaherty ML, Kleindorfer DO, Kissela BM, Moomaw CJ, Deka R, Broderick JP. Smoking and family history and risk of aneurysmal subarachnoid hemorrhage. *Neurology*. 2009;72:69–72. doi: 10.1212/01.wnl.0000338567.90260.46.
185. Broderick JP, Sauerbeck LR, Foroud T, Huston J 3rd, Pankratz N, Meissner I, Brown RD Jr. The Familial Intracranial Aneurysm (FIA) study protocol. *BMC Med Genet*. 2005;6:17. doi: 10.1186/1471-2350-6-17.
186. Foroud T, Sauerbeck L, Brown R, Anderson C, Woo D, Kleindorfer D, Flaherty ML, Deka R, Hornung R, Meissner I, Bailey-Wilson JE, Rouleau G, Connolly ES, Lai D, Koller DL, Huston J 3rd, Broderick JP; FIA Study Investigators. Genome screen to detect linkage to intracranial aneurysm susceptibility genes: the Familial Intracranial Aneurysm (FIA) study. *Stroke*. 2008;39:1434–1440. doi: 10.1161/STROKEAHA.107.502930.
187. Broderick JP, Brown RD Jr, Sauerbeck L, Hornung R, Huston J 3rd, Woo D, Anderson C, Rouleau G, Kleindorfer D, Flaherty ML, Meissner I, Foroud T, Moomaw EC, Connolly ES; FIA Study Investigators. Greater rupture risk for familial as compared to sporadic unruptured intracranial aneurysms. *Stroke*. 2009;40:1952–1957. doi: 10.1161/STROKEAHA.108.542571.
188. Bor AS, Koffijberg H, Wermer MJ, Rinkel GJ. Optimal screening strategy for familial intracranial aneurysms: a cost-effectiveness analysis. *Neurology*. 2010;74:1671–1679. doi: 10.1212/WNL.0b013e3181e04297.
189. Takao H, Nojo T, Ohtomo K. Screening for familial intracranial aneurysms: decision and cost-effectiveness analysis. *Acad Radiol*. 2008;15:462–471. doi: 10.1016/j.acra.2007.11.007.
190. Li LM, Bulters DO, Kirollos RW. A mathematical model of utility for single screening of asymptomatic unruptured intracranial aneurysms at the age of 50 years. *Acta Neurochir (Wien)*. 2012;154:1145–1152. doi: 10.1007/s00701-012-1371-8.
191. Sonobe M, Yamazaki T, Yonekura M, Kikuchi H. Small Unruptured Intracranial Aneurysm Verification Study: SUAVE study, Japan. *Stroke*. 2010;41:1969–1977. doi: 10.1161/STROKEAHA.110.585059.
192. Ishibashi T, Murayama Y, Urashima M, Saguchi T, Ebara M, Arakawa H, Irie K, Takao H, Abe T. Unruptured intracranial aneurysms: incidence of rupture and risk factors. *Stroke*. 2009;40:313–316. doi: 10.1161/STROKEAHA.108.521674.
193. Inoue T, Shimizu H, Fujimura M, Saito A, Tominaga T. Annual rupture risk of growing unruptured cerebral aneurysms detected by magnetic resonance angiography. *J Neurosurg*. 2012;117:20–25. doi: 10.3171/2012.4.JNS.112225.
194. Irazabal MV, Huston J 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, Harris PC, Brown RD Jr, Torres VE. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol*. 2011;6:1274–1285. doi: 10.2215/CJN.09731110.
195. King JT Jr, Berlin JA, Flamm ES. Morbidity and mortality from elective surgery for asymptomatic, unruptured, intracranial aneurysms: a meta-analysis. *J Neurosurg*. 1994;81:837–842. doi: 10.3171/jns.1994.81.6.0837.
196. Raaymakers TW, Rinkel GJ, Limburg M, Algra A. Mortality and morbidity of surgery for unruptured intracranial aneurysms: a meta-analysis. *Stroke*. 1998;29:1531–1538.
197. Kotowski M, Naggara O, Darsaut TE, Nolet S, Gevry G, Kouznetsov E, Raymond J. Safety and occlusion rates of surgical treatment of unruptured intracranial aneurysms: a systematic review and meta-analysis of the literature from 1990 to 2011. *J Neurol Neurosurg Psychiatry*. 2013;84:42–48. doi: 10.1136/jnnp-2011-302068.
198. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies [published correction appears in *Ann Intern Med*. 2008;148:168]. *Ann Intern Med*. 2007;147:573–577.
199. Alshekhlee A, Mehta S, Edgell RC, Vora N, Feen E, Mohammadi A, Kale SP, Cruz-Flores S. Hospital mortality and complications of electively clipped or coiled unruptured intracranial aneurysm. *Stroke*. 2010;41:1471–1476. doi: 10.1161/STROKEAHA.110.580647.
200. Barker FG 2nd, Amin-Hanjani S, Butler WE, Hoh BL, Rabinov JD, Pryor JC, Ogilvy CS, Carter BS. Age-dependent differences in short-term outcome after surgical or endovascular treatment of unruptured intracranial aneurysms in the United States, 1996–2000. *Neurosurgery*. 2004;54:18–28.
201. Barker FG, 2nd, Amin-Hanjani S, Butler WE, Ogilvy CS, Carter BS. In-hospital mortality and morbidity after surgical treatment of unruptured intracranial aneurysms in the United States, 1996–2000: the effect of hospital and surgeon volume. *Neurosurgery*. 2003;52:995–1007.
202. Berman MF, Solomon RA, Mayer SA, Johnston SC, Yung PP. Impact of hospital-related factors on outcome after treatment of cerebral aneurysms. *Stroke*. 2003;34:2200–2207. doi: 10.1161/01.STR.0000086528.32334.06.
203. Brinjikji W, Rabinstein AA, Nasr DM, Lanzino G, Kallmes DF, Cloft HJ. Better outcomes with treatment by coiling relative to clipping of unruptured intracranial aneurysms in the United States, 2001–2008. *AJNR Am J Neuroradiol*. 2011;32:1071–1075. doi: 10.3174/ajnr.A2453.
204. Higashida RT, Lahue BJ, Torbey MT, Hopkins LN, Leip E, Hanley DF. Treatment of unruptured intracranial aneurysms: a nationwide assessment of effectiveness. *AJNR Am J Neuroradiol*. 2007;28:146–151.
205. Johnston SC, Dudley RA, Gress DR, Ono L. Surgical and endovascular treatment of unruptured cerebral aneurysms at university hospitals. *Neurology*. 1999;52:1799–1805.
206. Johnston SC, Zhao S, Dudley RA, Berman MF, Gress DR. Treatment of unruptured cerebral aneurysms in California. *Stroke*. 2001;32:597–605. doi: 10.1161/01.STR.32.3.597.
207. McDonald JS, McDonald RJ, Fan J, Kallmes DF, Lanzino G, Cloft HJ. Comparative effectiveness of unruptured cerebral aneurysm therapies: propensity score analysis of clipping versus coiling. *Stroke*. 2013;44:988–994. doi: 10.1161/STROKEAHA.111.000196.
208. Zacharia BE, Ducruet AF, Hickman ZL, Grobelny BT, Badjatia N, Mayer SA, Berman MF, Solomon RA, Connolly ES Jr. Technological advances in the management of unruptured intracranial aneurysms fail to improve outcome in New York State. *Stroke*. 2011;42:2844–2849. doi: 10.1161/STROKEAHA.111.619767.
209. Lee T, Baytton M, Sciacca R, Mohr JP, Pile-Spellman J. Aggregate analysis of the literature for unruptured intracranial aneurysm treatment. *AJNR Am J Neuroradiol*. 2005;26:1902–1908.
210. Ohue S, Oka Y, Kumon Y, Ohta S, Sakaki S, Hatakeyama T, Shiraishi T, Takeda S, Ohnishi T. Importance of neuropsychological evaluation after

- surgery in patients with unruptured cerebral aneurysms. *Surg Neurol*. 2003;59:269–275.
211. Pereira-Filho AA, Pereira AG, Faria MB, Lima LC, Portuguese MW, Kraemer JL. Microsurgical clipping in forty patients with unruptured anterior cerebral circulation aneurysms: an investigation into cognitive outcome. *Arq Neuropsiquiatr*. 2010;68:770–774.
 212. Preiss M, Netuka D, Koblihová J, Bernardová L, Charvát F, Beneš V. Cognitive functions before and 1 year after surgical and endovascular treatment in patients with unruptured intracranial aneurysms. *Br J Neurosurg*. 2012;26:514–516. doi: 10.1093/02688697.2011.645915.
 213. Tuffiash E, Tamargo RJ, Hillis AE. Craniotomy for treatment of unruptured aneurysms is not associated with long-term cognitive dysfunction. *Stroke*. 2003;34:2195–2199. doi: 10.1161/01.STR.0000087787.38080.B8.
 214. Kim DH, Haney CL, Van Ginhoven G. Utility of outcome measures after treatment for intracranial aneurysms: a prospective trial involving 520 patients. *Stroke*. 2005;36:792–796. doi: 10.1161/01.STR.0000157594.58180.97.
 215. Brilstra EH, Rinkel GJ, van der Graaf Y, Sluzewski M, Groen RJ, Lo RT, Tulleken CA. Quality of life after treatment of unruptured intracranial aneurysms by neurosurgical clipping or by embolisation with coils: a prospective, observational study. *Cerebrovasc Dis*. 2004;17:44–52. doi: 10.1159/000073897.
 216. Yamashiro S, Nishi T, Koga K, Goto T, Kaji M, Muta D, Kuratsu J, Fujioka S. Improvement of quality of life in patients surgically treated for asymptomatic unruptured intracranial aneurysms. *J Neurol Neurosurg Psychiatry*. 2007;78:497–500. doi: 10.1136/jnnp.2006.098871.
 217. Hoh BL, Nathoo S, Chi YY, Mocco J, Barker FG 2nd. Incidence of seizures or epilepsy after clipping or coiling of ruptured and unruptured cerebral aneurysms in the Nationwide Inpatient Sample database: 2002–2007. *Neurosurgery*. 2011;69:644–650. doi: 10.1227/NEU.0b013e31821bc46d.
 218. Krayenbühl N, Erdem E, Oinas M, Krisht AF. Symptomatic and silent ischemia associated with microsurgical clipping of intracranial aneurysms: evaluation with diffusion-weighted MRI. *Stroke*. 2009;40:129–133. doi: 10.1161/STROKEAHA.108.524777.
 219. David CA, Vishteh AG, Spetzler RF, Lemole M, Lawton MT, Partovi S. Late angiographic follow-up review of surgically treated aneurysms. *J Neurosurg*. 1999;91:396–401. doi: 10.3171/jns.1999.91.3.0396.
 220. Tsutsumi K, Ueki K, Morita A, Usui M, Kirino T. Risk of aneurysm recurrence in patients with clipped cerebral aneurysms: results of long-term follow-up angiography. *Stroke*. 2001;32:1191–1194. doi: 10.1161/01.STR.32.5.1191.
 221. Tsutsumi K, Ueki K, Usui M, Kwak S, Kirino T. Risk of subarachnoid hemorrhage after surgical treatment of unruptured cerebral aneurysms. *Stroke*. 1999;30:1181–1184.
 222. el-Beltagy M, Muroi C, Roth P, Fandino J, Imhof HG, Yonekawa Y. Recurrent intracranial aneurysms after successful neck clipping. *World Neurosurg*. 2010;74:472–477. doi: 10.1016/j.wneu.2010.06.036.
 223. Ogilvy CS, Carter BS. Stratification of outcome for surgically treated unruptured intracranial aneurysms. *Neurosurgery*. 2003;52:82–87.
 224. Hauck EF, Wohlfield B, Welch BG, White JA, Samson D. Clipping of very large or giant unruptured intracranial aneurysms in the anterior circulation: an outcome study. *J Neurosurg*. 2008;109:1012–1018. doi: 10.3171/JNS.2008.109.12.1012.
 225. Nakase H, Shin Y, Kanemoto Y, Ohnishi H, Morimoto T, Sakaki T. Long-term outcome of unruptured giant cerebral aneurysms. *Neurol Med Chir (Tokyo)*. 2006;46:379–384.
 226. Bhatia S, Sekula RF, Quigley MR, Williams R, Ku A. Role of calcification in the outcomes of treated, unruptured, intracerebral aneurysms. *Acta Neurochir (Wien)*. 2011;153:905–911. doi: 10.1007/s00701-010-0846-8.
 227. Grigorian AA, Marcovici A, Flamm ES. Intraoperative factors associated with surgical outcome in patients with unruptured cerebral aneurysms: the experience of a single surgeon. *J Neurosurg*. 2003;99:452–457. doi: 10.3171/jns.2003.99.3.0452.
 228. Ohno K, Arai T, Isotani E, Nariai T, Hirakawa K. Ischaemic complication following obliteration of unruptured cerebral aneurysms with atherosclerotic or calcified neck. *Acta Neurochir (Wien)*. 1999;141:699–705.
 229. Orz YI, Hongo K, Tanaka Y, Nagashima H, Osawa M, Kyoshima K, Kobayashi S. Risks of surgery for patients with unruptured intracranial aneurysms. *Surg Neurol*. 2000;53:21–27.
 230. Khanna RK, Malik GM, Qureshi N. Predicting outcome following surgical treatment of unruptured intracranial aneurysms: a proposed grading system. *J Neurosurg*. 1996;84:49–54. doi: 10.3171/jns.1996.84.1.0049.
 231. Brinjikji W, Rabinstein AA, Lanzino G, Kallmes DF, Cloft HJ. Effect of age on outcomes of treatment of unruptured cerebral aneurysms: a study of the National Inpatient Sample 2001–2008. *Stroke*. 2011;42:1320–1324. doi: 10.1161/STROKEAHA.110.607986.
 232. Asari S. Surgical management of the unruptured cerebral aneurysm accompanied by ischemic cerebrovascular disease. *Clin Neurol Neurosurg*. 1992;94:119–125.
 233. Wirth FP, Laws ER Jr, Piepgras D, Scott RM. Surgical treatment of incidental intracranial aneurysms. *Neurosurgery*. 1983;12:507–511.
 234. Cowan JA Jr, Dimick JB, Wainess RM, Upchurch GR Jr, Thompson BG. Outcomes after cerebral aneurysm clip occlusion in the United States: the need for evidence-based hospital referral. *J Neurosurg*. 2003;99:947–952. doi: 10.3171/jns.2003.99.6.0947.
 235. Solomon RA, Mayer SA, Tarmey JJ. Relationship between the volume of craniotomies for cerebral aneurysm performed at New York state hospitals and in-hospital mortality. *Stroke*. 1996;27:13–17. doi: 10.1161/01.STR.27.1.13.
 236. Chyatte D, Porterfield R. Functional outcome after repair of unruptured intracranial aneurysms. *J Neurosurg*. 2001;94:417–421. doi: 10.3171/jns.2001.94.3.0417.
 237. Klopstein JD, Spetzler RF, Kim LJ, Feiz-Erfan I, Han PP, Zabramski JM, Porter RW, Albuquerque FC, McDougall CG, Fiorella DJ. Comparison of routine and selective use of intraoperative angiography during aneurysm surgery: a prospective assessment. *J Neurosurg*. 2004;100:230–235. doi: 10.3171/jns.2004.100.2.0230.
 238. Nanda A, Willis BK, Vannemreddy PS. Selective intraoperative angiography in intracranial aneurysm surgery: intraoperative factors associated with aneurysmal remnants and vessel occlusions. *Surg Neurol*. 2002;58:309–314.
 239. Tang G, Cawley CM, Dion JE, Barrow DL. Intraoperative angiography during aneurysm surgery: a prospective evaluation of efficacy. *J Neurosurg*. 2002;96:993–999. doi: 10.3171/jns.2002.96.6.0993.
 240. Yanaka K, Asakawa H, Noguchi S, Matsumaru Y, Hyodo A, Anno I, Meguro K, Nose T. Intraoperative angiography evaluation of the microsurgical clipping of unruptured cerebral aneurysms. *Neurol Med Chir (Tokyo)*. 2002;42:193–200.
 241. Chalouhi N, Theofanis T, Jabbour P, Dumont AS, Fernando Gonzalez L, Starke RM, Dalyai RT, Hann S, Rosenwasser R, Tjoumakaris S. Safety and efficacy of intraoperative angiography in craniotomies for cerebral aneurysms and arteriovenous malformations: a review of 1093 consecutive cases. *Neurosurgery*. 2012;71:1162–1169. doi: 10.1227/NEU.0b013e318271ebfc.
 242. Chiang VL, Gailloud P, Murphy KJ, Rigamonti D, Tamargo RJ. Routine intraoperative angiography during aneurysm surgery. *J Neurosurg*. 2002;96:988–992. doi: 10.3171/jns.2002.96.6.0988.
 243. Bailes JE, Tantuwaya LS, Fukushima T, Schurman GW, Davis D. Intraoperative microvascular Doppler sonography in aneurysm surgery. *Neurosurgery*. 1997;40:965–970.
 244. Amin-Hanjani S, Meglio G, Gatto R, Bauer A, Charbel FT. The utility of intraoperative blood flow measurement during aneurysm surgery using an ultrasonic perivascular flow probe. *Neurosurgery*. 2006;58(suppl 2):ONS-305–ONS-312. doi: 10.1227/01.NEU.0000209339.47929.34.
 245. Raabe A, Nakaji P, Beck J, Kim LJ, Hsu FP, Kamerman JD, Seifert V, Spetzler RF. Prospective evaluation of surgical microscope-integrated intraoperative near-infrared indocyanine green videoangiography during aneurysm surgery. *J Neurosurg*. 2005;103:982–989. doi: 10.3171/jns.2005.103.6.0982.
 246. Washington CW, Zipfel GJ, Chicoine MR, Derdeyn CP, Rich KM, Moran CJ, Cross DT, Dacey RG Jr. Comparing indocyanine green videoangiography to the gold standard of intraoperative digital subtraction angiography used in aneurysm surgery. *J Neurosurg*. 2013;118:420–427. doi: 10.3171/2012.10.JNS11818.
 247. Wicks RT, Pradilla G, Raza SM, Hadelsberg U, Coon AL, Huang J, Tamargo RJ. Impact of changes in intraoperative somatosensory evoked potentials on stroke rates after clipping of intracranial aneurysms. *Neurosurgery*. 2012;70:1114–1124. doi: 10.1227/NEU.0b013e31823f5cf7.
 248. Yeon JY, Seo DW, Hong SC, Kim JS. Transcranial motor evoked potential monitoring during the surgical clipping of unruptured intracranial aneurysms. *J Neurol Sci*. 2010;293:29–34. doi: 10.1016/j.jns.2010.03.013.
 249. Bendok BR, Gupta DK, Rahme RJ, Eddleman CS, Adel JG, Sherma AK, Surdell DL, Bewaw JF, Koht A, Batjer HH. Adenosine for temporary flow arrest during intracranial aneurysm surgery: a single-center retrospective review. *Neurosurgery*. 2011;69:815–820. doi: 10.1227/NEU.0b013e318226632c.

250. Charbel FT, Ausman JI, Diaz FG, Malik GM, Dujovny M, Sanders J. Temporary clipping in aneurysm surgery: technique and results. *Surg Neurol.* 1991;36:83–90.
251. Hindman BJ, Todd MM, Gelb AW, Loftus CM, Craen RA, Schubert A, Mahla ME, Torner JC. Mild hypothermia as a protective therapy during intracranial aneurysm surgery: a randomized prospective pilot trial. *Neurosurgery.* 1999;44:23–32.
252. Todd MM, Hindman BJ, Clarke WR, Torner JC; Intraoperative Hypothermia for Aneurysm Surgery Trial (IHAST) Investigators. Mild intraoperative hypothermia during surgery for intracranial aneurysm. *N Engl J Med.* 2005;352:135–145. doi: 10.1056/NEJMoa040975.
253. Yoon JR, Kim YS, Kim TK. Thiopental-induced burst suppression measured by the bispectral index is extended during propofol administration compared with sevoflurane. *J Neurosurg Anesthesiol.* 2012;24:146–151. doi: 10.1097/ANA.0b013e3182429829.
254. Krayenbühl N, Oinas M, Erdem E, Krisht AF. The impact of minimizing brain retraction in aneurysm surgery: evaluation using magnetic resonance imaging. *Neurosurgery.* 2011;69:344–348. doi: 10.1227/NEU.0b013e31821819a0.
255. Spetzler RF, Sanai N. The quiet revolution: retractorless surgery for complex vascular and skull base lesions. *J Neurosurg.* 2012;116:291–300. doi: 10.3171/2011.8.JNS101896.
256. Park J, Woo H, Kang DH, Sung JK, Kim Y. Superciliary keyhole approach for small unruptured aneurysms in anterior cerebral circulation. *Neurosurgery.* 2011;68(suppl operative):300–309. doi: 10.1227/NEU.0b013e3182124810.
257. Eskridge JM, Song JK. Endovascular embolization of 150 basilar tip aneurysms with Guglielmi detachable coils: results of the Food and Drug Administration multicenter clinical trial. *J Neurosurg.* 1998;89:81–86. doi: 10.3171/jns.1998.89.1.0081.
258. Singh V, Gress DR, Higashida RT, Dowd CF, Halbach VV, Johnston SC. The learning curve for coil embolization of unruptured intracranial aneurysms. *AJNR Am J Neuroradiol.* 2002;23:768–771.
259. Cowan JA Jr, Ziewacz J, Dimick JB, Upchurch GR Jr, Thompson BG. Use of endovascular coil embolization and surgical clip occlusion for cerebral artery aneurysms. *J Neurosurg.* 2007;107:530–535. doi: 10.3171/JNS-07/09/0530.
260. Willis S, Ronkainen A, van der Voet M, Kuivaniemi H, Helin K, Leinonen E, Frösen J, Niemela M, Jääskeläinen J, Hernesniemi J, Tromp G. Familial intracranial aneurysms: an analysis of 346 multiplex Finnish families. *Stroke.* 2003;34:1370–1374. doi: 10.1161/01.STR.0000072822.35605.8B.
261. Mueller OM, Schlamann M, Mueller D, Sandalcioğlu IE, Forsting M, Sure U. Intracranial aneurysms: optimized diagnostic tools call for thorough interdisciplinary treatment strategies. *Ther Adv Neurol Disord.* 2011;4:267–279. doi: 10.1177/1756285611415309.
262. Murayama Y, Viñuela F, Duckwiler GR, Gobin YP, Guglielmi G. Embolization of incidental cerebral aneurysms by using the Guglielmi detachable coil system. *J Neurosurg.* 1999;90:207–214. doi: 10.3171/jns.1999.90.2.0207.
263. Wanke I, Doerfler A, Dietrich U, Egelhof T, Schoch B, Stolke D, Forsting M. Endovascular treatment of unruptured intracranial aneurysms. *AJNR Am J Neuroradiol.* 2002;23:756–761.
264. Soeda A, Sakai N, Sakai H, Iihara K, Yamada N, Imakita S, Nagata I. Thromboembolic events associated with Guglielmi detachable coil embolization of asymptomatic cerebral aneurysms: evaluation of 66 consecutive cases with use of diffusion-weighted MR imaging. *AJNR Am J Neuroradiol.* 2003;24:127–132.
265. Gonzalez N, Murayama Y, Nien YL, Martin N, Frazee J, Duckwiler G, Jahan R, Gobin YP, Viñuela F. Treatment of unruptured aneurysms with GDCs: clinical experience with 247 aneurysms. *AJNR Am J Neuroradiol.* 2004;25:577–583.
266. Terada T, Tsuura M, Matsumoto H, Masuo O, Tsumoto T, Yamaga H, Itakura T. Endovascular treatment of unruptured cerebral aneurysms. *Acta Neurochir Suppl.* 2005;94:87–91.
267. Grunwald IQ, Papanagiotou P, Politi M, Struffert T, Roth C, Reith W. Endovascular treatment of unruptured intracranial aneurysms: occurrence of thromboembolic events. *Neurosurgery.* 2006;58:612–618. doi: 10.1227/01.NEU.0000204101.00996.D9.
268. Roy D, Milot G, Raymond J. Endovascular treatment of unruptured aneurysms. *Stroke.* 2001;32:1998–2004. doi: 10.1161/STROKEAHA.107.496372.
269. Ng P, Khangure MS, Phatouros CC, Bynevelt M, ApSimon H, McAuliffe W. Endovascular treatment of intracranial aneurysms with Guglielmi detachable coils: analysis of midterm angiographic and clinical outcomes. *Stroke.* 2002;33:210–217. doi: 10.1161/hs0102.100486.
270. Raftopoulos C, Mathurin P, Boscherini D, Billa RF, Van Boven M, Hantson P. Prospective analysis of aneurysm treatment in a series of 103 consecutive patients when endovascular embolization is considered the first option. *J Neurosurg.* 2000;93:175–182. doi: 10.3171/jns.2000.93.2.0175.
271. Brilstra EH, Rinkel GJ, van der Graaf Y, van Rooij WJ, Algra A. Treatment of intracranial aneurysms by embolization with coils: a systematic review. *Stroke.* 1999;30:470–476. doi: 10.1161/01.STR.30.2.470.
272. Goddard AJ, Annesley-Williams D, Gholkar A. Endovascular management of unruptured intracranial aneurysms: does outcome justify treatment? *J Neurol Neurosurg Psychiatry.* 2002;72:485–490.
273. Johnston SC, Wilson CB, Halbach VV, Higashida RT, Dowd CF, McDermott MW, Applebury CB, Farley TL, Gress DR. Endovascular and surgical treatment of unruptured cerebral aneurysms: comparison of risks. *Ann Neurol.* 2000;48:11–19.
274. Weir B. Unruptured intracranial aneurysms: a review. *J Neurosurg.* 2002;96:3–42. doi: 10.3171/jns.2002.96.1.0003.
275. White PM, Raymond J. Endovascular coiling of cerebral aneurysms using “bioactive” or coated-coil technologies: a systematic review of the literature. *AJNR Am J Neuroradiol.* 2009;30:219–226. doi: 10.3174/ajnr.A1324.
276. Lanterna LA, Tredici G, Dimitrov BD, Biroli F. Treatment of unruptured cerebral aneurysms by embolization with Guglielmi detachable coils: case-fatality, morbidity, and effectiveness in preventing bleeding: a systematic review of the literature. *Neurosurgery.* 2004;55:767–775.
277. Naggara ON, White PM, Guilbert F, Roy D, Weill A, Raymond J. Endovascular treatment of intracranial unruptured aneurysms: systematic review and meta-analysis of the literature on safety and efficacy. *Radiology.* 2010;256:887–897. doi: 10.1148/radiol.10091982.
278. Pierot L, Spelle L, Vitry F; ATENA Investigators. Immediate clinical outcome of patients harboring unruptured intracranial aneurysms treated by endovascular approach: results of the ATENA study. *Stroke.* 2008;39:2497–2504. doi: 10.1161/STROKEAHA.107.512756.
279. Molyneux AJ, Kerr RS, Birks J, Ramzi N, Yarnold J, Sneade M, Rischmiller J; ISAT Collaborators. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. *Lancet Neurol.* 2009;8:427–433. doi: 10.1016/S1474-4422(09)70080-8.
280. Nguyen TN, Hoh BL, Amin-Hanjani S, Pryor JC, Ogilvy CS. Comparison of ruptured vs unruptured aneurysms in recanalization after coil embolization. *Surg Neurol.* 2007;68:19–23. doi: 10.1016/j.surneu.2006.10.021.
281. Mitchell P, Kerr R, Mendelow AD, Molyneux A. Could late rebleeding overturn the superiority of cranial aneurysm coil embolization over clip ligation seen in the International Subarachnoid Aneurysm Trial? *J Neurosurg.* 2008;108:437–442. doi: 10.3171/JNS/2008/108/3/0437.
282. Heros RC. International Subarachnoid Aneurysm Trial analysis. *J Neurosurg.* 2008;108:433–435. doi: 10.3171/JNS/2008/108/3/0433.
283. Schaafsma JD, Sprengers ME, van Rooij WJ, Sluzewski M, Majoie CB, Wermer MJ, Rinkel GJ. Long-term recurrent subarachnoid hemorrhage after adequate coiling versus clipping of ruptured intracranial aneurysms. *Stroke.* 2009;40:1758–1763. doi: 10.1161/STROKEAHA.108.524751.
284. Molyneux AJ, Clarke A, Sneade M, Mehta Z, Coley S, Roy D, Kallmes DF, Fox AJ. Cerecyte Coil Trial: angiographic outcomes of a prospective randomized trial comparing endovascular coiling of cerebral aneurysms with either Cerecyte or bare platinum coils. *Stroke.* 2012;43:2544–2550. doi: 10.1161/STROKEAHA.112.657254.
285. White PM, Lewis SC, Gholkar A, Sellar RJ, Nahser H, Cognard C, Forrester L, Wardlaw JM; HELPS Trial Collaborators. Hydrogel-coated coils versus bare platinum coils for the endovascular treatment of intracranial aneurysms (HELPS): a randomised controlled trial. *Lancet.* 2011;377:1655–1662. doi: 10.1016/S0140-6736(11)60408-X.
286. Cloft HJ; HEAL Investigators. HydroCoil for Endovascular Aneurysm Occlusion (HEAL) study: 3–6 month angiographic follow-up results. *AJNR Am J Neuroradiol.* 2007;28:152–154.
287. Youn SW, Cha SH, Kang HS, Cho YD, Han MH. Matrix² coils in embolization of intracranial aneurysms: 1-year outcome and comparison with bare platinum coil group in a single institution. *AJNR Am J Neuroradiol.* 2011;32:1745–1750. doi: 10.3174/ajnr.A2579.
288. Kang HS, Han MH, Kwon BJ, Kwon OK, Kim SH, Choi SH, Chang KH. Short-term outcome of intracranial aneurysms treated with polyglycolic acid/lactide copolymer-coated coils compared to historical controls treated with bare platinum coils: a single-center experience. *AJNR Am J Neuroradiol.* 2005;26:1921–1928.

289. Piotin M, Pistocchi S, Bartolini B, Blanc R. Intracranial aneurysm coiling with PGLA-coated coils versus bare platinum coils: long-term anatomic follow-up. *Neuroradiology*. 2012;54:345–348. doi: 10.1007/s00234-011-0870-2.
290. Wong GK, Yu SC, Poon WS. Clinical and angiographic outcome of intracranial aneurysms treated with Matrix detachable coils in Chinese patients. *Surg Neurol*. 2007;67:122–126. doi: 10.1016/j.surneu.2006.05.063.
291. Khan SH, Nichols C, Depowell JJ, Abruzzo TA, Ringer AJ. Comparison of coil types in aneurysm recurrence. *Clin Neurol Neurosurg*. 2012;114:12–16. doi: 10.1016/j.clineuro.2011.07.017.
292. Ringer AJ, Rodriguez-Mercado R, Veznedaroglu E, Levy EI, Hanel RA, Mericle RA, Lopes DK, Lanzino G, Boulos AS. Defining the risk of retreatment for aneurysm recurrence or residual after initial treatment by endovascular coiling: a multicenter study. *Neurosurgery*. 2009;65:311–315. doi: 10.1227/01.NEU.0000349922.05350.96.
293. Shapiro M, Babb J, Becske T, Nelson PK. Safety and efficacy of adjunctive balloon remodeling during endovascular treatment of intracranial aneurysms: a literature review. *AJNR Am J Neuroradiol*. 2008;29:1777–1781. doi: 10.3174/ajnr.A1216.
294. Soeda A, Sakai N, Sakai H, Iihara K, Nagata I. Endovascular treatment of asymptomatic cerebral aneurysms: anatomic and technical factors related to ischemic events and coil stabilization. *Neurol Med Chir (Tokyo)*. 2004;44:456–465.
295. Fargen KM, Hoh BL, Welch BG, Pride GL, Lanzino G, Boulos AS, Carpenter JS, Rai A, Veznedaroglu E, Ringer A, Rodriguez-Mercado R, Kan P, Siddiqui A, Levy EI, Mocco J. Long-term results of enterprise stent-assisted coiling of cerebral aneurysms. *Neurosurgery*. 2012;71:239–244.
296. Hwang G, Park H, Bang JS, Jin SC, Kim BC, Oh CW, Kang HS, Han MH, Kwon OK. Comparison of 2-year angiographic outcomes of stent- and nonstent-assisted coil embolization in unruptured aneurysms with an unfavorable configuration for coiling. *AJNR Am J Neuroradiol*. 2011;32:1707–1710. doi: 10.3174/ajnr.A2592.
297. Jahshan S, Abila AA, Natarajan SK, Drummond PS, Kan P, Karmon Y, Snyder KV, Hopkins LN, Siddiqui AH, Levy EI. Results of stent-assisted vs non-stent-assisted endovascular therapies in 489 cerebral aneurysms: single-center experience. *Neurosurgery*. 2013;72:232–239. doi: 10.1227/NEU.0b013e31827b93ea.
298. Lylyk P, Cohen JE, Ceratto R, Ferrario A, Miranda C. Endovascular reconstruction of intracranial arteries by stent placement and combined techniques. *J Neurosurg*. 2002;97:1306–1313. doi: 10.3171/jns.2002.97.6.1306.
299. Matrix and Platinum Science (MAPS) Trial. Abstract presented at: 8th Annual Meeting of the Society of NeuroInterventional Surgery (SNIS); July 25, 2011; Colorado Springs, CO.
300. Kallmes DF, Kallmes MH, Cloft HJ, Dion JE. Guglielmi detachable coil embolization for unruptured aneurysms in nonsurgical candidates: a cost-effectiveness exploration. *AJNR Am J Neuroradiol*. 1998;19:167–176.
301. Johnston SC, Gress DR, Kahn JG. Which unruptured cerebral aneurysms should be treated? A cost-utility analysis. *Neurology*. 1999;52:1806–1815.
302. Higashida RT, Justason BJ, Clark M, Torbey MT. Endovascular treatment of unruptured cerebral aneurysms may lead to improved outcomes and lower hospital resources. Paper presented at: American Society of Neuroradiology 40th Annual Meeting; May 13–17, 2002; Vancouver, British Columbia, Canada.
303. Huang MC, Baaj AA, Downes K, Youssef AS, Sauvageau E, van Loveren HR, Agazzi S. Paradoxical trends in the management of unruptured cerebral aneurysms in the United States: analysis of nationwide database over a 10-year period. *Stroke*. 2011;42:1730–1735. doi: 10.1161/STROKEAHA.110.603803.
304. Wolstenholme J, Rivero-Arias O, Gray A, Molyneux AJ, Kerr RS, Yarnold JA, Sneade M; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. Treatment pathways, resource use, and costs of endovascular coiling versus surgical clipping after aSAH. *Stroke*. 2008;39:111–119. doi: 10.1161/STROKEAHA.107.482570.
305. Connolly ES Jr, Meyers PM. Cerebral aneurysms: to clip or to coil? That is no longer the question. *Nat Rev Neurol*. 2009;5:412–413. doi: 10.1038/nrneurol.2009.106.
306. Johnston SC. Effect of endovascular services and hospital volume on cerebral aneurysm treatment outcomes. *Stroke*. 2000;31:111–117.
307. Fiorella D, Hirsch JA, Woo HH, Rasmussen PA, Shazam Hussain M, Hui FK, Frei D, Meyers PM, Jabbour P, Gonzalez LF, Mocco J, Turk A, Turner RD, Arthur AS, Gupta R, Cloft HJ. Should neurointerventional fellowship training be suspended indefinitely? *J Neurointerv Surg*. 2012;4:315–318. doi: 10.1136/neurintsurg-2012-010471.
308. Becske T, Kallmes DF, Saatci I, McDougall CG, Szikora I, Lanzino G, Moran CJ, Woo HH, Lopes DK, Berez AL, Cher DJ, Siddiqui AH, Levy EI, Albuquerque FC, Fiorella DJ, Berentei Z, Marosfoi M, Cekirge SH, Nelson PK. Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. *Radiology*. 2013;267:858–868. doi: 10.1148/radiol.13120099.
309. Piano M, Valvassori L, Quilici L, Pero G, Boccardi E. Midterm and long-term follow-up of cerebral aneurysms treated with flow diverter devices: a single-center experience. *J Neurosurg*. 2013;118:408–416. doi: 10.3171/2012.10.JNS11222.
310. Molyneux AJ, Cekirge S, Saatci I, Gál G. Cerebral Aneurysm Multicenter European Onyx (CAMEO) trial: results of a prospective observational study in 20 European centers. *AJNR Am J Neuroradiol*. 2004;25:39–51.
311. Meyers PM, Blackham KA, Abruzzo TA, Gandhi CD, Higashida RT, Hirsch JA, Hsu D, Moran CJ, Narayanan S, Prestigiacomo CJ, Tarr R, Hussein MS; Society for NeuroInterventional Surgery. Society of NeuroInterventional Surgery Standards of Practice: general considerations [published corrections appear in *J Neurointerv Surg*. 2012;4:195 and *J Neurointerv Surg*. 2012;4:115]. *J Neurointerv Surg*. 2012;4:11–15. doi: 10.1136/neurintsurg-2011-010180.
312. Hendee WR, Edwards FM. ALARA and an integrated approach to radiation protection. *Semin Nucl Med*. 1986;16:142–150.
313. Alexander MD, Oliff MC, Olorunsola OG, Brus-Ramer M, Nickoloff EL, Meyers PM. Patient radiation exposure during diagnostic and therapeutic interventional neuroradiology procedures. *J Neurointerv Surg*. 2010;2:6–10. doi: 10.1136/jnis.2009.000802.
314. Darsaut TE, Findlay JM, Raymond J; CURES Collaborative Group. The design of the Canadian UnRuptured Endovascular versus Surgery (CURES) trial. *Can J Neurol Sci*. 2011;38:236–241.
315. Shohji T, Ishibashi T, Murayama Y, Saguchi T, Ebara M, Irie K, Takao H, Abe T. Radiation exposure during cerebral artery aneurysm coil embolization: the current situation and measures to prevent radiation injury. *Interv Neuroradiol*. 2007;13(suppl 1):73–83.
316. Stecker MS, Balter S, Towbin RB, Miller DL, Vañó E, Bartal G, Angle JF, Chao CP, Cohen AM, Dixon RG, Gross K, Hartnell GG, Schueler B, Statler JD, de Baère T, Cardella JF; SIR Safety and Health Committee; CIRSE Standards of Practice Committee. Guidelines for patient radiation dose management. *J Vasc Interv Radiol*. 2009;20(suppl):S263–S273. doi: 10.1016/j.jvir.2009.04.037.
317. Miller DL, Balter S, Dixon RG, Nikolic B, Bartal G, Cardella JF, Dauer LT, Stecker MS; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for recording patient radiation dose in the medical record for fluoroscopically guided procedures. *J Vasc Interv Radiol*. 2012;23:11–18. doi: 10.1016/j.jvir.2011.09.004.
318. Meyers PM, Schumacher HC, Higashida RT, Barnwell SL, Creager MA, Gupta R, McDougall CG, Pandey DK, Sacks D, Wechsler LR; American Heart Association. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Interdisciplinary Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. *Circulation*. 2009;119:2235–2249. doi: 10.1161/CIRCULATIONAHA.109.192217.
319. Hoh BL, Chi YY, Lawson MF, Mocco J, Barker FG 2nd. Length of stay and total hospital charges of clipping versus coiling for ruptured and unruptured adult cerebral aneurysms in the Nationwide Inpatient Sample database 2002 to 2006 [published correction appears in *Stroke*. 2011;42:e356]. *Stroke*. 2010;41:337–342. doi: 10.1161/STROKEAHA.109.569269.
320. CARAT Investigators. Rates of delayed rebleeding from intracranial aneurysms are low after surgical and endovascular treatment. *Stroke*. 2006;37:1437–1442. doi: 10.1161/01.STR.0000221331.01830.ce.
321. Johnston SC, Dowd CF, Higashida RT, Lawton MT, Duckwiler GR, Gress DR; CARAT Investigators. Predictors of rehemorrhage after treatment of ruptured intracranial aneurysms: the Cerebral Aneurysm Rerupture After Treatment (CARAT) study. *Stroke*. 2008;39:120–125. doi: 10.1161/STROKEAHA.107.495747.
322. Burns JD, Huston J 3rd, Layton KF, Piepgras DG, Brown RD Jr. Intracranial aneurysm enlargement on serial magnetic resonance angiography: frequency and risk factors. *Stroke*. 2009;40:406–411. doi: 10.1161/STROKEAHA.108.519165.

323. Ferns SP, Sprengers ME, van Rooij WJ, van den Berg R, Velthuis BK, de Kort GA, Sluzewski M, van Zwam WH, Rinkel GJ, Majoie CB. De novo aneurysm formation and growth of untreated aneurysms: a 5-year MRA follow-up in a large cohort of patients with coiled aneurysms and review of the literature. *Stroke*. 2011;42:313–318. doi: 10.1161/STROKEAHA.110.591594.
324. Jiang T, Wang P, Qian Y, Zheng X, Xiao L, Yu S, Liu S. A follow-up study of autosomal dominant polycystic kidney disease with intracranial aneurysms using 3.0 T three-dimensional time-of-flight magnetic resonance angiography. *Eur J Radiol*. 2013;82:1840–1845. doi: 10.1016/j.ejrad.2013.01.024.
325. Juvela S, Poussa K, Porras M. Factors affecting formation and growth of intracranial aneurysms: a long-term follow-up study. *Stroke*. 2001;32:485–491. doi: 10.1161/01.STR.32.2.485.
326. Matsumoto K, Oshino S, Sasaki M, Tsuruzono K, Taketsuna S, Yoshimine T. Incidence of growth and rupture of unruptured intracranial aneurysms followed by serial MRA. *Acta Neurochir (Wien)*. 2013;155:211–216. doi: 10.1007/s00701-012-1566-z.
327. Miyazawa N, Akiyama I, Yamagata Z. Risk factors for growth of unruptured intracranial aneurysms: follow-up study by serial 0.5-T magnetic resonance angiography. *Neurosurgery*. 2006;58:1047–1053. doi: 10.1227/01.NEU.0000217366.02567.D2.
328. Wiebers DO. Unruptured intracranial aneurysms: natural history and clinical management: update on the International Study of Unruptured Intracranial Aneurysms. *Neuroimaging Clin N Am*. 2006;16:383–390, vii. doi: 10.1016/j.nic.2006.04.005.
329. Wiebers DO, Piegras DG, Meyer FB, Kallmes DF, Meissner I, Atkinson JL, Link MJ, Brown RD Jr. Pathogenesis, natural history, and treatment of unruptured intracranial aneurysms. *Mayo Clin Proc*. 2004;79:1572–1583. doi: 10.4065/79.12.1572.



Stroke

Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

B. Gregory Thompson, Robert D. Brown Jr, Sepideh Amin-Hanjani, Joseph P. Broderick, Kevin M. Cockcroft, E. Sander Connolly Jr, Gary R. Duckwiler, Catherine C. Harris, Virginia J. Howard, S. Claiborne (Clay) Johnston, Philip M. Meyers, Andrew Molyneux, Christopher S. Ogilvy, Andrew J. Ringer and James Torner

Stroke. published online June 18, 2015;

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2015 American Heart Association, Inc. All rights reserved.

Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://stroke.ahajournals.org/content/early/2015/06/18/STR.0000000000000070>

Data Supplement (unedited) at:

<http://stroke.ahajournals.org/content/suppl/2015/06/18/STR.0000000000000070.DC1>

<http://stroke.ahajournals.org/content/suppl/2016/05/30/STR.0000000000000070.DC2>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Stroke* is online at:
<http://stroke.ahajournals.org/subscriptions/>

SUPPLEMENTAL MATERIAL

Supplemental Table I: Number and percentage of stroke centers by state and region in the United States in 2013. (PSC=Primary Stroke Center)

States	Census Region	Stroke Legislation	PSC	PSC by Joint Commission	Other PSC	Total General Hospitals	PSC as % of General Hospitals
Wyoming	West	No	1	1	0	25	4%
Hawaii	West	No	1	1	0	21	5%
Arkansas	South	No	4	4	0	74	5%
Mississippi	South	No	6	5	1	93	6%
South Dakota	Midwest	No	3	3	0	49	6%
Vermont	Northeast	No	1	1	0	14	7%
West Virginia	South	No	4	4	0	51	8%
Louisiana	South	No	10	10	0	119	8%
Montana	West	No	4	4	0	49	8%
Alabama	South	No	9	9	0	99	9%
Kansas	Midwest	No	11	11	0	127	9%
Idaho	West	No	4	3	1	39	10%
Alaska	West	No	2	2	0	21	10%
Maine	Northeast	No	4	4	0	36	11%
New Mexico	West	No	4	2	2	35	11%
New Hampshire	Northeast	No	3	2	1	26	12%
Nebraska	Midwest	No	11	11	0	82	13%
North Dakota	Midwest	Yes	5	5	0	38	13%
Minnesota	Midwest	No	17	17	0	124	14%
Iowa	Midwest	No	18	14	4	116	16%
Tennessee	South	No	19	19	0	114	17%
Utah	West	No	7	6	1	39	18%
Kentucky	South	Yes	21	20	1	99	19%
Wisconsin	Midwest	No	30	30	0	127	24%
Oregon	West	No	14	13	1	58	24%
Missouri	Midwest	Yes	29	28	1	114	25%
South Carolina	South	No	17	14	3	58	28%
Indiana	Midwest	No	33	24	9	117	28%
Georgia	South	Yes	41	38	3	140	29%
Oklahoma	South	Yes	32	8	24 by state	110	29%
Ohio	Midwest	No	49	43	6	159	31%
North Carolina	South	No	35	35	0	111	32%
Colorado	West	No	23	23	0	70	33%
Michigan	Midwest	No	46	37	9	133	34%
Texas	South	Yes	130	104	16 by state	382	34%
Maryland	South	Yes	17	17	0	46	37%
Arizona	West	No	25	20	5	64	39%

Illinois	Midwest	Yes	72	64	8	183	39%
Pennsylvania	Northeast	Yes	69	63	6	163	41%
California	West	No	148	145	3	346	43%
Nevada	West	No	14	14	0	32	44%
Washington	West	Yes	39	20	18 by state	87	45%
Virginia	South	Yes	40	34	6	81	49%
New York	Northeast	Yes	121	17	102 by state	189	64%
Connecticut	Northeast	Yes	22	15	7 by state	30	73%
Florida	South	Yes	144	100	39 by state	195	74%
District of Columbia	South	No	6	6	0	8	75%
Rhode Island	Northeast	Yes	9	9	0	10	90%
New Jersey	Northeast	Yes	65	29	34 by state	69	96%
Massachusetts	Northeast	Yes	61	5	56 by state	63	97%
Delaware	South	Yes	5	5	0	5	100%
Total		18	150 5	1118	387	4640	32.4%

AHA/ASA Guideline

未破裂脳動脈瘤の管理に関するガイドライン

A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

*The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Endorsed by the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the Society of NeuroInterventional Surgery*

B. Gregory Thompson, MD, Chair; Robert D. Brown, Jr, MD, MPH, FAHA, Co-Chair; Sepideh Amin-Hanjani, MD, FAHA; Joseph P. Broderick, MD, FAHA; Kevin M. Cockcroft, MD, MSc, FAHA; E. Sander Connolly, Jr, MD, FAHA; Gary R. Duckwiler, MD, FAHA; Catherine C. Harris, PhD, RN, MBA, CRNP; Virginia J. Howard, PhD, MSPH, FAHA; S. Claiborne (Clay) Johnston, MD, PhD; Philip M. Meyers, MD, FAHA; Andrew Molyneux, MD; Christopher S. Ogilvy, MD; Andrew J. Ringer, MD; James Torner, PhD, MS, FAHA; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention

Stroke. 2015;46:2368-2400. DOI: 10.1161/STR.0000000000000070.

本ガイドラインの執筆グループは、1977年1月から2014年6月までの未破裂動脈瘤（UIA）に関する文献とこれまでのエビデンスに基づいたガイドラインを検索し、米国心臓協会（AHA）のエビデンス基準を用いてUIAの危険因子（表1）、臨床所見（表2）、診断と画像（表3）、スクリーニング（表4）、自然歴（表5）、開頭クリッピング術（表6）、血管内コイル塞栓術（表7）、クリッピング術と血管内治療の比較（表8）、非侵襲的管理（表9）、について推奨を提供し、最後に推奨の重要事項を結論としてまとめている（表10）。推奨に用いられたAHAエビデンスのクラスとレベルについては、Stroke 日本語版 Vol.10, No.4, 2015 p29-32 掲載の「脳内出血の管理に関するガイドライン」を参照していただきたい。UIAの管理には自然歴が治療法とともに重要であり、日本ではUIAの破裂リスクが高いことから（後述）、紙面が限られる本稿では、UIAの自然歴と破裂リスクにつき、欧米と日本の代表的な研究に限定して述べる。

UIAは比較的多く、世界的には成人の約3.2%に存在するとされる。しかし、大多数のUIAは無症状で終わり、破裂してくも膜下出血（SAH）を起こすのは0.25%とされる。そのため、どのUIAに予防的治療の必要があるかが議論的になってきたが、1998年に1,449例の国際的後向き研究で（*N Engl J Med* 1998; 339: 1725-1733）、UIAが10mm以下でSAHの既往がない場合には年間破裂率は0.05%であり、SAHの既往があっても0.5%と低率であることが示された。2003年には前向きISUIS研究（*Lancet* 2003; 362: 103-110）で年間破裂率が前方循環系の7mm以下のUIAで0%、7～12mmで0.5%、

13～24mmで2.9%、25mm以上で8%であり、後交通動脈と後方循環では7mm以下で0.5%、7～12mmで2.9%、13～24mmで3.7%、25mm以上で10%であった。日本においては2010年にSUAVE研究（*Stroke* 2010; 41: 1969-1977）が5mm以下のUIAをもつ374例により1,306.2人・年の観察で7例の破裂から年間破裂率0.54%を報告し、4mm以上のUIA、複数UIA、高血圧をもつ症例で破裂リスクが高いたした。更に2012年には5,720例（6,697UIA）による11,660動脈瘤・年の観察に基づいたUCAS研究が報告されたが（*N Engl J Med* 2012; 366: 2474-2482）、111人にUIAの破裂が起こり、年間破裂率は0.95%であった。UIAの大きさでは、3～4mmと比較して5～6mmではハザード比（HR）が1.13、7～9mmでは3.35、10～24mmでは9.09、25mm以上では76.25であり、7mm以上で破裂のリスクが有意に増加していた。また中大脳動脈に比して後交通動脈のHRは1.90、前交通動脈のHRは2.02であった。更に上記の前向き研究を含めた6件の研究に基づいた系統的レビューでは（*Lancet Neurology* 2014; 13: 54-66）、8,382例による29,166人・年の経過観察で230例に破裂がみられ、平均1年破裂率が1.4%、5年間の破裂リスクが3.4%であったと報告されたが、UIA破裂率には地域差があり、欧米（フィンランドを除く）と比較して、日本では2.8倍、フィンランドでは3.6倍高かった。地域差以外のUIA破裂の予測因子としては、年齢、高血圧、SAHの既往、UIAの大きさ、UIAの発現部位が指摘された。年齢については、日本の3篇の前向き研究に基づいた70歳以上の解析（*Neurology* 2015; 85: 1879-1885）においても、

80歳以上では70～79歳に比してHRが2.02と増加していた($P = 0.012$)。ISUIS研究の結果を踏まえて、欧米では7mm以上のUIAで破裂リスクが有意に増加すると考えられることが多いが、本ガイドラインでは言及されているものの、推奨ではUIAの大きさについて明確な数値を示していない。UIAのサイズ以外では、喫煙と高血圧が危険因子とされ、UIAの拡大、SAHの既往、家族歴などが破裂の予測因子として重視されている(表1, 5, 10)。日本の脳卒中治療ガイドライン2015(日本

脳卒中学会 発行: 協和企画)では5～7mm以上のUIAは破裂のリスクが高く、5mm以下でも部位、形状などによりリスクが高くなるとしている。

治療については、開頭クリッピング術と血管内コイル塞栓術の両者間の無作為比較試験がないため、本ガイドラインではそれぞれの推奨(表6, 7)と両者の比較をし、治療が考慮されるUIA患者には両者の利点と問題点を充分説明すべきとしている(表8, 10)。

(文責: 柳原武彦)

表1 動脈瘤の発生、増大、破裂の危険因子に関する推奨

推 奨	エビデンスのクラスとレベル
1. 喫煙は未破裂頭蓋内動脈瘤(UIA)形成のリスクを増加させると考えられることから、UIAを有する患者には禁煙の重要性についてカウンセリングを行うべきである。	クラスI; エビデンスレベルB
2. 高血圧が頭蓋内動脈瘤(IA)の増大および破裂に関与していると考えられることから、UIAを有する患者では、血圧をモニタリングし、高血圧治療を行うべきである。	クラスI; エビデンスレベルB
3. 動脈瘤の増大により破裂のリスクが増加する可能性があることから、保存的に管理されたUIAの経過観察のため、間歇的に画像検査を考慮すべきである。	クラスI; エビデンスレベルB

表2 臨床所見に関する推奨

推 奨	エビデンスのクラスとレベル
1. 動脈瘤性くも膜下出血(aSAH)を発症した患者では、UIAの合併の有無を慎重に評価すべきである。	クラスI; エビデンスレベルB
2. 一般に、UIAによる脳神経麻痺を呈する患者は早期治療の適応となる。	クラスI; エビデンスレベルC)。
3. 虚血性脳血管障害の予防を目的としたUIAの日常的治療の有効性は確実でない。	クラスIIb; エビデンスレベルC

表3 診断/画像検査に関する推奨

推 奨	エビデンスのクラスとレベル
1. 外科的治療または血管内治療が考慮されている場合、デジタルサブトラクション動脈造影法(DSA)は非侵襲的な撮影法と比較して脳動脈瘤の同定および評価により有用と考えられる。	クラスIIa; エビデンスレベルB
2. DSAは、治療した動脈瘤の経過観察のための最も高感度の撮影法として妥当である。	クラスIIa; エビデンスレベルC
3. CT血管造影(CTA)およびMR血管造影(MRA)はUIAの発見および経過観察に有用である。	クラスI; エビデンスレベルB
4. 治療した動脈瘤の経過観察のための代替方法としてMRAを施行し、治療法を決定する際に必要に応じてDSAを併用することは妥当である。	クラスIIa; エビデンスレベルC
5. コイルを挿入した動脈瘤、特にネック径またはドーム径が大きい動脈瘤やコイルが十分に充填されていない残存動脈瘤については、経過観察における評価を行うべきである。 経過観察の時期および期間は確定しておらず、さらに検討を行う必要がある。	クラスI; エビデンスレベルB
6. 再発リスクが高いことを示す特徴がみられないUIAの血管内治療後のサーベイランス画像検査の重要性は明確にされていないが、サーベイランス画像検査はおそらく適応となるだろう。	クラスIIa; エビデンスレベルC

表4 スクリーニングに関する推奨

推 奨	エビデンスのクラスとレベル
1. IAまたはSAHを発症した家族が2名以上いる患者には、CTAまたはMRAによる動脈瘤のスクリーニング検査を提案すべきである。このような家族において動脈瘤発症のリスクが特に高いことを予測する危険因子として、高血圧の既往歴、喫煙、女性であることがあげられる。	クラスI; エビデンスレベルB
2. 常染色体優性多発性嚢胞腎の既往歴がある患者、特にIAの家族歴がある患者には、CTAまたはMRAによるスクリーニング検査を提案すべきである。また大動脈縮窄がある患者および小頭性骨異形成性原発性小人症患者にCTAまたはMRAを提案することは妥当である。	クラスI; エビデンスレベルB クラスIIa; エビデンスレベルB

表5 自然経過に関する推奨

推 奨	エビデンスのクラスとレベル
1. aSAHの既往歴は、別の小さな未破裂動脈瘤による将来の出血の独立した危険因子であると考えてよい。	クラスIIb; エビデンスレベルB
2. 経過観察中に動脈瘤の拡大を認める患者には、手術を禁止される併発疾患がない場合には治療を提案すべきである。	クラスI; エビデンスレベルB
3. IAの家族歴がある患者でのUIAの治療は、特発性のIAより小さな動脈瘤においても妥当である。	クラスIIa; エビデンスレベルB

表 6 外科的クリッピング術に関する推奨

推 奨	エビデンスのクラスとレベル
1. UIA の治療として外科的クリッピング術を考慮する際には、患者の年齢、動脈瘤の位置および大きさなど、いくつかの因子を念頭に置くべきである。	クラス I；エビデンスレベル B
2. 完全に閉塞された動脈瘤と閉塞が不完全な動脈瘤では増大および出血のリスクが異なることから、動脈瘤の閉塞を確認するために外科的介入後の画像検査が推奨される。	クラス I；エビデンスレベル B
3. 外科的クリッピング術後は、動脈瘤の再発と新規の動脈瘤形成のリスクがあることから、長期の経過観察における画像検査を考慮してもよい。初回治療時に閉塞が不完全であった動脈瘤では、長期の経過観察が特に重要と考えられる。	クラス IIb；エビデンスレベル B
4. UIA の外科的治療は、症例数の多い施設（例えば年間症例数が 20 例以上）で行うことが推奨される。	クラス I；エビデンスレベル B
5. UIA の手術管理でみられる有害な転帰を軽減するため、血管の損傷や残存動脈瘤を回避するための専門的な術中器具および手技の利用を考慮してもよい。	クラス IIb；エビデンスレベル C

表 7 血管内治療に関する推奨

推 奨	エビデンスのクラスとレベル
1. 管腔内血流迂回術（Endoluminal flow diversion）は新しい治療戦略の 1 つであり、厳選した症例で考慮してもよい。このほか、液体塞栓剤など未破裂脳動脈瘤を治療するための新しい技術も新しい治療戦略であり、厳選した症例で考慮してもよい。	クラス IIb；エビデンスレベル B クラス IIb；エビデンスレベル C
このような新しいアプローチの長期的な効果はほとんどわかっていない。既存の技術よりも安全性および有効性が徐々に向上していることが示されるまでは、米国食品医薬品局の適応を厳密に遵守することがおそらく必要である。	クラス IIa；エビデンスレベル C
2. コーティングコイルの使用は、コーティングしていない金属コイルと比較して有益ではない。	クラス III；エビデンスレベル A
3. UIA の血管内治療は症例数の多い施設で行うことが推奨される。	クラス I；エビデンスレベル B
4. 血管内手技の同意取得においては、放射線照射に伴うリスクを明確に説明すべきである。	クラス I；エビデンスレベル C

表 8 クリッピング術とコイル塞栓術の有効性の比較：推奨

推 奨	エビデンスのクラスとレベル
1. 外科的クリッピング術は、治療が考慮されている UIA に有効な治療法である。	クラス I；エビデンスレベル B
2. 血管内コイル塞栓術は、治療が考慮されている特定の UIA に有効な治療法である。	クラス IIa；エビデンスレベル B
3. 治療が考慮されている UIA 患者には、血管内コイル塞栓術および顕微鏡下動脈瘤クリッピング術両方のリスクとベネフィットについて十分に説明すべきである。	クラス I；エビデンスレベル B
4. 血管内コイル塞栓術は、厳選した症例では外科的クリッピング術と比較して手術による罹病率および死亡率が低い、全体的には再発リスクが高い。	クラス IIb；エビデンスレベル B

表 9 動脈瘤の経過観察に関する推奨（手術または血管内コイル塞栓術以外の方法で治療した患者）

推 奨	エビデンスのクラスとレベル
1. 外科的介入または血管内介入を行わず非侵襲的に管理された UIA 患者は、MRA または CTA による定期的な経過観察の適応となる。推奨される経過観察の最適な間隔および期間は確定していない。	クラス I；エビデンスレベル B
2. 外科的介入または血管内介入を行わず非侵襲的に管理された UIA 患者には、最初の発見から 6 ～ 12 ヶ月後に初回の経過観察の検査を行い、以後 1 年に 1 回または 2 年に 1 回経過観察を行うことが妥当と考えられる。	クラス IIb；エビデンスレベル C
3. 非侵襲的に管理され、MRI の禁忌のない UIA 患者では、長期の反復的な経過観察に CTA ではなく TOF MRA を考慮することが妥当と考えられる。	クラス IIb；エビデンスレベル C

表 10 結論：推奨

推 奨	エビデンスのクラスとレベル
1. UIA の最適な管理方法の選択においては、動脈瘤の大きさ、位置および他の形態学的特徴、連続撮像で確認された増大、患者の年齢、aSAH の既往歴、脳動脈瘤の家族歴、複数の動脈瘤の存在、出血リスクを高める傾向をもつ動静脈奇形または他の脳血管疾患、遺伝性疾患といった併発疾患の存在など、いくつかの因子を考慮すべきである。	クラス I；エビデンスレベル C
2. 治療が考慮されている未破裂脳動脈瘤患者には、UIA を治療し、出血を予防するための方法として、血管内治療および顕微鏡下治療両方のリスクとベネフィットについて十分に説明すべきである。	クラス I；エビデンスレベル B
3. UIA の治療成績は症例数の少ない施設では劣っているため、治療は症例数の多い施設で行うことが推奨される。	クラス I；エビデンスレベル B
4. 国内外の複数の調査における前向き試験および後向き研究のデータから、顕微鏡下クリップ結紮術が動脈瘤の再増大を長期にわたり予防するが、手術による罹病率および死亡率、入院期間および病院費用に関してはコイル塞栓術の方が外科的クリッピング術より優れていることが示されているため、特定の UIA の治療、特に脳底動脈先端動脈瘤などの手術による罹病率が高い症例および高齢者では、外科的クリッピングではなく血管内治療を選択することが妥当と考えられる。	クラス IIb；エビデンスレベル B
5. UIA 患者の治療リスクは加齢、併発疾患、動脈瘤の位置および大きさと関連するため、高齢（65 歳以上）の患者および小さな無症候性 UIA をもち、位置、大きさ、形態、家族歴および他の関連因子から出血リスクが低く、併発疾患がある患者では、経過観察が妥当な代替方法である。	クラス IIa；エビデンスレベル B